{"100-1.\n\u4e00\u4f4d\u75c5\u4eba\u7684\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\u986f\u793a pH:7.62, PaCO2:32mmHg, HCO3-:29mEq/L\uff0c\u8acb\u554f\u662f\u4f55\u7a2e\u60c5\u6cc1\uff1f\nA. \u547c\u5438\u9e7c\u8840\u75c7\uff0c\u6709\u90e8\u4efd\u4ee3\u8b1d\u4ee3\u511f\nB. \u547c\u5438\u9e7c\u8840\u75c7\uff0c\u7121\u4ee3\u8b1d\u4ee3\u511f\nC. \u547c\u5438\u9e7c\u8840\u75c7\u5408\u4f75\u4ee3\u8b1d\u9e7c\u8840\u75c7\nD. \u4ee3\u8b1d\u9e7c\u8840\u75c7\uff0c\u7121\u547c\u5438\u4ee3\u511f\nE. \u4ee3\u8b1d\u9e7c\u8840\u75c7\uff0c\u6709\u90e8\u4efd\u547c\u5438\u4ee3\u511f\n": "(C)", "100-2.\n\u4e0b\u5217\u6709\u95dc\u4e00\u822c\u81e8\u5e8a\u4f7f\u7528\u4e4b\u8108\u885d\u5f0f\u8840\u6c27\u5075\u6e2c\u5100\uff08pulse oximetry\uff09\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u7576\u5fc3\u81df\u8f38\u51fa\u91cf\u660e\u986f\u4e0b\u964d\u6642\uff0c\u6240\u6e2c\u503c\u66f4\u6e96\u78ba\nB. \u7121\u6cd5\u5206\u8fa8methemoglobin\u8207Oxyhemoglobin\nC. \u7576\u6e2c\u5f97SpO2 > 90% \u6642\uff0c\u4e5f\u8868\u793aPaCO2\u4e0d\u6703\u592a\u9ad8\nD. \u5176\u6e2c\u503c\u4e0d\u53d7\u662f\u5426\u4f7f\u7528\u8840\u7ba1\u6536\u7e2e\u5291\u4e4b\u5f71\u97ff\nE. \u8840\u4e2dPaO2\u8207\u6240\u6e2cSpO2\u6210\u7dda\u6027\u6b63\u76f8\u95dc\n": "(B)", "100-3.\n66\u6b72\u5a66\u4eba\u56e0\u54b3\u8840\u548c\u547c\u5438\u56f0\u96e3\u6c42\u8a3a\uff0c\u80f8\u90e8X\u5149\u5982\u5716\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u5c0d\u8a3a\u65b7\u6700\u6709\u52a9\u76ca\uff1f\nA. \u62bd\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\nB. \u505a\u80f8\u8154\u7a7f\u523a\u62bd\u6c34\u6aa2\u67e5\nC. \u505a\u75f0\u6aa2\u67e5\u7d30\u83cc\u8207\u764c\u7d30\u80de\nD. \u505a\u652f\u6c23\u7ba1\u93e1\u6aa2\u67e5\nE. \u505a\u6838\u91ab\u80ba\u90e8\u6383\u7784\n": "(D)", "100-4.\n60\u6b72B\u7d30\u80de\u6dcb\u5df4\u7624\u75c5\u4eba\uff0c\u5316\u7642\u4e2d\u51fa\u73fe\u767c\u71d2\u3001\u4e7e\u54b3\u548c\u5598\uff0c\u5176\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u7a2e\u611f\u67d3\u6700\u53ef\u80fd\uff1f\nA. Pneumocystis jirovecii\nB. Hemophilus influenzae\nC. Nontuberculosis Mycobacterium\nD. Cryptococcus neoformans\nE. Pseudomonas aeruginosa\n": "(A)", "100-5.\n\u4e0b\u5217\u6709\u95dc\u80ba\u7d50\u6838\u75c5\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u4e00\u822c\u6a19\u6e96\u6cbb\u7642\u662fHERZ 6\u500b\u6708\nB. \u6cbb\u7642\u4e00\u500b\u6708\u5f8c\u7684\u75f0\u57f9\u990a\u4ecd\u7136\u967d\u6027\uff0c\u61c9\u5c6c\u6cbb\u7642\u5931\u6557\nC. \u5c0dIsoniazid \u548cRifampin\u7686\u6297\u85e5\u6027\u8005\uff0c\u7a31\u70ba\u591a\u91cd\u6297\u85e5\u6027(MDR)\nD. Pyrazinamide \u4e4b\u4e3b\u8981\u526f\u4f5c\u7528\u662f\u8996\u795e\u7d93\u840e\u7e2e\nE. \u4e00\u822c\u6a19\u6e96\u6cbb\u7642\u5c0dHIV\u967d\u6027\u8005\u4e4b\u7642\u6548\u751a\u5dee\n": "(C)", "100-6.\n\u4e0b\u5217\u6709\u95dc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\uff08COPD\uff09\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u80ba\u90e8\u5fa9\u5065\u7121\u6cd5\u6539\u5584\u80ba\u529f\u80fd\nB. \u53ea\u8981\u9577\u671f\u7d66\u4e88\u6c27\u6c23\u7686\u53ef\u6e1b\u5c11\u6b7b\u4ea1\u7387\nC. \u53ea\u8981\u5438\u7159\u8d85\u904e60\u5e74(pack years)\u5fc5\u6703\u5f97COPD\nD. \u9808\u7d66\u4e88\u9577\u671f\u4f4e\u5291\u91cf\u53e3\u670d\u985e\u56fa\u9187\u4ee5\u6e1b\u7de9\u80ba\u529f\u80fd\u4e4b\u8870\u9000\nE. \u767c\u71d2 > 38.5\u2103 \u5373\u8868\u793a\u6025\u6027\u60e1\u5316\uff08acute exacerbation)\n": "(A)", "100-7.\n\u4e0b\u5217\u6709\u95dc\u6c23\u5598\u75c5\u85e5\u7269\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u77ed\u6548beta 2-agonist \u5438\u5165\u5291\u53ea\u53ef\u9593\u6b47\u4f7f\u7528\nB. \u75c5\u60c5\u7a69\u5b9a\u6642\uff0c\u53ef\u63a1\u7528\u9577\u6548bata 2-agonist\u5438\u5165\u5291\u55ae\u7368\u4f7f\u7528\nC. \u5438\u5165\u5f0f\u985e\u56fa\u9187\u662f\u76ee\u524d\u6700\u6709\u6548\u7684\u63a7\u5236\u5291 (controller)\nD. \u53e3\u670d\u8336\u9e7c\u88fd\u5291\u4e0d\u53ef\u7576\u4f5c\u7b2c\u4e00\u7dda\u6cbb\u7642\u85e5\nE. \u767d\u4e09\u70ef(leukotriene)\u53d7\u9ad4\u62ee\u6297\u5291\u4e4b\u526f\u4f5c\u7528\u6975\u5c11\n": "(B)", "100-8.\n68\u6b72\u7537\u6027\u4e3b\u8a34\u6162\u6027\u54b3\u548c\u5598\uff0c\u80f8\u90e8X\u5149\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u7a2e\u5f71\u50cf\u6aa2\u67e5\u6700\u6709\u52a9\u65bc\u8a3a\u65b7\uff1f\nA. \u80f8\u90e8\u78c1\u632f\u9020\u5f71\uff08MRI\uff09\nB. \u8d85\u97f3\u6ce2\u6383\u63cf\nC. \u6ce8\u5c04\u986f\u5f71\u5291\u4e4b\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\nD. \u9ad8\u89e3\u6790\u5ea6\u4e4b\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\nE. \u6b63\u5b50\u96fb\u8166\u65b7\u5c64(PET-CT)\n": "(D)", "100-9.\n\u4e0b\u5217\u6709\u95dc\u5fc3\u81df\u8870\u7aed\u5f15\u8d77\u80ba\u6c34\u816b\u5c0e\u81f4\u547c\u5438\u8870\u7aed\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r1.\u5e38\u6709\u63db\u6c23-\u704c\u6ce8\uff08V/Q\uff09\u4e0d\u914d\u5408\r2.\u5e38\u5408\u4f75dead space\u589e\u52a0\r3. \u901a\u5e38PaCO2\u660e\u986f\u6607\u9ad8\r4.\u5e38\u6709\u80ba\u5167\u5206\u6d41(shunt)\nA. 1+2\nB. 1+4\nC. 2+3\nD. 2+4\nE. 3+4\n": "(B)", "100-10.\n\u4e0b\u5217\u6709\u95dc\u8f38\u8840\u5f15\u8d77\u6025\u6027\u80ba\u640d\u50b7\uff08TRALI\uff09\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r1.\u8f38\u8840\u904e\u91cf\u6216\u904e\u5feb\u6240\u81f4.\r2.\u6709\u5fc3\u81df\u75c5\u8005\u6613\u767c\u751f.\r3.\u56e0\u4f9b\u8840\u8005\u8840\u6f3f\u542b\u9ad8\u6297HLA\u6297\u9ad4\u6240\u81f4.\r4.\u53ea\u9808\u4fdd\u5b88\u7642\u6cd5\u5373\u53ef\r5.\u9700\u4f7f\u7528\u9ad8\u5291\u91cf\u985e\u56fa\u9187\nA. 1+2\nB. 1+4\nC. 2+5\nD. 3+4\nE. 3+5\n": "(D)", "100-11.\n\u4e0b\u5217\u6709\u95dc\u54b3\u55fd\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r1.\u670d\u7528\u8840\u7ba1\u7dca\u7e2e\u7d20\u8f49\u5316\u9175\u7d20\u6291\u5236\u5291(ACEI)\u5f15\u8d77\u7684\u54b3\u55fd\u5e38\u5728\u670d\u7528\u6eff6\u500b\u6708\u624d\u51fa\u73fe\r2.\u5982\u679c\u61f7\u7591\u662f\u80ba\u764c\u5f15\u8d77\uff0c\u61c9\u505a\u9ad8\u89e3\u6790\u5ea6\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\r3.\u7a69\u5b9a\u7684\u6162\u6027\u652f\u6c23\u7ba1\u708e\u75c5\u4eba\uff0c\u4e0d\u5b9c\u670d\u7528\u6b62\u54b3\u85e5\r4.\u6240\u8b02 \"cough syncope\" \u662f\u56e0\u5fc3\u81df\u8f38\u51fa\u91cf\u6e1b\u5c11\u6240\u81f4\nA. 1+2\nB. 1+3\nC. 2+3\nD. 2+4\nE. 3+4\n": "(E)", "100-12.\n\u4e0b\u5217\u95dc\u65bcMDR-TB\u7684\u6558\u8ff0\u54ea\u4e00\u500b\u4e0d\u6b63\u78ba\uff1f\nA. MDR-TB\u6307\u81f3\u5c11\u5c0dIsoniazid\u53caRifampicin\u5177\u6297\u85e5\u6027\u7684\u60a3\u8005\nB. MDR-TB\u7684\u75c5\u60a3\u4ee5\u4e00\u958b\u59cb\u5373\u611f\u67d3\u5177\u6297\u85e5\u6027\u7684\u83cc\u682a\u70ba\u6700\u5e38\u898b\u7684\u539f\u56e0\nC. \u81f3\u5c11\u9700\u4f7f\u75284\u7a2e\u6709\u6548\u7684\u85e5\u7269\u6cbb\u764218\u500b\u6708\u4ee5\u4e0a\uff0c\u4e14\u9700\u6703\u8a3a\u5177\u6cbb\u7642\u591a\u91cd\u6297\u85e5\u7d50\u6838\u6709\u7d93\u9a57\u7684\u91ab\u5e2b\nD. \u75c5\u60a3\u4e0d\u898f\u5247\u670d\u85e5\u3001\u670d\u85e5\u671f\u9593\u4e0d\u8db3\u5373\u81ea\u884c\u505c\u85e5\u662f\u9020\u6210MDR-TB\u7684\u539f\u56e0\u4e4b\u4e00\nE. Isoniazid\u9810\u9632\u6027\u6cbb\u7642\u4e0d\u9069\u7528\u65bcMDR-TB\u75c5\u4eba\u4e4b\u89aa\u5bc6\u63a5\u89f8\u8005\n": "(B)", "100-13.\n\u4f9d\u64da\u300c\u50b3\u67d3\u75c5\u9632\u6cbb\u6cd5\u300d\u7684\u898f\u5b9a\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6240\u6709\u63a5\u53d7\u6297\u7d50\u6838\u85e5\u7269\u6cbb\u7642\u4e4b\u7d50\u6838\u75c5\u4eba\u7686\u61c9\u901a\u5831\nB. \u7d30\u83cc\u5b78\u78ba\u8a3a\u4e4b\u7d50\u6838\u75c5\u4eba\u5728\u78ba\u8a3a\u524d\u6b7b\u4ea1\uff0c\u4e14\u672a\u63a5\u53d7\u6297\u7d50\u6838\u85e5\u7269\u6cbb\u7642\u4e0d\u9700\u901a\u5831\nC. \u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u5c6c\u7b2c\u4e8c\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u9808\u5728\u4e03\u5929\u5167\u901a\u5831\nD. \u80ba\u5916\u7d50\u6838\u75c5\u4e0d\u5177\u50b3\u67d3\u6027\uff0c\u4e0d\u9700\u901a\u5831\nE. \u63a5\u53d7\u9810\u9632\u6027\u6cbb\u7642\u4e4b\u6f5b\u4f0f\u6027\u7d50\u6838\u611f\u67d3\u60a3\u8005\u5fc5\u9808\u901a\u5831\n": "(A)", "100-14.\n\u6c23\u5598\u7684\u75c7\u72c0\u6709\u53ef\u80fd\u6642\u597d\u6642\u58de\uff0c\u4f46\u662f\u547c\u5438\u9053\u7684\u767c\u708e\u53cd\u61c9\u537b\u662f\u6162\u6027\u6301\u7e8c\u5b58\u5728\u7684\u3002\u56e0\u6b64\uff0c\u5c0d\u65bc\u5927\u90e8\u5206\u7684\u6c23\u5598\u60a3\u8005\uff0c\u9700\u8981\u6bcf\u5929\u898f\u5f8b\u4f7f\u7528\u300c\u63a7\u5236\u578b\u85e5\u7269\u300d\uff0c\u9810\u9632\u75c7\u72c0\u7684\u51fa\u73fe\u3001\u6539\u5584\u80ba\u529f\u80fd\u3002\u76ee\u524d\u7684\u85e5\u7269\u5df2\u7d93\u80fd\u5920\u8b93\u5927\u591a\u6578\u7684\u6c23\u5598\u75c5\u4eba\u7372\u5f97\u826f\u597d\u7684\u63a7\u5236\u3002\u7576\u6c23\u5598\u63a7\u5236\u826f\u597d\u6642\uff0c\u75c5\u4eba\u5c31\u80fd\u5920\u9054\u5230\u4ee5\u4e0b\u7684\u76ee\u6a19\uff0c\u4f55\u8005\u9664\u5916\uff1f\nA. \u767d\u5929\u3001\u591c\u665a\u90fd\u6c92\u6709\u75c7\u72c0\nB. \u4e0d\u9700\u8981\u4f7f\u7528\u7de9\u89e3\u578b\u85e5\u7269\nC. \u4e0d\u5f71\u97ff\u5e73\u65e5\u6d3b\u52d5\nD. \u80ba\u529f\u80fd\u6b63\u5e38\uff08\u6216\u63a5\u8fd1\u6b63\u5e38\uff09\nE. \u6c92\u6709\u56b4\u91cd\u767c\u4f5c\u6216\u6025\u6027\u60e1\u5316\n": "(B)", "100-15.\n\u6709\u95dc\u9000\u4f0d\u8ecd\u4eba\u75c7(Legionnaire's disease)\u7684\u8840\u6e05\u5b78\u6aa2\u67e5\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6297\u9ad4\u503c 1:128 \u5373\u53ef\u78ba\u8a3a\nB. \u6297\u9ad4\u5728\u611f\u67d3\u5f8c4-6\u9031\u624d\u6703\u5347\u9ad8\nC. \u6297\u9ad4\u503c\u5927\u65bc 1:256 \u8868\u793a\u6025\u6027\u611f\u67d3\nD. \u6297\u9ad4\u5347\u9ad8\u53ef\u6301\u7e8c\u8d85\u904e\u4e00\u5e74\nE. \u5c3f\u6297\u539f\u5c0d\u7b2c\u4e00\u578b\u55dc\u80ba\u9000\u4f0d\u8ecd\u4eba\u83cc\u611f\u67d3\u6709\u5f88\u597d\u7684\u8a3a\u65b7\u654f\u611f\u6027 (>80%) \u53ca\u5c08\u4e00\u6027 (100%)\uff0c\u81e8\u5e8a\u5e38\u7528\u4f86\u4f5c\u70ba\u5176\u4ed6\u8840\u6e05\u578b\u9000\u4f0d\u8ecd\u4eba\u83cc\u611f\u67d3\u4e4b\u5075\u6e2c\u7528\n": "(D)", "100-16.\n\u4e00\u4f4d50\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u660f\u8ff7\u88ab\u9001\u81f3\u6025\u8a3a\u6c42\u8a3a\uff0c\u52d5\u8108\u6c23\u9ad4\u5206\u6790\u5448\u73fepH 7.10\uff0cPCO2 80 mmHg\uff0cPO2 40 mmHg\u3002\u6700\u53ef\u80fd\u7684\u539f\u56e0\u70ba\u4f55\uff1f\uff1f\nA. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316\nB. \u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4 (ARDS)\nC. \u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2\nD. \u56b4\u91cd\u80ba\u7e96\u7dad\u5316\nE. \u670d\u7528\u904e\u91cf\u93ae\u975c\u5291\n": "(E)", "100-17.\n\u4e00\u4f4d40\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u6700\u8fd1\u4e00\u9031\u6301\u7e8c\u767c\u71d2\u81f339\u5ea6\uff0c\u54b3\u55fd\u5e36\u81bf\u75f0\uff0c\u5de6\u5074\u80f8\u75db\u5f15\u767c\u9593\u6b47\u6027\u547c\u5438\u56f0\u96e3\u800c\u5230\u6025\u8a3a\u6c42\u8a3a\u3002\u80f8\u90e8X\u5149\u5448\u73fe\u5de6\u4e0a\u80ba\u8449\u6d78\u6f64\u6027\u75c5\u8b8a\u8207\u5de6\u5074\u808b\u819c\u7a4d\u6c34\u3002\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u80f8\u7ba1\u5f15\u6d41\u6cbb\u7642\u4e4b\u9069\u61c9\u75c7\uff1f\nA. \u5f62\u6210\u8154\u5ba4\u5316\u808b\u819c\u7a4d\u6db2(loculated effusion)\nB. \u808b\u819c\u6db2pH<7.2\nC. \u808b\u819c\u6db2 glucose<60 mg/dl\nD. \u808b\u819c\u6db2Gram's stain\u767c\u73fe\u7d30\u83cc\nE. \u808b\u819c\u6db2\u4e4b\u767d\u8840\u7403\u4e2d\uff0c\u6dcb\u5df4\u7403\u6bd4\u4f8b >50%\n": "(E)", "100-18.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u5c0f\u7d30\u80de\u80ba\u764c(small cell carcinoma of lung)\u5e38\u898b\u4e4b\u4f34\u96a8\u816b\u7624\u65b0\u751f\u5f15\u8d77\u7684\u9ad4\u5167\u7cfb\u7d71\u5931\u8abf (paraneoplastic phenomena)\uff1f\nA. \u6297\u5229\u5c3f\u6fc0\u7d20\u4e0d\u9069\u7576\u5206\u6ccc\u75c7\u5019\u7fa4 (SIADH)\nB. Lamber-Eaton myasthenic syndrmoe\nC. Cushing's syndrome\nD. Humoral hypercalcemia\nE. Coagulopathy\n": "(E)", "100-19.\n\u5927\u591a\u6578\u9593\u8cea\u6027\u80ba\u75c5\u7684\u81f4\u75c5\u539f\u56e0\u4e0d\u660e\uff0c\u4e0b\u5217\u4f55\u8005\u9664\u5916\uff1f\nA. Hypersensitivity pneumonitis\nB. Eosinophilic pneumonia\nC. Pulmonary hemorrhage syndrome\nD. Lymphomatoid granulomatosis\nE. Sarcoidosis\n": "(A)", "100-20.\n\u81e8\u5e8a\u8a3a\u65b7\u80ba\u6813\u585e\u75c7\u5e38\u7528\u4e4b\u300cVirchow's Triad\u300d\u5305\u542b\u54ea\u4e9b\u8b8a\u5316\uff1f\r1.Stasis.\r2.Hyperventilation.\r3.Nocturnal hemoglobinuria.\r4.Vessel wall injury.\r5.Hypercoagulability.\nA. 1+2+3\nB. 2+3+4\nC. 1+3+5\nD. 1+4+5\nE. 2+3+5\n": "(D)", "100-21.\n\u4e0b\u5217\u6709\u95dc\u6cbb\u7642\u6297\u85e5\u6027\u7d50\u6838\u75c5\u7684\u539f\u5247\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\r1.\u82e5\u767c\u73fe\u6cbb\u7642\u7121\u6548\u6642\uff0c\u61c9\u518d\u52a0\u5165\u4e00\u7a2e\u672a\u66fe\u4f7f\u7528\u904e\u7684\u6297\u7d50\u6838\u85e5\u7269.\r2.\u82e5\u611f\u67d3\u591a\u91cd\u6297\u85e5\u7d50\u6838\u83cc\u6642\uff0c\u9700\u4f7f\u7528\u81f3\u5c11\u4e09\u7a2e\u4ee5\u4e0a\u654f\u611f\u4e4b\u6297\u7d50\u6838\u85e5\u7269.\r3.\u53ef\u8003\u616e\u5916\u79d1\u624b\u8853\u5207\u9664\u4e3b\u8981\u75c5\u7076\u90e8\u4efd\uff0c\u518d\u63a5\u53d7\u5b8c\u6574\u6297\u7d50\u6838\u85e5\u7269\u6cbb\u7642.\r4.\u9700\u6cbb\u7642\u81f3\u57f9\u990a\u7d50\u679c\u8f49\u9670\u6027\u81f3\u5c1112\u500b\u6708\u624d\u53ef\u8003\u616e\u505c\u85e5.\r5.\u4e0d\u9069\u5408\u4f7f\u7528\u76f4\u63a5\u89c0\u5bdf\u7d66\u85e5\u65b9\u5f0f(directly observed therapy, DOT).\nA. 1+2+3\nB. 2+4+5\nC. 1+3+5\nD. 1+4+5\nE. 2+3+5\n": "(D)", "100-22.\n\u7761\u7720\u547c\u5438\u7d42\u6b62\u75c7\u5019\u7fa4 (sleep apnea syndrome) \u7684\u75c5\u4eba\u767c\u4f5c\u6642\uff0c\u8840\u6c27\u4e0b\u964d\u3001\u4e8c\u6c27\u5316\u78b3\u4e0a\u5347\u3001\u9178\u9e7c\u503c\u504f\u4f4e\uff0c\u53ef\u5c0e\u81f4\u54ea\u4e9b\u751f\u7406\u5b78\u8b8a\u5316\u8207\u81e8\u5e8a\u8868\u5fb5\uff1f\r1.\u808b\u819c\u58d3\u529b\u964d\u4f4e\uff0c\u589e\u52a0\u5fc3\u81df\u4e4b\u5f8c\u8ca0\u8377(afterload)\uff0c\u5c0e\u81f4\u53f3\u5fc3\u5ba4\u8870\u7aed\r2.\u5fc3\u8df3\u6e1b\u6162\uff0c\u5fc3\u5f8b\u4e0d\u6574\uff0c\u5c0e\u81f4\u7121\u9810\u8b66\u4e4b\u591c\u9593\u6b7b\u4ea1 (nocturnal death)\r3.\u80ba\u90e8\u8840\u7ba1\u7e2e\u6536\uff0c\u5c0e\u81f4\u80ba\u52d5\u8108\u58d3\u4e0a\u5347\r4.\u5168\u8eab\u8840\u7ba1\u64f4\u5f35\uff0c\u9020\u6210\u8840\u58d3\u964d\u4f4e\uff0c\u5f15\u767c\u4f11\u514b\r5.\u4e8c\u6c27\u5316\u78b3\u6eef\u7559\uff0c\u5f15\u8d77\u6162\u6027\u901a\u6c23\u4e0d\u8db3 (chronic hypoventilation)\nA. 1+2+3\nB. 2+3+4\nC. 1+3+4\nD. 2+3+5\nE. 1+4+5\n": "(D)", "101-1.\n\u5973\u602721\u6b72,\u672a\u5438\u7159,\u4e3b\u8a34\u9577\u671f\u547c\u5438\u56f0\u96e3\u3002\u80f8\u90e8X\u5149\u5982\u5716\u3002\r\u53ef\u9810\u671f\u6703\u51fa\u73fe\u4e0b\u5217\u80ba\u90e8\u7570\u5e38\uff0c\u4f55\u8005\u9664\u5916\uff1f\nA. \u4fb7\u9650\u6027\u80ba\u90e8\u75be\u75c5\nB. \u80ba\u6ce1\u63db\u6c23\u4f4e\u4e0b (hypoventilation)\nC. \u963b\u585e\u6027\u80ba\u90e8\u75be\u75c5\nD. \u63db\u6c23-\u704c\u6ce8 (V-Q) \u7570\u5e38\nE. \u80ba\u52d5\u8108\u9ad8\u58d3\u75c7\n": "(C)", "101-2.\n\u4e0b\u5217\u6709\u95dc\u80ba\u7d50\u6838\u75c5\u85e5\u7269\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\r( R= Rifampin, Z= Pyrazinamide, E= Ethambutol, H= INH )\nA. Pyrazinamide \u5c0d\u5b55\u5a66\u61c9\u5c6c\u5b89\u5168\nB. \u5c0d INH\u6709\u6297\u85e5\u6027\u8005\uff0c\u53ea\u670dRZE 6\u500b\u6708\u4ea6\u53ef\nC. \u7121\u6cd5\u670d\u7528 Pyrazinamide \u8005\uff0c\u53ef\u670d HRE 9\u500b\u6708\nD. \u5c0d INH\u548cRifampin \u6709\u6297\u85e5\u6027\u8005\uff0c\u61c9\u670dZE 18\u500b\u6708\nE. Ethambutol \u6709\u5f15\u8d77\u8996\u795e\u7d93\u708e\u4e4b\u526f\u4f5c\u7528\n": "(D)", "101-3.\n\u4e0b\u5217\u6709\u95dc\u7b2c\u4e00\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u65b0TNM\u5206\u985e\u6cd5\uff0cT1a\u8207T1b\u4e4b\u5206\u5225\u754c\u7dda\u662f\u816b\u7624\u76f4\u5f913\u516c\u5206\nB. \u5728\u80ba\u8449\u5207\u9664\u5f8c\uff0c\u9808\u52a0\u5c40\u90e8\u653e\u5c04\u7dda\u6cbb\u7642\nC. \u5728\u80ba\u8449\u5207\u9664\u5f8c\uff0c\u9808\u8f14\u52a9cisplatin-based\u5316\u7642\nD. \u5728\u80ba\u8449\u5207\u9664\u5f8c\uff0c\u9808\u8f14\u52a9\u6a19\u9776\u6cbb\u7642\nE. \u5c11\u6709\u9ad8\u8840\u9223 ( hypercalcemia )\u4e4b\u60c5\u5f62\n": "(E)", "101-4.\n\u7537\u6027\uff0c61\u6b72\uff0c\u6709\u5438\u7159\u53f2\uff0c\u4e3b\u8a34\u54b3\u55fd\u548c\u5598\uff0c\u80f8\u90e8X\u5149\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u7a2e\u8a3a\u65b7\u6700\u53ef\u80fd\uff1f\nA. \u9c57\u72c0\u7d30\u80de\u80ba\u764c\nB. \u5c0f\u7d30\u80de\u80ba\u764c\nC. \u6dcb\u5df4\u7624\nD. \u4e3b\u52d5\u8108\u7624\nE. \u7532\u72c0\u817a\u816b\n": "(E)", "101-5.\n\u4e0b\u5217\u6709\u95dc\u963b\u585e\u6027\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4 ( OSAHS ) \u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u7761\u7720\u4e2d\u51fa\u73fe apnea \u6216 hypopnea \u81f3\u5c11\u6bcf\u5c0f\u664220\u6b21\nB. \u5176\u591c\u9593\u7761\u7720\u6642\u9593\u6703\u660e\u986f\u5ef6\u9577\nC. \u61c9\u5148\u7528\u85e5\u7269\u6cbb\u7642\uff0c\u7121\u6548\u5f8c\u624d\u5617\u8a66\u547c\u5438\u5668 CPAP\nD. \u82e5\u5408\u4f75\u7cd6\u5c3f\u75c5\u6642\uff0c\u8f03\u5e38\u51fa\u73fe\u80f0\u5cf6\u7d20\u6297\u6027 ( resistance )\nE. \u5176\u5e73\u5747\u8840\u58d3\u6703\u8f03\u9ad8\uff0c\u4f46\u8207\u591c\u9593\u7f3a\u6c27\u7121\u95dc\n": "(D)", "101-6.\n\u7537\u602738\u6b72\uff0c\u6709\u5438\u7159\u53f2\uff0c\u56e0\u767c\u71d2\u3001\u54b3\u3001\u5598\u4f86\u6025\u8a3a\uff0c\u80f8\u90e8X\u5149\u5982\u57161\uff0c\u9694\u5929\u5598\u52a0\u5287\u3001\u80f8\u90e8X\u5149\u5982\u57162\uff0c\u5176\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u6d41\u611f\u80ba\u708e\nB. \u8461\u8404\u7403\u83cc\u80ba\u708e\nC. \u7da0\u81bf\u687f\u83cc\u80ba\u708e\nD. \u514b\u96f7\u767d ( Klebsiella ) \u83cc\u80ba\u708e\nE. \u9000\u4f0d\u8ecd\u4eba\u75c7\u80ba\u708e\n": "(A)", "101-7.\n\u7d30\u83cc\u6027\u80ba\u708e\u5408\u4f75\u808b\u819c\u7a4d\u6db2\uff0c\u4e0b\u5217\u4f55\u7a2e\u808b\u819c\u7a4d\u6db2\u4e4b\u6578\u64da\u8868\u793a\u9808\u63d2\u80f8\u7ba1\u5f15\u6d41\uff1f\nA. PMN > 90%\nB. WBC > 1000/mm3\nC. Glucose < 100 mg/dL\nD. pH < 7.2\nE. LDH > 300 IU/L\n": "(D)", "101-8.\n\u4e0b\u5217\u6709\u95dc\u6c23\u5598\u75c5\u5b55\u5a66\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u61f7\u5b55\u671f\u9593\uff0c\u6c23\u5598\u90fd\u6703\u6539\u5584\uff0c\u53ef\u6e1b\u85e5\nB. \u61f7\u5b55\u671f\u9593\uff0c\u61c9\u5118\u91cf\u907f\u514d\u4f7f\u7528\u5438\u5165\u6027\u985e\u56fa\u9187\nC. \u8336\u9e7c\u88fd\u5291\u53ef\u80fd\u5f15\u8d77\u7578\u80ce\uff0c\u61c9\u907f\u514d\u670d\u7528\nD. \u8981\u5118\u91cf\u907f\u514d\u5f15\u8d77\u6025\u6027\u60e1\u5316\uff0c\u5176\u4ed6\u6cbb\u7642\u540c\u4e00\u822c\u4eba\nE. \u7522\u5f8c\u61c9\u907f\u514d\u54fa\u4e73\uff0c\u4ee5\u514d\u5b30\u5152\u5403\u5230\u6c23\u5598\u7528\u85e5\n": "(D)", "101-9.\n\u7537\u6027\uff0c83\u6b72\uff0c\u6709\u5438\u7159\u53f2\uff0c\u56e0\u767c\u71d2\u3001\u54b3\u55fd\u6709\u75f0\u4f86\u8a3a\uff0c\u80f8\u90e8X\u5149\u548c\u65b7\u5c64\u5982\u5716\u6240\u793a\uff0c\u5176\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u7a7a\u6d1e\u6027\u80ba\u764c\u4f75\u963b\u585e\u6027\u80ba\u708e\nB. \u80ba\u708e\u4f75\u80ba\u81bf\u760d ( abscess )\nC. \u80ba\u708e\u4f75\u6c23\u56ca ( pneumatocele )\nD. \u80ba\u56ca\u816b ( lung cyst ) \u4f75\u80ba\u708e\nE. \u80ba\u7d50\u6838\n": "(B)", "101-10.\n\u4e0b\u5217\u4f55\u8005\u662f\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 ( COPD )\u6709 air trapping \u4e4b\u80ba\u529f\u80fd\u8b8a\u5316\uff1f\r(1)TV \u6e1b\u5c11\r(2)FRC \u6e1b\u5c11\r(3)RV \u589e\u52a0\r(4) RV/TLC \u4e0a\u5347\nA. (1)+(2)\nB. (1)+(3)\nC. (2)+(3)\nD. (2)+(4)\nE. (3)+(4)\n": "(E)", "101-11.\n\u4e0b\u5217\u4f55\u7a2e\u60c5\u6cc1\u53ef\u898b\u65bc\u767b\u4e0a\u9ad8\u5c71\u4e0a\u7684\u4eba\uff1f\r(1) PaO2 \u4e0b\u964d\r(2)PaCO2 \u4e0b\u964d\r(3)PaCO2 \u4e0a\u5347\r(4)PAO2-PaO2 \u4e0a\u5347\r(5) PAO2-PaO2 \u4e0b\u964d\nA. (1+)(2)\nB. (1)+(3)\nC. (2)+(4)\nD. (3)+(4)\nE. (3)+(5)\n": "(A)", "101-12.\n\u6839\u64da\u5be6\u8b49\u91ab\u5b78\uff0c\u6210\u4eba\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4 (ARDS)\u521d\u671f\u6cbb\u7642\u4e4b\u901a\u6c23\u547c\u5438\u8a2d\u5b9a\u70ba\u4f55\uff1f\r(1)\u6f6e\u6c50\u5bb9\u7a4d (TV) <= 6mL/kg PBW\r(2)PEEP 10-20 cmH2O,\r(3)\u9ad8\u539f (plateau )\u58d3\u529b <= 30 cm H2O\r(4) \u547c\u5438\u6b21\u6578<= 20 \u6b21/\u5206\nA. (1)+(2)\nB. (1)+(3)\nC. (2)+(3)\nD. (2)+(4)\nE. (3)+(4)\n": "(B)", "101-13.\n\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u6700\u5e38\u898b\u7684\u9593\u8cea\u6027\u80ba\u75c5(interstitial lung disease, ILD)\nA. \u985e\u8089\u7624(Sarcoidosis)\nB. \u85e5\u7269\u76f8\u95dc\u7684\u9593\u8cea\u6027\u80ba\u75c5(Drug-induced ILD)\nC. \u8077\u696d\u6216\u74b0\u5883\u76f8\u95dc\u7684\u9593\u8cea\u6027\u80ba\u75c5(Occupational and environmental-related ILD)\nD. \u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u76f8\u95dc\u7684\u9593\u8cea\u6027\u80ba\u75c5(Connective tissue disease-related ILD)\nE. \u81ea\u767c\u6027\u9593\u8cea\u6027\u80ba\u708e(Idiopathic interstitial pneumonia)\n": "(E)", "101-14.\n\u4ee5\u4e0b\u95dc\u65bc\u5404\u985e\u708e\u75c7\u7d30\u80de\u5728\u6c23\u5598(asthma)\u81f4\u75c5\u6a5f\u8f49\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u80a5\u80d6\u7d30\u80de(mast cell)\u548c\u904e\u654f\u539f\u9020\u6210\u7684\u6025\u6027\u7d30\u652f\u6c23\u7ba1\u6536\u7e2e\u6709\u95dc\nB. \u55dc\u4e2d\u6027\u767d\u8840\u7403(neutrophil)\u5728\u6c23\u5598\u767c\u4f5c\u7684\u65e9\u671f\u53cd\u61c9\u4e2d\u626e\u6f14\u91cd\u8981\u89d2\u8272\nC. \u55dc\u4f9d\u7d05\u767d\u8840\u7403(eosinophil)\u5728\u6c23\u5598\u767c\u4f5c\u7684\u665a\u671f\u53cd\u61c9\u4e2d\u626e\u6f14\u91cd\u8981\u89d2\u8272\nD. \u76f8\u8f03\u65bc\u6b63\u5e38\u4eba\u7684\u6c23\u9053\uff0c\u6c23\u5598\u75c5\u60a3\u7684T helper 2 \u7d30\u80de\u6bd4\u65bcT helper 1 \u7d30\u80de\u6d3b\u5316\nE. \u547c\u5438\u4e0a\u76ae\u7d30\u80de\u4e5f\u53c3\u8207\u4e86\u6c23\u5598\u7684\u708e\u75c7\u53cd\u61c9\n": "(B)", "101-15.\n\u4e0b\u5217\u95dc\u65bc\u80ba\u81bf\u760d\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u662f\u4e00\u7a2e\u4e9e\u6025\u6027\uff0c\u9032\u5c55\u8f03\u7de9\u6162\u7684\u611f\u67d3\u75c7\nB. \u75c5\u60a3\u7684\u81e8\u5e8a\u8868\u73fe\u5e38\u898b\u662f\u6162\u6027\u54b3\u55fd\uff0c\u6fc3\u75f0\uff0c\u75b2\u5026\uff0c\u9ad4\u91cd\u6e1b\u8f15\u53ca\u8ca7\u8840\nC. \u75c5\u60a3\u5728\u767c\u71d2\u524d\u5e38\u6703\u5148\u51fa\u73fe\u51b7\u986b\nD. \u5e38\u898b\u65bc\u53e3\u8154\u885b\u751f\u4e0d\u597d\u6216\u662f\u5bb9\u6613\u55c6\u5230\u7684\u75c5\u60a3\nE. \u901a\u5e38\u662f\u53ad\u6c27\u6027\u7d30\u83cc\n": "(C)", "101-16.\n\u4e0b\u5217\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5728\u5168\u4e16\u754c\uff0c\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u662f\u7b2c\u516d\u5927\u6b7b\u4ea1\u539f\u56e0\nB. \u5438\u83f8\u662f\u6700\u91cd\u8981\u7684\u81f4\u75c5\u539f\u56e0\uff0c\u548c\u5438\u83f8\u91cf\u53ca\u958b\u59cb\u5438\u83f8\u7684\u5e74\u9f61\u6709\u95dc\nC. \u6709\u6c23\u9053\u654f\u611f\u6027(airway hyperresponsiveness)\u7684\u5438\u83f8\u8005\uff0c\u66f4\u5bb9\u6613\u767c\u751f\nD. \u9999\u83f8\u5c0d\u6c23\u9053\u7684\u5f71\u97ff\u4e3b\u8981\u767c\u751f\u5728\u7d30\u652f\u6c23\u7ba1\uff0c\u4e0d\u6703\u5230\u9054\u80ba\u6ce1\nE. \u9664\u6212\u83f8\u548c\u63d0\u4f9b\u6c27\u6c23\u7d66\u9577\u671f\u7f3a\u6c27\u8005\uff0c\u78ba\u77e5\u53ef\u4ee5\u63d0\u9ad8\u75c5\u60a3\u7684\u5b58\u6d3b\u671f\uff1b\u76ee\u524d\u6240\u6709\u85e5\u7269\u5c0d\u75c5\u60a3\u5b58\u6d3b\u671f\u7684\u6539\u5584\u90fd\u4ecd\u6709\u722d\u8b70\n": "(D)", "101-17.\n\u4e0b\u5217\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u7684\u80ba\u529f\u80fd\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7528\u529b\u5410\u6c23\u7684\u6c23\u9ad4\u6d41\u901f\u4e0b\u964d\nB. \u6b98\u9918\u80ba\u5bb9\u7a4d(residual volume)\u589e\u52a0\nC. \u6b98\u9918\u80ba\u5bb9\u7a4d\u4f54\u7e3d\u80ba\u5bb9\u7a4d(total lung capacity)\u7684\u6bd4\u4f8b\u4e0a\u5347\nD. \u529f\u80fd\u6027\u6b98\u6c23\u91cf(functional residual capacity)\u6e1b\u5c11\nE. \u5e38\u898b\u901a\u6c23\u53ca\u704c\u6d41\u4e0d\u5747(ventilation-perfusion mismatching)\n": "(D)", "101-18.\n\u4e0b\u5217\u95dc\u65bc\u808b\u819c\u7a4d\u6db2\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u808b\u819c\u7a4d\u6db2\u5c0d\u8840\u6e05\u7684\u86cb\u767d\u8cea\u6bd4\u4f8b\u5927\u65bc0.5\uff0c\u808b\u819c\u7a4d\u6db2\u5c0d\u8840\u6e05\u7684LDH\u6bd4\u4f8b\u5927\u65bc0.6\uff0c\u6216\u662f\u808b\u819c\u7a4d\u6db2\u7684LDH\u5927\u65bc\u8840\u6e05LDH\u6b63\u5e38\u503c\u4e0a\u9650\u7684\u4e09\u5206\u4e4b\u4e8c\uff0c\u7b26\u5408\u4ee5\u4e0a\u81f3\u5c11\u4e8c\u500b\u689d\u4ef6\u8005\uff0c\u5373\u70baLight's criteria\u5b9a\u7fa9\u7684exudate\nB. Light's criteria\u7684\u654f\u611f\u6027\u5f88\u9ad8\uff0c\u4f46\u7279\u7570\u6027\u8f03\u5dee\nC. \u7576\u4f9d\u7167Light's criteria\u7684\u5b9a\u7fa9\u70baexudate\uff0c\u4f46\u81e8\u5e8a\u61f7\u7591\u70batransudate\u6642\uff0c\u53ef\u7528\u8840\u6e05\u5c0d\u808b\u819c\u7a4d\u6db2\u86cb\u767d\u8cea\u7684\u5dee\u503c\u5927\u65bc3.1 g/dL\u4f86\u6392\u9664\u5176\u70baexudate\nD. \u808b\u819c\u7a4d\u6db2\u4e2d\u7684NT-proBNP\u82e5\u5927\u65bc1500 pg/mL\uff0c\u5373\u5f88\u53ef\u80fd\u662f\u9b31\u8840\u6027\u5fc3\u8870\u7aed\u6240\u9020\u6210\u7684\u808b\u819c\u7a4d\u6db2\nE. \u809d\u6e90\u6027\u808b\u819c\u7a4d\u6db2(hepatic hydrothorax)\u4e3b\u8981\u767c\u751f\u5728\u53f3\u5074\n": "(A)", "101-19.\n\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u63a5\u53d7\u5668(epidermal growth factor receptor, EGFR)\u5728\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4f54\u6709\u4e00\u500b\u975e\u5e38\u91cd\u8981\u7684\u89d2\u8272\uff0c\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. EGFR\u916a\u80fa\u9178\u6fc0\u8122\u7684\u7a81\u8b8a\u5e7e\u4e4e\u53ea\u51fa\u73fe\u5728\u80ba\u817a\u764c\nB. \u5177\u6709\u9019\u985e\u7a81\u8b8a\u7684\u75c5\u60a3\u7d93\u5e38\u662f\u4e0d\u5438\u83f8\uff0c\u5973\u6027\u53ca\u6771\u65b9\u4eba\nC. \u6700\u5e38\u898b\u7684\u7a81\u8b8a\u662fexon 19 deletion\u548cL858R point mutation\nD. \u5177\u6709\u9019\u985e\u7a81\u8b8a\u7684\u80ba\u764c\u5c0d\u53e3\u670d\u7684EGFR\u916a\u80fa\u9178\u6fc0\u8122\u6291\u5236\u5291\u7684\u6709\u6548\u7387(Objective response rate)\u8d85\u904e\u4e5d\u6210\nE. T790M\u7a81\u8b8a\u662f\u9019\u4e9b\u75c5\u60a3\u5f8c\u4f86\u51fa\u73fe\u6297\u85e5\u6027\u6700\u91cd\u8981\u7684\u539f\u56e0\n": "(D)", "101-20.\n\u9ad8\u89e3\u50cf\u5ea6\u96fb\u8166\u65b7\u5c64(high resolution computed tomography, HRCT)\u5728\u9593\u8cea\u6027\u80ba\u75c5\u7684\u9451\u5225\u8a3a\u65b7\u4e0a\u5177\u6709\u76f8\u7576\u5927\u7684\u50f9\u503c\uff0c\u5728\u67d0\u4e9b\u60c5\u6cc1\u4e0b\uff0c\u751a\u81f3\u8db3\u4ee5\u8a3a\u65b7\u800c\u4e0d\u9700\u8981\u75c5\u60a3\u5192\u96aa\u505a\u80ba\u5207\u7247\u3002\u4ee5\u4e0b\u5e7e\u7a2e\u75be\u75c5\u4e2d\uff0c\u54ea\u4e00\u4e9b\u5373\u662f\u5728HRCT\u4e0a\u5177\u6709\u8868\u5fb5\u6027\u7684\u5f71\u50cf\u8b8a\u5316\u3002\r(1)\u81ea\u767c\u6027\u9593\u8cea\u6027\u80ba\u7e96\u7dad\u5316(idiopathic pulmonary fiborsis)\r(2)\u7d30\u652f\u6c23\u7ba1\u80ba\u6ce1\u7d30\u80de\u764c(bronchioloalveolar cell carcinoma)\r(3)\u985e\u8089\u7624(sarcoidosis)\r(4)\u80ba\u862d\u683c\u7f55\u6c0f\u7d30\u80de\u7d44\u7e54\u7403\u589e\u751f\u75c7(pulmonary Langerhans cell histiocytosis)\r(5)\u5de8\u7d30\u80de\u80ba\u708e(cytomegalovirus pneumonitis)\r(6)\u514b\u96f7\u4f2f\u6c0f\u80ba\u708e(Klebsiella pneumonia)\nA. (1)+(3)+(4)\nB. (2)(3)+(6)\nC. (1)+(2)+(4)\nD. (2)+(4)+(6)\nE. (3)+(5)+(6)\n": "(A)", "101-21.\n\u4e0b\u5217\u54ea\u4e9b\u662f\u5728\u9580\u8a3a\u6cbb\u7642\u7684\u793e\u5340\u578b\u80ba\u708e(outpatient community-acquired pneumonia)\u6700\u5e38\u898b\u7684\u81f4\u75c5\u539f\r(1)Streptococcus pneumoniae\r(2)Klebsiella pneumoniae\r(3)Mycoplasma pneumoniae\r(4)Chlamydia pneumoniae\r(5)Staphylococcus aureus\r(6)Haemophilus influenzae\nA. (1)+(2)+(5)+(6)\nB. (1)+(3)+(4)+(6)\nC. (2)+(3)+(4)+(5)\nD. (1)+(2)+(4)+(5)\nE. (1)+(4)+(5)+(6)\n": "(B)", "101-22.\n\u8acb\u554f\u6839\u64daWHO\u5c0d\u8d85\u7d1a\u6297\u85e5\u6027\u7d50\u6838\u83cc(Extensively drug-resistant tuberculosis\uff0cXDR-TB)\u7684\u5b9a\u7fa9\uff0c\u5fc5\u9808\u81f3\u5c11\u5c0d\u4e0b\u5217\u54ea\u4e9b\u85e5\u7269\u6709\u6297\u85e5\u6027\uff1f\r(1)Isoniazid\r(2)Rifampicin\r(3)Ethambutol\r(4)Pyrazinamide\r(5)\u6240\u6709\u7a2e\u985e\u7684fluoroquinolones\r(6)kanamycin\uff0ccapreomycin\uff0camikacin\u5176\u4e2d\u4e00\u7a2e\nA. (1)+(2)\nB. (1)+(2)+(3)+(4)\nC. (1)+(2)+(3)+(4)+(5)\nD. (1)+(2)+(3)+(4)+(6)\nE. (1)+(2)+(5)+(6)\n": "(E)", "102-1.\n\u4e0b\u5217\u5404\u7a2e\u904e\u654f\u6027\u80ba\u708e(hypersensitivity pneumonitis, HP)\u548c\u904e\u654f\u539f\u7684\u76f8\u95dc\u6027\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8fb2\u592b\u80ba\u708eFarmer's lung - Thermophilic actinomycetes\nB. \u5be6\u9a57\u5ba4\u5de5\u4f5c\u8005\u80ba\u708eLaboratory worker's HP - Male rat urine\nC. \u71b1\u6c34\u6c60\u80ba\u708eHot tub lung - Mycobacterium avium complex\nD. \u81ea\u4f86\u6c34\u80ba\u708eTap water lung - Legionella spp.\nE. \u98fc\u990a\u8005\u80ba\u708eBreeder's lung - Pigeon proteins\n": "(D)", "102-2.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u904e\u654f\u6027\u80ba\u652f\u6c23\u7ba1\u9eb4\u83cc\u75c5(allergic bronchopulmonary aspergillosis)\u7684\u4e3b\u8981\u8a3a\u65b7\u689d\u4ef6\uff1f\nA. \u75f0\u6db2Aspergillus fumigatus\u57f9\u990a\u967d\u6027\nB. \u5c0dAspergillus fumigatus\u7684\u76ae\u819a\u654f\u611f\u8a66\u9a57\u967d\u6027\nC. \u8840\u6e05IgE\u4e0a\u5347\nD. \u4e2d\u592e\u578b\u652f\u6c23\u7ba1\u64f4\u5f35\nE. \u652f\u6c23\u7ba1\u6c23\u5598\n": "(A)", "102-3.\n\u80ba\u764c\u764c\u578b\u7684\u5224\u65b7\uff0c\u5c0d\u80ba\u764c\u6cbb\u7642\u85e5\u7269\u7684\u9078\u64c7\u5177\u6709\u76f8\u7576\u5927\u7684\u5f71\u97ff\uff0c\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5c0f\u7d30\u80de\u80ba\u764c\u7684\u9996\u9078\u8655\u65b9\u70bacisplatin + etoposide\nB. Gemcitabine\u5c0d\u9c57\u72c0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u6cbb\u7642\u6548\u679c\u6bd4Pemetrexed\u597d\nC. Pemetrexed\u5c0d\u975e\u9c57\u72c0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u6cbb\u7642\u6548\u679c\u6bd4Gemcitabine\u597d\nD. Bevacizumab\u5c0d\u817a\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u6cbb\u7642\u6548\u679c\u6bd4\u5c0d\u9c57\u72c0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u597d\nE. Gefitinib\u5c0d\u817a\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u6cbb\u7642\u6548\u679c\u6bd4\u5c0d\u9c57\u72c0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u597d\n": "(D)", "102-4.\n\u4e0b\u5217\u95dc\u65bc\u54b3\u55fd\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8ca0\u8cac\u54b3\u55fd\u7684\u611f\u89ba\u795e\u7d93\u662fC-fiber\nB. \u8188\u795e\u7d93(phrenic nerve)\u662f\u8ca0\u8cac\u50b3\u5c0e\u54b3\u55fd\u611f\u89ba\u7684\u4e3b\u8981\u795e\u7d93\nC. \u9f3b\u6d95\u5012\u6d41\u662f\u6162\u6027\u54b3\u55fd\u7684\u5e38\u898b\u539f\u56e0\nD. \u6c23\u5598\u8a98\u767c\u8a66\u9a57\u5982\u679c\u662f\u9670\u6027\uff0c\u5927\u81f4\u53ef\u4ee5\u6392\u9664\u6c23\u5598\u662f\u75c5\u60a3\u6162\u6027\u54b3\u55fd\u7684\u539f\u56e0\nE. \u80c3\u98df\u9053\u9006\u6d41\u4e5f\u6703\u5f15\u8d77\u54b3\u55fd\n": "(B)", "102-5.\n\u81e8\u5e8a\u4e0a\u6703\u9020\u6210\u75c5\u60a3\u7684\u4e00\u6c27\u5316\u78b3\u80ba\u7030\u6563\u91cf(diffusion capacity of carbon monoxide\uff0cDLCO)\u4e0b\u964d\u7684\u5e38\u898b\u539f\u56e0\u4e0d\u5305\u62ec\uff1a\nA. \u80ba\u6c23\u816b\nB. \u80ba\u52d5\u8108\u9ad8\u58d3\nC. \u6c23\u5598\u6025\u6027\u767c\u4f5c\nD. \u80ba\u7e96\u7dad\u5316\nE. \u8ca7\u8840\n": "(C)", "102-6.\n\u4e00\u540d60\u6b72\u7537\u6027\u56e0\u70ba\u6557\u8840\u75c7\u5408\u4f75\u547c\u5438\u8870\u7aed\u81f3\u6025\u8a3a\u6c42\u8a3a\uff0c\u5165\u9662\u6642\u7684\u8840\u6db2\u6aa2\u67e5\u767c\u73fe\u767d\u8840\u7403\u6578\u70ba15900/\u03bcL\uff0c\u8840\u7d05\u7d20\u70ba11.0 g/dl\uff0c\u8840\u5bb9\u6bd4\u70ba33.3%\uff0c\u8840\u5c0f\u677f\u6578\u70ba457000/\u03bcL\u3002\u75c5\u60a3\u5728\u4f7f\u7528\u975e\u518d\u5438\u5165\u6027\u9762\u7f69(non-rebreathing mask)\u6642\u52d5\u8108\u8840\u7684pH\u503c\u70ba7.196\uff0c\u6c27\u6c23\u5206\u58d3\u70ba352.3 mmHg\uff0c\u4e8c\u6c27\u5316\u78b3\u5206\u58d3\u70ba40.1 mmHg\uff0c\u78b3\u9178\u6c2b\u9e7d\u6fc3\u5ea6\u70ba15.2 mmol/L\uff0c\u6c27\u6c23\u98fd\u548c\u5ea6\u70ba100%\u3002\u8acb\u554f\u6b64\u75c5\u60a3\u52d5\u8108\u8840\u6db2\u4e2d\u7684\u542b\u6c27\u91cf(oxygen content\uff0cCaO2) \u4f30\u8a08\u7d04\u70ba\u591a\u5c11(mL O2/dL)\uff1f\nA. 15.8\nB. 296.6\nC. 14.9\nD. 45.3\nE. 76.3\n": "(A)", "102-7.\n\u80ba\u52d5\u8108\u6813\u585e(pulmonary thromboembolism)\u5e38\u5f15\u8d77\u7684\u80ba\u751f\u7406\u7570\u5e38\u4e0d\u5305\u62ec\uff1a\nA. \u80ba\u8840\u7ba1\u963b\u529b\u589e\u52a0 (increased pulmonary vascular resistance)\nB. \u6c23\u9053\u963b\u529b\u589e\u52a0 (increased airway resistance)\nC. \u80ba\u6ce1\u904e\u5ea6\u63db\u6c23 (alveolar hyperventilation)\nD. \u6c23\u9ad4\u4ea4\u63db\u969c\u7919 (impaired gas exchange)\nE. \u80ba\u9806\u5f9e\u6027\u589e\u52a0 (increased pulmonary compliance)\n": "(E)", "102-8.\n\u4e0b\u5217\u4f55\u8005\u5c0d\u65bc\u6539\u5584\u6210\u4eba\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(ARDS)\u7684\u9810\u5f8c\u5177\u6709\u6700\u660e\u78ba\u7684\u8b49\u64da\uff1f\nA. \u4f4e\u6f6e\u6c23\u5bb9\u7a4d(low tidal volume)\u7684\u547c\u5438\u5668\u8a2d\u5b9a\nB. \u8f03\u9ad8\u7684\u5410\u6c23\u672b\u967d\u58d3(PEEP)\u7684\u547c\u5438\u5668\u8a2d\u5b9a\nC. \u4fef\u81e5\u901a\u6c23(prone position)\nD. \u5168\u8eab\u6027\u985e\u56fa\u9187\nE. \u8449\u514b\u819c\u9ad4\u5916\u7dad\u751f\u7cfb\u7d71(ECMO)\n": "(A)", "102-9.\n\u67d0\u4e9b\u80ba\u90e8\u75be\u75c5\u7684\u767c\u751f\u7387\u6709\u6027\u5225\u4e0a\u7684\u5dee\u7570\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(1)\u6dcb\u5df4\u8840\u7ba1\u5e73\u6ed1\u808c\u589e\u751f\u75c7(Lymphangioleiomyomatosis)\u8f03\u5e38\u898b\u65bc\u5973\u6027 (2)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(Rheumatoid arthritis)\u76f8\u95dc\u7684\u9593\u8cea\u6027\u80ba\u75c5\u8f03\u5e38\u898b\u65bc\u5973\u6027 (3)\u7d50\u7bc0\u6027\u786c\u5316\u75c7(Tuberous sclerosis)\u76f8\u95dc\u7684\u9593\u8cea\u6027\u80ba\u75c5\u8f03\u5e38\u898b\u65bc\u7537\u6027 (4)\u81ea\u767c\u6027\u9593\u8cea\u6027\u80ba\u7e96\u7dad\u5316(Idiopathic pulmonary fibrosis)\u8f03\u5e38\u898b\u65bc\u7537\u6027 (5)\u5875\u80ba\u75c7(Pneumoconiosis)\u8f03\u5e38\u898b\u65bc\u7537\u6027\nA. (1)+(2)+(3)\nB. (1)+(4)+(5)\nC. (2)+(3)+(4)\nD. (1)+(2)+(5)\nE. (2)+(4)+(5)\n": "(B)", "102-10.\n\u4e0b\u5217\u95dc\u65bc\u54b3\u8840\u7684\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(1)\u5728\u5df2\u958b\u767c\u570b\u5bb6\uff0c\u75c5\u6bd2\u6216\u7d30\u83cc\u6027\u652f\u6c23\u7ba1\u708e\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (2)\u5728\u5df2\u958b\u767c\u570b\u5bb6\uff0c\u80ba\u764c\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (3)\u4ee5\u5168\u7403\u800c\u8a00\uff0c\u80ba\u7d50\u6838\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (4)\u4ee5\u5168\u7403\u800c\u8a00\uff0c\u80ba\u764c\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (5)\u80ba\u52d5\u8108\u51fa\u8840\u6642\u7684\u51fa\u8840\u91cf\u6bd4\u8f03\u5927 (6)\u652f\u6c23\u7ba1\u52d5\u8108\u51fa\u8840\u6642\u7684\u51fa\u8840\u91cf\u6bd4\u8f03\u5927\nA. (1)+(3)+(5)\nB. (2)+(3)+(6)\nC. (1)+(4)+(5)\nD. (2)+(3)+(5)\nE. (1)+(3)+(6)\n": "(E)", "102-11.\n\u514d\u75ab\u7d44\u7e54\u67d3\u8272\u662f\u9451\u5225\u60e1\u6027\u816b\u7624\u764c\u578b\u7684\u91cd\u8981\u5de5\u5177\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u7d44\u5408\u6b63\u78ba? (1)\u80ba\u817a\u764c-TTF-1 (2)\u80ba\u817a\u764c-CK7 (3)\u9c57\u72c0\u4e0a\u76ae\u764c-CK20 (4)\u9c57\u72c0\u4e0a\u76ae\u764c-CK56 (5)\u5c0f\u7d30\u80de\u80ba\u764c-TTF-1 (6)\u5c0f\u7d30\u80de\u80ba\u764c-CK56 (7)\u808b\u819c\u9593\u76ae\u7624-TTF-1 (8)\u808b\u819c\u9593\u76ae\u7624-WT-1\nA. (1)+(3)+(6)+(8)\nB. (1)+(4)+(5)+(8)\nC. (2)+(3)+(5)+(7)\nD. (1)+(2)+(6)+(8)\nE. (1)+(2)+(5)+(8)\n": "(E)", "102-12.\n\u4e0b\u5217\u6709\u95dc\u547c\u5438\u56f0\u96e3(dyspnea)\u4e4b\u6558\u8ff0,\u4f55\u8005\u6b63\u78ba?\nA. \u547c\u5438\u56f0\u96e3\u901a\u5e38\u8207\u6240\u6e2c\u91cf\u4e4b\u8840\u6c27\u5206\u58d3(PO2)\u6709\u95dc\nB. \u547c\u5438\u56f0\u96e3\u901a\u5e38\u8207\u547c\u5438\u901f\u7387\u6210\u6b63\u76f8\u95dc\nC. \u8108\u885d\u5f0f\u8840\u6c27\u5075\u6e2c\u5100(pulse oximetry) \u7121\u6cd5\u4f5c\u70ba\u547c\u5438\u56f0\u96e3\u4e4b\u6cbb\u7642\u6307\u5f15\nD. \u53ef\u5f85\u56e0(codeine)\u662f\u4e00\u7a2e\u5f37\u7684\u9d09\u7247\u985e\u85e5,\u53ef\u7de9\u89e3\u56b4\u91cd\u7684\u547c\u5438\u56f0\u96e3\u3002\nE. \u55ce\u5561(morphine)\u4e0d\u53ef\u4f5c\u70ba\u7de9\u89e3\u547c\u5438\u56f0\u96e3\u4e4b\u7528\n": "(C)", "102-13.\n\u4e0b\u5217\u6709\u95dc\u6210\u4eba\u6c23\u5598\u75c5\u8a3a\u7642\u4e4b\u6558\u8ff0,\u4f55\u8005\u932f\u8aa4?\nA. \u65b0\u7248\u8a3a\u7642\u6307\u5f15\u662f\u4ee5\u63a7\u5236\u662f\u5426\u826f\u597d\u70ba\u6cbb\u7642\u4f9d\u64da\nB. \u82e5\u591c\u9593\u56e0\u75c7\u72c0\u9192\u4f86\u4e4b\u6b21\u6578\u6bcf\u6708\u4e0d\u591a\u65bc2\u6b21,\u8868\u793a\u63a7\u5236\u826f\u597d\nC. \u6c23\u5598\u4e4b\u56b4\u91cd\u5ea6\u5206\u985e\u4ecd\u7136\u662f\u521d\u59cb\u6cbb\u7642\u4e4b\u91cd\u8981\u4f9d\u64da\nD. \u904e\u53bb\u4e00\u5e74\u5167\u66fe\u56e0\u6025\u6027\u60e1\u5316\u9700\u53e3\u670d\u985e\u56fa\u9187\u4e8c\u6b21\u4ee5\u4e0a,\u5373\u5c6c\u63a7\u5236\u4e0d\u826f\nE. \u80ba\u529f\u80fd\u4e4b\u8ffd\u8e64\u53ef\u4ee5\u4f7f\u7528peak expiratory flow rate(PEFR)\u4e5f\u53ef\u7528FEV1\n": "(C)", "102-14.\n\u7537\u6027,70\u6b72,\u56e0\u6025\u6027\u547c\u5438\u56f0\u96e3\u88ab\u9001\u5230\u6025\u8a3a,\u5176\u80f8\u90e8X\u5149\u548c\u96fb\u8166\u65b7\u5c64\u5982\u5716\u793a ,\u5176\u8a3a\u65b7\u70ba\u4f55?\nA. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316\nB. \u80ba\u52d5\u8108\u9ad8\u58d3\u75c7\u6025\u6027\u60e1\u5316\nC. \u6025\u6027\u80ba\u6813\u585e(thromboembolism)\nD. \u5927\u6ce1\u6027(bullous)\u80ba\u6c23\u816b\nE. \u6dcb\u5df4\u7624(lymphoma)\u58d3\u8feb\u6c23\u9053\n": "(C)", "102-15.\n\u4e0b\u5217\u7b56\u7565\u53ef\u4ee5\u907f\u514d\u6a5f\u68b0\u901a\u6c23\u547c\u5438\u6216\u4f7f\u5176\u4f7f\u7528\u6642\u9593\u6e1b\u5c11,\u4f55\u8005\u9664\u5916?\nA. \u5c0d\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316\u8005,\u53ef\u5148\u63a1\u7528\u975e\u4fb5\u8972\u6027\u901a\u6c23(noninvasive ventilation)\nB. \u5c0d\u67d0\u4e9b\u6025\u6027\u5fc3\u56e0\u6027\u80ba\u6c34\u816b\u8005,\u53ef\u5148\u63a1\u7528\u975e\u4fb5\u8972\u6027\u901a\u6c23\nC. \u5c0d\u6210\u4eba\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(ARDS)\u8005,\u5b9c\u63a1\u7528\u4f4e\u6f6e\u6c23\u5bb9\u7a4d(tidal volume)\nD. \u5c0d\u6025\u6027\u80ba\u640d\u50b7\u8005,\u4f7f\u7528\u6db2\u9ad4\u8f38\u6ce8\u61c9\u8a72\u4fdd\u5b88\nE. \u5728\u5617\u8a66\u81ea\u4e3b\u547c\u5438\u524d,\u5b9c\u7e7c\u7e8c\u4f7f\u7528\u93ae\u975c\u5291(sedative)\u8f38\u6ce8\n": "(E)", "102-16.\n\u4ee5\u4f4e\u5291\u91cf\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cf(LDCT)\u7be9\u6aa2\u80ba\u764c,\u4f9d\u76ee\u524d\u6240\u5f97\u8cc7\u8a0a,\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u78ba\u53ef\u63d0\u9ad8\u65e9\u671f\u80ba\u764c\u4e4b\u8a3a\u65b7\u7387\nB. \u5c0d\u9ad8\u5371\u96aa\u7fa4\u8005, \u53ef\u6e1b\u5c11\u80ba\u764c\u6b7b\u4ea1\u7387\nC. \u662f\u5426\u53ef\u666e\u904d\u65bd\u884c\u65bc\u4f4e\u5371\u96aa\u6027\u65cf\u7fa4,\u5c1a\u7121\u5b9a\u8ad6\nD. \u6700\u5927\u7684\u7f3a\u9ede\u548c\u5371\u96aa\u662f\u8cbb\u7528\u592a\u8cb4\u548c\u8f3b\u5c04\nE. \u9ad8\u507d\u967d\u6027\u662f\u76ee\u524d\u6700\u5927\u7684\u56f0\u64fe\u548c\u5371\u96aa\n": "(D)", "102-17.\n\u7537\u602773\u6b72,\u6709\u5438\u83f8\u53ca\u9ad8\u8840\u58d3\u53f2,\u56e0\u80f8\u75db\u524d\u4f86,\u80f8\u90e8X\u5149\u5982\u5716\u793a,\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\u4f55?\nA. \u5c0f\u7d30\u80de\u80ba\u764c\nB. \u6dcb\u5df4\u7624\nC. \u80f8\u817a\u7624\nD. \u98df\u9053\u816b\u7624\nE. \u4e3b\u52d5\u8108\u7624\n": "(E)", "102-18.\n\u5973\u6027,31\u6b72,\u4e3b\u8a34\u54b3\u55fd\u4e8c\u500b\u6708,\u80f8\u90e8X\u5149\u5982\u5716\u6240\u793a,\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\u4f55?\nA. \u80ba\u7d50\u6838\nB. \u96b1\u7403\u83cc(Cryptococcus)\u611f\u67d3\nC. \u9ef4\u6f3f\u83cc(Mycoplasma)\u611f\u67d3\nD. \u80ba\u708e\u7403\u83cc(S. pneumoniae)\u611f\u67d3\nE. \u80ba\u817a\u764c\n": "(A)", "102-19.\n\u7537\u6027,35\u6b72,\u9577\u671f\u54b3\u55fd\u591a\u75f0,\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u5982\u5716\u793a,\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55?\nA. \u6162\u6027\u652f\u6c23\u7ba1\u708e\nB. \u652f\u6c23\u7ba1\u64f4\u5f35\u75c7\nC. \u80ba\u56ca\u866b(Pneumocystis jirovecii)\u611f\u67d3\nD. \u96b1\u7403\u83cc(Cryptococcus)\u611f\u67d3\nE. \u8f49\u79fb\u764c\n": "(B)", "102-20.\n\u7537\u6027,30\u6b72,\u4e2d\u5ea6\u80a5\u80d6,\u7121\u5438\u83f8\u53f2,\u4e5f\u7121\u547c\u5438\u7cfb\u7d71\u75be\u75c5,\u4e0b\u5217\u80ba\u529f\u80fd\u6578\u503c,\u90a3\u4e9b\u8f03\u7b26\u5408\u5176\u8eab\u6750?  (\u6578\u503c\u662f\u4ee5\u9810\u4f30\u503c\u4e4b%\u8868\u793a)\r(1)FEV1 65% (2) TLC 95% (3)RV 100% (4)DLco 70% (5)Raw 120%\nA. (1)+(2)\nB. (1)+(3)\nC. (2)+(3)\nD. (3)+(4)\nE. (4)+(5)\n": "(C)", "102-21.\n\u4e0b\u5217\u6240\u8ff0,\u90a3\u4e9b\u53ef\u80fd\u8207\u670d\u7528\u6297\u7d50\u6838\u85e5pyrazinamide (PZA)\u6709\u95dc?\r(1)\u8840\u4e2d\u5c3f\u9178\u589e\u52a0 (2)\u8840\u4e2daminotransferase\u589e\u9ad8 (3)\u8840\u4e2d\u5c3f\u7d20\u6c2e(BUN)\u589e\u52a0 (4)\u8840\u4e2dpyridoxine\u529b\u50f9\u6e1b\u5f31 (5)\u8840\u4e2d\u8449\u9ec3\u7d20(lutein)\u529b\u50f9\u4e0b\u964d\nA. (1)+(2)\nB. (1)+(4)\nC. (2)+(3)\nD. (2)+(5)\nE. (3)+(5)\n": "(A)", "102-22.\n\u7576\u52d5\u8108\u8840\u6c27\u5206\u58d3(PaO2)\u964d\u4f4e\u6642, \u5982\u679c\u4f5c\u904e\u5ea6\u63db\u6c23(hyperventilation), \u4f7f\u8840\u4e2d\u4e8c\u6c27\u5316\u78b3\u5206\u58d3(PaCO2)\u4e5f\u4e0b\u964d, \u6b64\u6642\u8166\u8840\u7ba1\u6703\u6709\u4f55\u8b8a\u5316?\r(1)\u963b\u529b\u589e\u52a0 (2)\u963b\u529b\u964d\u4f4e (3)\u8840\u6d41\u589e\u52a0 (4)\u8840\u6d41\u6e1b\u5c11 (5)\u8840\u6d41\u4e0d\u8b8a (6)\u963b\u529b\u4e0d\u8b8a\nA. (1)+(3)\nB. (1)+(4)\nC. (2)+(5)\nD. (3)+(6)\nE. (4)+(6)\n": "(B)", "103-1.\n\u4e0b\u5217\u95dc\u65bc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(Acute respiratory distress syndrome,ARDS)\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. severe ARDS\u5176PaO2/FiO2<100mmHg\nB. \u56e0\u5916\u50b7\u800c\u9020\u6210\u7684ARDS\u9810\u5f8c\u6700\u597d\nC. \u4fef\u81e5(prone position)\u53ef\u6e1b\u5c1190\u5929\u6b7b\u4ea1\u7387\nD. \u80ba\u52d5\u8108\u5c0e\u7ba1\u5728\u8a3a\u65b7\u4e0a\u5f88\u91cd\u8981\nE. \u4f7f\u7528PEEP\u53ef\u6539\u5584shunt-associated hypoxemia\n": "(D)", "103-2.\n\u4e0b\u5217\u4f55\u8005\u6bd4\u8f03\u4e0d\u9069\u5408\u4f7f\u7528\u975e\u4fb5\u8972\u6027\u547c\u5438\u5668(noninvasive positive pressure ventilation)?\nA. \u4e2d\u6216\u91cd\u5ea6COPD\u6025\u6027\u60e1\u5316\nB. \u5fc3\u56e0\u6027\u80ba\u6c34\u816b(cardiogenic pulmonary edema)\nC. \u6557\u8840\u6027\u4f11\u514b\nD. \u514d\u75ab\u4e0d\u5168\u75c5\u4eba\u4f75\u767c\u547c\u5438\u8870\u7aed\nE. \u8179\u90e8\u624b\u8853\u5f8c\u4f75\u767c\u7f3a\u6c27\u6027\u547c\u5438\u8870\u7aed\n": "(C)", "103-3.\n\u4e0b\u5217\u95dc\u65bc\u7d50\u6838\u6027\u808b\u819c\u708e\u9020\u6210\u7684\u808b\u819c\u7a4d\u6c34\u751f\u5316\u53ca\u93e1\u6aa2\u4e4b\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. lymphocyte predominant exudate\nB. adenosine deaminase>40 IU/L\nC. Interferon gamma (INF-r) >140 pg/ml\nD. mesothelial cell\u7684\u6bd4\u7387\u9ad8\nE. smear \u7684acid fast stain \u967d\u6027\u7387 <5%\n": "(D)", "103-4.\n\u6709\u95dcparapneumonic effusion\u4e4b\u751f\u5316\u53ca\u93e1\u6aa2\u9700\u8981\u9032\u4e00\u6b65\u8003\u616e\u80f8\u7ba1\u5f15\u6d41\u7684\u72c0\u6cc1\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. glucose <60mg/dl.\nB. PH<7.3\nC. positive Gram stain\nD. positive culture\nE. presence of gross pus.\n": "(B)", "103-5.\n\u5728\u4e00\u4f4d\u5065\u5eb7\u7684\u5e74\u8f15\u4eba,\u611f\u67d3\u6d41\u611f\u75c5\u6bd2\u5f8c\u4f75\u767c\u6025\u6027\u80ba\u81bf\u760d\u6700\u53ef\u80fd\u7684\u75c5\u539f\u83cc\u70ba?\nA. Legionella pneumophila\nB. Pseudomonas aeruginosa\nC. M. tuberculosis\nD. Aspergillus spp.\nE. Staphylococcus aureus\n": "(E)", "103-6.\n\u4e0b\u5217\u95dc\u65bcCOPD\u75c5\u751f\u7406\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4? (\u61c9\u9078\u51fa\u6240\u6709\u7b54\u6848) (1)\u589e\u52a0residual volume \u548c\u589e\u52a0residual volume/total lung capacity\u4ee3\u8868air  trapping. (2)\u589e\u52a0total lung capacity\u4ee3\u8868hyperinflation of thorax. (3)\u4e00\u79d2\u91cf(FEV1)\u5c0f\u65bc50%\u9810\u6e2c\u503c\u6642PaCO2\u624d\u6703\u4e0a\u5347 (4)PaO2\u4e0b\u964d\u7684\u4e3b\u56e0\u662fshunting (5)nonuniform ventilation \u4e5f\u662fCOPD\u6c23\u9ad4\u4ea4\u63db\u969c\u7919\u7684\u539f\u56e0\u4e4b\u4e00\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(5)\nD. (3)+(4)\nE. (3)+(4)+(5)\n": "(D)", "103-7.\n\u4e0b\u5217\u95dc\u65bcCOPD\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u6c23\u9053\u7684\u904e\u5ea6\u53cd\u61c9\u6027(airway hyperresponsiveness)\u4e0d\u61c9\u8a72\u662fCOPD\u6240\u5177\u6709\u7684\u7279\u5fb5\nB. \u5438\u83f8\u662fCOPD\u7684\u5371\u96aa\u56e0\u5b50\nC. \u71c3\u71d2\u751f\u8cea\u71c3\u6599(biomass combustion)\u662f\u4e0d\u62bd\u83f8\u5973\u6027\u7f79\u60a3COPD\u7684\u5371\u96aa\u56e0\u5b50\nD. \u03b11 antitrypsin \u7f3a\u4e4f\u75c7\u662fCOPD\u7684\u5371\u96aa\u56e0\u5b50.\nE. \u662f\u4e00\u7a2e\u6162\u6027\u6c23\u9053\u767c\u708e\n": "(A)", "103-8.\n\u4e0b\u5217\u95dc\u65bc\u5167\u56e0\u6027\u6c23\u5598(intrinsic asthma)\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?  (\u61c9\u9078\u51fa\u6240\u6709\u7b54\u6848)  (1)\u5167\u56e0\u6027\u6c23\u5598\u7d04\u4f5410%\u7684\u6c23\u5598\u75c5\u4eba (2)\u5167\u56e0\u6027\u6c23\u5598\u5e38\u5408\u4f75\u9f3b\u606f\u8089\u4e14\u5c0d\u963f\u65af\u5339\u6797\u654f\u611f (3)\u8207atopy\u76f8\u95dc\u7684\u57fa\u56e0\u57286q (4)\u5167\u56e0\u6027\u6c23\u5598\u8207IgE\u76f8\u95dc\u7684\u514d\u75ab\u6a5f\u8f49\u8f03\u7121\u95dc (5)\u6c23\u5598\u662f\u591a\u57fa\u56e0\u63a7\u5236\u7684\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(3)\nD. (3)+(4)\nE. (3)+(4)+(5)\n": "(D)", "103-9.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u5c0e\u81f4\u6c23\u5598(asthma)\u6b7b\u4ea1\u7684\u4e3b\u8981\u5371\u96aa\u56e0\u5b50?\nA. \u6210\u4eba\u6642\u671f\u624d\u767c\u751f\u7684\u6c23\u5598\nB. \u63a7\u5236\u4e0d\u4f73\u6c23\u5598\u800c\u9700\u7d93\u5e38\u4f7f\u7528\u5438\u5165\u578b\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u7684\u75c5\u4eba\nC. \u672a\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187(inhaled corticosteroids)\u7684\u75c5\u4eba\nD. \u4e4b\u524d\u56e0\u7015\u6b7b\u578b\u6c23\u5598(near-fatal asthma)\u800c\u4f4f\u9662\u7684\u75c5\u4eba\nE. \u4ee5\u4e0a\u7686\u975e\n": "(A)", "103-10.\n\u4e0b\u5217\u95dc\u65bc\u80ba\u81bf\u760d(lung abscess)\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. nonspecific lung abscess\u8207aspiration \u6709\u95dc\nB. \u96fb\u8166\u65b7\u5c64\u82e5\u5408\u4f75\u51fa\u73fe\u6dcb\u5df4\u817a\u816b\u5927(lymphadenopathy),\u61c9\u8003\u616e\u5176\u4ed6\u8a3a\u65b7.\nC. \u75f0\u6db2\u57f9\u990a\u7684\u7d50\u679c,\u5e38\u53ef\u4ee3\u8868\u611f\u67d3\u7684\u75c5\u539f\u83cc\nD. \u70ba\u4e86\u78ba\u7acb\u7d30\u83cc\u5b78\u8a3a\u65b7,\u96fb\u8166\u65b7\u5c64\u6307\u5f15\u7d93\u80f8\u7a7f\u523a\u5438\u5f15\u8853,\u5df2\u6f38\u53d7\u91cd\u8996\nE. \u6709\u81ed\u5473\u7684\u75f0\u6db2\u4ee3\u8868\u53ef\u80fd\u6709\u53ad\u6c27\u83cc\u611f\u67d3\n": "(C)", "103-11.\n\u4ee5\u4e0b\u95dc\u65bc\u54b3\u55fd\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8ca0\u8cac\u54b3\u55fd\u7684\u611f\u89ba\u795e\u7d93\u662fC-fiber\nB. \u6025\u6027\u548c\u6162\u6027\u54b3\u55fd\u5b9a\u7fa9\u7684\u6642\u9593\u754c\u9650\u4e00\u822c\u5b9a\u70ba\u516b\u9031\nC. \u80c3\u98df\u9053\u9006\u6d41\u662f\u6162\u6027\u54b3\u55fd\u5e38\u898b\u7684\u539f\u56e0\u4e4b\u4e00\nD. \u9223\u96e2\u5b50\u963b\u65b7\u5291\u964d\u8840\u58d3\u85e5\u7269\u662f\u6162\u6027\u54b3\u55fd\u5e38\u898b\u7684\u539f\u56e0\u4e4b\u4e00\nE. methacholine\u8a98\u767c\u8a66\u9a57\u53ef\u7528\u4f86\u6392\u9664\u652f\u6c23\u7ba1\u6c23\u5598\u6240\u9020\u6210\u6162\u6027\u54b3\u55fd\u7684\u539f\u56e0\n": "(D)", "103-12.\n\u4ee5\u4e0b\u95dc\u65bc\u80ba\u89e3\u5256\u751f\u7406\u7684\u63cf\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u4eba\u985e\u547c\u5438\u9053\u5927\u7d04\u670940\u7a2e\u6b63\u5e38\u7d30\u80de\nB. \u5f9e\u6c23\u7ba1\u958b\u59cb\u7d04\u524d14\u500b\u5206\u652f\u7684\u547c\u5438\u9053\u4e0d\u5177\u6c23\u9ad4\u4ea4\u63db\u529f\u80fd\nC. \u80ba\u5c16\u7684\u901a\u6c23\u91cf(ventilation)\u6bd4\u80ba\u5e95\u5927\nD. \u8ca7\u8840\u6703\u964d\u4f4e\u80ba\u5f4c\u6563\u91cf(diffusion capacity)\nE. \u80ba\u6c23\u816b(emphysema)\u75c5\u60a3\u7684\u529f\u80fd\u80ba\u9918\u91cf(functional residual capacity)\u6703\u504f\u9ad8\n": "(C)", "103-13.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u963b\u585e\u6027\u547c\u5438\u7761\u7720\u4e2d\u6b62\u75c7\u75c5\u60a3\u5e38\u898b\u7684\u81e8\u5e8a\u8868\u5fb5\nA. \u9ad4\u91cd\u904e\u91cd\nB. \u4e0b\u5df4\u8f03\u5c0f\u6216\u5f8c\u7e2e\nC. \u6241\u6843\u817a\u6216\u61f8\u96cd\u5782\u904e\u5927\nD. \u6253\u9f3e\nE. \u7121\u6027\u5225\u5dee\u7570\n": "(E)", "103-14.\n78\u6b72\u7537\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u53ca\u5fc3\u81df\u75c5\u75c5\u53f2\uff0c\u9577\u671f\u4f7f\u7528\u9223\u96e2\u5b50\u963b\u65b7\u5291\u53ca\u5229\u5c3f\u5291\u3002\u6b64\u6b21\u56e0\u9019\u4e00\u9031\u547c\u5438\u8d8a\u4f86\u8d8a\u56f0\u96e3\u800c\u81f3\u80f8\u8154\u79d1\u9580\u8a3a\u6c42\u91ab\u3002\u80f8\u90e8X\u5149\u6aa2\u67e5\u767c\u73fe\u96d9\u5074\u808b\u819c\u7a4d\u6c34\uff0c\u4f46\u53f3\u5074\u8f03\u660e\u986f\u3002\u4ee5\u7d30\u91dd\u62bd\u5438\u5f8c\u6aa2\u9a57\u767c\u73fe\u53f3\u5074\u808b\u819c\u7a4d\u6db2\u7684total protein\u70ba2.8 g/dL\uff0cLDH\u70ba112 U/L\uff0c\u540c\u6642\u75c5\u60a3\u8840\u6db2\u4e2d\u7684total protein\u70ba6.2 g/dL(\u6b63\u5e38\u7bc4\u570d\u70ba6.4 - 8.4 g/dL)\uff0cLDH\u70ba150 U/L(\u6b63\u5e38\u7bc4\u570d\u70ba131 - 250 U/L)\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u95dc\u65bc\u4f7f\u7528Light's criteria\u7684\u5224\u65b7\uff0c\u4f55\u8005\u6b63\u78ba?\nA. \u56e0\u70ba\u7b26\u5408\u4e09\u500bcriteria\u4e2d\u7684\u4e00\u500b\uff0c\u6240\u4ee5\u662fexudate\nB. \u56e0\u70ba\u7b26\u5408\u56db\u500bcriteria\u4e2d\u7684\u5169\u500b\uff0c\u6240\u4ee5\u662fexudate\nC. \u56e0\u70ba\u7b26\u5408\u4e09\u500bcriteria\u4e2d\u7684\u4e00\u500b\uff0c\u6240\u4ee5\u662ftransudate\nD. \u56e0\u70ba\u7b26\u5408\u56db\u500bcriteria\u4e2d\u7684\u5169\u500b\uff0c\u6240\u4ee5\u662ftransudate\nE. \u56e0\u70ba\u8840\u6db2\u8207\u808b\u819c\u7a4d\u6db2\u7684total protein\u5dee\u503c\u5927\u65bc3.1 g/dL\uff0c\u6240\u4ee5\u662ftransudate\n": "(A)", "103-15.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u80ba\u6813\u585e\u5e38\u898b\u7684\u5371\u96aa\u56e0\u5b50?\nA. \u9157\u9152\nB. \u62bd\u83f8\nC. \u5973\u6027\u8cc0\u723e\u8499\u88dc\u5145\u6cbb\u7642\nD. \u764c\u75c7\nE. \u9577\u9014\u98db\u884c\n": "(A)", "103-16.\n\u8acb\u554f\u4e0b\u5217\u95dc\u65bc\u5438\u5165\u6027\u985e\u56fa\u9187\u5728\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6cbb\u7642\u7684\u89d2\u8272\uff0c\u4f55\u8005\u722d\u8b70\u6700\u5c0f?\nA. \u964d\u4f4e\u6b7b\u4ea1\u7387\nB. \u6e1b\u7de9\u80ba\u529f\u80fd\u4e0b\u964d\u7684\u901f\u7387\nC. \u6e1b\u5c11\u6bcf\u5e74\u6025\u6027\u60e1\u5316\u7684\u6b21\u6578\nD. \u589e\u52a0\u80ba\u708e\u7684\u6a5f\u7387\nE. \u6e1b\u5c11\u80ba\u764c\u767c\u751f\u7387\n": "(C)", "103-17.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u958b\u6d1e\u6027\u80ba\u90e8\u611f\u67d3\u7684\u5e38\u898b\u81f4\u75c5\u83cc?\nA. \u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc(Staphylococcus aureus)\nB. A\u578b\u93c8\u7403\u83cc(Group A Streptococcus)\nC. \u514b\u96f7\u767d\u6c0f\u80ba\u708e\u83cc(Klebsiella pneumoniae)\nD. \u55dc\u80ba\u6027\u9000\u4f0d\u8ecd\u4eba\u687f\u83cc(Legionella pneumophila)\nE. \u80ba\u708e\u9ef4\u6f3f\u83cc(Mycoplasma pneumoniae)\n": "(E)", "103-18.\n67\u6b72\u7537\u6027\uff0c\u904e\u53bb\u7121\u62bd\u83f8\u53f2\uff0c\u6b64\u6b21\u56e0\u767c\u71d2\u6578\u65e5\u81f3\u9580\u8a3a\u5c31\u91ab\uff0c\u80f8\u90e8X\u5149\u986f\u793a\u53f3\u4e0a\u80ba\u5be6\u8cea\u5316\u9670\u5f71\uff0c\u6295\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u5f8c\u7121\u660e\u986f\u8b8a\u5316\uff0c\u6545\u5b89\u6392\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5(\u5982\u5716)\uff0c\u7d93\u652f\u6c23\u7ba1\u93e1\u5207\u7247\u75c5\u7406\u767c\u73fe\u70ba\u80ba\u817a\u764c\u3002\u5f8c\u4f86\u5b89\u6392\u5168\u8eab\u6b63\u5b50\u6383\u63cf\u4ee5\u53ca\u8166\u90e8\u6838\u78c1\u5171\u632f\uff0c\u767c\u73fe\u53f3\u4e0a\u80ba\u816b\u7624\u7684SUVmax\u70ba4.5\uff0c\u53f3\u4e0b\u6c23\u7ba1\u65c1\u6dcb\u5df4\u7d50\u7684SUVmax\u70ba2.7\uff0c\u6b64\u5916\u7121\u5176\u4ed6\u75c5\u7076\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u6700\u9069\u7576\u7684\u8655\u7f6e\u70ba\u4f55\uff1f\nA. \u6aa2\u9a57EGFR\u57fa\u56e0\u662f\u5426\u6709\u7a81\u8b8a\nB. \u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u5207\u7247\u75c5\u7406\u6aa2\u67e5\nC. \u624b\u8853\u5207\u9664\nD. \u5316\u5b78\u6cbb\u7642\nE. \u540c\u6b65\u6027\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\n": "(B)", "103-19.\n78\u6b72\u7537\u6027\uff0c\u670925\u5e74\u7684\u62bd\u83f8\u53f2\uff0c\u4f46\u81ea\u5f9e55\u6b72\u5c31\u6212\u83f8\u4e86\uff0c\u6b64\u6b21\u56e0\u8fd1\u4e09\u500b\u6708\u4f86\u51fa\u73fe\u4e7e\u54b3\u53ca\u547c\u5438\u56f0\u96e3\u4e14\u65e5\u6f38\u56b4\u91cd\uff0c\u6545\u81f3\u9580\u8a3a\u5c31\u91ab\u3002\u75c5\u60a3\u904e\u53bb\u6709\u5fc3\u623f\u986b\u52d5\u75c5\u53f2\uff0c\u6700\u5f8c\u4e00\u6b21\u767c\u751frapid ventricular response\u662f\u56db\u500b\u6708\u524d\uff0c\u75c5\u60a3\u9577\u671f\u4f7f\u7528\u7684\u85e5\u7269\u5305\u62ecmetoprolol\u548cwarfarin\uff0c\u4ee5\u53ca\u81ea\u56db\u500b\u6708\u524d\u958b\u59cb\u52a0\u4e0a\u7684amiodarone\u3002\u75c5\u60a3\u7684\u80f8\u90e8X\u5149\u6aa2\u67e5\u7121\u767c\u73fe\u660e\u986f\u7570\u5e38\uff0c\u7406\u5b78\u6aa2\u67e5\u9664\u80ba\u5e95\u90e8\u807d\u5230\u4e00\u4e9bcrackles\u4ee5\u5916\u4ea6\u7121\u660e\u986f\u7570\u5e38\u3002\u80ba\u529f\u80fd\u6aa2\u67e5\u7d50\u679c\u5982\u4e0b: FEV1= 72%\uff0cFEV1/FVC= 78%\uff0cVC= 72%\uff0cTLC= 65%\uff0cDLCO=50%\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u6700\u9069\u7576\u7684\u6aa2\u67e5\u70ba\u4f55\uff1f\nA. \u9ad8\u89e3\u6790\u5ea6\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\nB. \u652f\u6c23\u7ba1\u93e1\u6aa2\u67e5\nC. \u75f0\u6db2\u7d30\u80de\u5b78\u6aa2\u67e5\nD. \u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\nE. \u6838\u91ab\u80ba\u81df\u704c\u6ce8(perfusion)\u8207\u901a\u6c23(ventilation)\u6383\u63cf\n": "(A)", "103-20.\n\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u80ba\u764c\u7684\u9ad8\u5371\u96aa\u7fa4 (1)\u62bd\u83f8 (2)\u4e8c\u624b\u83f8 (3)\u7cd6\u5c3f\u75c5 (4)\u9ad8\u8840\u58d3 (5)\u7d50\u6838\u75c5\u53f2 (6)\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(7)\u505c\u7d93 (8)\u80ba\u764c\u5bb6\u65cf\u53f2 (9)\u77f3\u7dbf\u88fd\u9020\u5de5\u4eba\nA. (1)+(2)+(5)+(6)+(7)+(8)\nB. (1)+(2)+(5)+(6)+(8)+(9)\nC. (1)+(2)+(3)+(6)+(8)+(9)\nD. (1)+(2)+(6)+(7)+(8)+(9)\nE. (1)+(2)+(4)+(5)+(6)+(8)\n": "(B)", "103-21.\n\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u60c5\u6cc1\u53ef\u80fd\u5c0e\u81f4\u808b\u819c\u7a4d\u6db2\u4e2d\u7684\u55dc\u4f0a\u7d05\u6027\u767d\u8840\u7403\u6bd4\u4f8b\u589e\u52a0 (1)\u6c23\u80f8 (2)\u4e73\u7cdc\u80f8 (3)\u809d\u6027\u808b\u819c\u7a4d\u6c34 (4)\u85e5\u7269 (5)\u7d50\u6838\u6027\u808b\u819c\u708e (6)\u5fc3\u81df\u624b\u8853\u5f8c (7)\u6dcb\u5df4\u764c (8)\u80ba\u764c (9)\u77f3\u7dbf\u808b\u819c\u708e\nA. (1)+(2)+(4)+(6)+(8)\nB. (3)+(5)+(6)+(7)+(9)\nC. (2)+(3)+(4)+(5)+(9)\nD. (2)+(4)+(5)+(7)+(9)\nE. (1)+(4)+(6)+(7)+(9)\n": "(E)", "103-22.\n\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u60c5\u6cc1\u5c0e\u81f4\u547c\u5438\u56f0\u96e3\u7684\u6a5f\u8f49\u5305\u62ec\u547c\u5438\u529f(work of breath)\u589e\u52a0 (1)\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (2)\u6c23\u5598 (3)\u9593\u8cea\u6027\u80ba\u75c5 (4)\u80ba\u52d5\u8108\u9ad8\u58d3 (5)\u5fc3\u56e0\u6027\u80ba\u6c34\u816b (6)\u975e\u5fc3\u56e0\u6027\u80ba\u6c34\u816b (7)\u8ca7\u8840 (8)\u5931\u7528(deconditioning)\nA. (3)+(4)+(5)+(6)+(8)\nB. (1)+(2)+(4)+(6)+(8)\nC. (3)+(4)+(6)+(7)+(8)\nD. (1)+(2)+(3)+(5)+(6)\nE. (1)+(2)+(4)+(6)+(7)\n": "(D)", "104-1.\n\u95dc\u65bc\u80ba\u90e8\u807d\u8a3a\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u6b63\u78ba?\r\n(1)\u54ee\u9cf4\u97f3(wheezes)\u4ee3\u8868\u6c23\u9053\u963b\u585e\r\n(2)\u56c9\u97f3(crackles)\u4ee3\u8868\u80ba\u6ce1\u75be\u75c5\r\n(3)\u80ba\u9593\u8cea\u7e96\u7dad\u5316(interstitial fibrosis)\u6703\u51fa\u73feegophony\r\n(4)\u80ba\u5be6\u8cea\u5316(consolidation)\u4e0d\u6703\u51fa\u73fewhispered pectoriloquy\r\n(5)\u80ba\u6c23\u816b(emphysema)\u53ef\u51fa\u73fe\u547c\u5438\u97f3\u964d\u4f4e\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(5)\nD. (4)+(5)\nE. (3)+(4)+(5)\n": "(C)", "104-2.\n\u95dc\u65bc\u6c23\u5598\u968e\u68af\u5f0f\u6cbb\u7642(stepwise therapy)\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u6b63\u78ba?\r\n(1)\u6bcf\u5468\u4f7f\u7528\u7de9\u89e3\u85e5\u7269(reliever medication)\u5927\u65bc\u5169\u6b21\u4ee5\u4e0a, \u5c31\u9700\u898f\u5f8b\u4f7f\u7528\u63a7\u5236\u85e5\u7269(controller medication)\r\n(2)\u63a7\u5236\u85e5\u7269\u7684\u9996\u9078\u70ba\u5438\u5165\u578b\u985e\u56fa\u9187(inhaled corticosteroids)\r\n(3)\u7b2c\u4e00\u968e\u75c5\u4eba\u50c5\u4f7f\u7528\u5438\u5165\u578b\u77ed\u6548\u4e4b\u4e59\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5c31\u53ef\u4ee5\r\n(4)\u5438\u5165\u578b\u985e\u56fa\u9187\u7684\u8d77\u59cb\u5291\u91cf\u70ba\u4e2d\u5291\u91cf(\u76f8\u7576200 \u03bcg BID/day beclomethasone dipropionate )\r\n(5)\u4f7f\u7528\u63a7\u5236\u85e5\u7269\u5f8c\u5169\u500b\u6708\u5c31\u53ef\u8a55\u4f30\u6cbb\u7642\u6548\u679c\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(5)\nD. (4)+(5)\nE. (3)+(4)+(5)\n": "(B)", "104-3.\n\u95dc\u65bc\u7279\u6b8a\u56e0\u5b50\u548c\u793e\u5340\u6027\u80ba\u708e\u53ef\u80fd\u75c5\u539f\u83cc\u7684\u7d44\u5408,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. Bronchiectasis--P.aeruginosa\nB. \u80ba\u81bf\u760d--oral anaerobes\nC. \u6d41\u611f(influenza)--Klebsiella pneumoniae\nD. COPD--Haemophilus influenzae\nE. \u9ce5\u985e\u63a5\u89f8--Chlamydia psittaci\n": "(C)", "104-4.\n\u95dc\u65bc\u547c\u5438\u5668\u76f8\u95dc\u80ba\u708e(ventilator-associated pneumonia)\u75c5\u7406\u6a5f\u8f49\u548c\u76f8\u95dc\u9810\u9632\u7b56\u7565\u7684\u7d44\u5408,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u6b63\u5e38\u83cc\u7684\u6e1b\u5c11(elimination of normal flora)--\u907f\u514d\u6297\u751f\u7d20\u4f7f\u7528\u6642\u9593\u904e\u9577\nB. \u4e0b\u547c\u5438\u9053\u62b5\u6297\u529b\u6539\u8b8a(altered lower respiratory  host defense)--\u964d\u4f4e\u8f38\u8840\u6642\u8840\u7d05\u7d20\u7684\u95be\u503c(hemoglobin transfusion threshold)\nC. \u6c23\u7ba1\u5167\u7ba1\u5468\u570d\u7269\u8cea\u7684\u5438\u5165(microaspiration around endotracheal tube)--\u52a0\u5f37\u93ae\u975c\nD. \u547c\u5438\u5668\u4f7f\u7528\u6642\u9593\u904e\u9577--\u547c\u5438\u5668\u812b\u96e2\u6d41\u7a0b(weaning protocols)\nE. \u80c3\u98df\u9053\u9006\u6d41--prokinetic agents\n": "(C)", "104-5.\n\u95dc\u65bc\u9020\u6210\u808b\u819c\u7a4d\u6db2(pleural effusion)\u7684\u539f\u56e0,\u4e0b\u5217\u4f55\u8005\u662f\u6f0f\u51fa\u6db2(transudate)?\nA. Meig's syndrome\nB. ovarian hyperstimulation syndrome\nC. myxedema\nD. uremia\nE. rheumatoid pleuritis\n": "(C)", "104-6.\n\u4e0b\u5217\u72c0\u6cc1\u6700\u9069\u5408\u4f7f\u7528\u975e\u4fb5\u8972\u6027\u547c\u5438\u5668(noninvasive ventilation)\u8005\u70ba?\nA. \u5fc3\u8df3\u505c\u6b62\nB. \u56b4\u91cd\u8178\u80c3\u9053\u51fa\u8840\nC. \u4e0d\u7a69\u5b9a\u5fc3\u7d5e\u75db\nD. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316\nE. \u4e0a\u547c\u5438\u9053\u963b\u585e\n": "(D)", "104-7.\n\u95dc\u65bc\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7(obstructive sleep apnea)\u7684\u6558\u8ff0\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u53ef\u589e\u52a0\u5fc3\u808c\u6897\u585e\u7684\u5371\u96aa\nB. \u53ef\u5f15\u8d77\u809d\u529f\u80fd\u7570\u5e38\nC. \u53ef\u9020\u6210\u80f0\u5cf6\u7d20\u6297\u6027(insulin resistance)\nD. \u6cbb\u7642\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u53ef\u6539\u5584\u4e2d\u98a8\u75c5\u4eba\u7684\u9810\u5f8c\nE. \u6703\u589e\u52a0\u9ebb\u9189\u98a8\u96aa\n": "(D)", "104-8.\n\u5be6\u884c\u8eab\u9ad4\u6aa2\u67e5\u6642,\u65bc\u80ba\u90e8\u807d\u8a3a,\u767c\u73fe\u547c\u5438\u97f3\u6e1b\u5c11,\u6263\u8a3a\u6642\u70badullness\u8005,\u6700\u53ef\u80fd\u70ba\u4e0b\u5217\u4f55\u8005?\nA. \u6c23\u80f8(pneumothorax)\nB. \u808b\u819c\u7a4d\u6db2(pleural effusion)\nC. \u5927\u8449\u6027\u80ba\u708e(lobar pneumonia)\nD. \u80ba\u6c23\u816b(emphysema)\nE. \u7e31\u8188\u6c23\u816b(pneumomediastinum)\n": "(B)", "104-9.\n\u95dc\u65bc\u7d50\u6838\u6027\u808b\u819c\u708e(tuberculous pleuritis)\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u7d93\u5e38\u8207primary TB \u6709\u95dc\nB. \u70ba\u6dcb\u5df4\u7403\u70ba\u4e3b\u7684\u6ef2\u51fa\u6db2(exudate)\nC. \u5c0d\u7d50\u6838\u83cc\u86cb\u767d(tuberculous protein) \u7684\u4e00\u7a2e\u904e\u654f\u53cd\u61c9(hypersensitivity reaction)\nD. \u808b\u819c\u7a4d\u6db2\u70baadenosine deaminase >40 IU/L\u6216interferon- r<140pg/ml\nE. \u808b\u819c\u5207\u7247\u5c0d\u8a3a\u65b7\u6709\u5e6b\u52a9\n": "(D)", "104-10.\n\u95dc\u65bc\u80ba\u708e\u56b4\u91cd\u5ea6\u8a55\u4f30CURB-65\u7684\u9805\u76ee,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u5e74\u9f61\nB. \u610f\u8b58\u4e0d\u6e05\nC. BUN\nD. CRP(C-reactive protein)\nE. \u547c\u5438\u6b21\u6578\n": "(D)", "104-11.\n\u95dc\u65bc\u6c23\u5598\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u5438\u5165\u578b\u985e\u56fa\u9187\u662f\u6cbb\u7642\u7684\u4e3b\u8981\u85e5\u7269\nB. \u5408\u4f75\u6cbb\u7642(ICS+LABA,inhaled corticosteroid+long acting beta adrenergic agonist)\u5efa\u8b70\u65bcstep2 (\u542b)\u4ee5\u4e0a\u4e4b\u75c5\u4eba\u4f7f\u7528\nC. \u6297\u767d\u4e09\u70ef\u7d20(antileukotrienes)\u53ef\u4f5c\u70bacontroller \u85e5\u7269\nD. \u6025\u6027\u60e1\u5316\u6642\u53ef\u4f7f\u7528\u5168\u8eab\u6027\u985e\u56fa\u9187(systemic steroid)\nE. \u5c11\u90e8\u5206\u56b4\u91cd\u75c5\u4eba\u53ef\u4f7f\u7528anti-IgE\n": "(B)", "104-12.\n\u4e0b\u5217\u54ea\u4e00\u500b\u4e0d\u662f\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291\u7684\u4f5c\u7528\uff1f\nA. \u653e\u9b06\u547c\u5438\u9053\u7684\u5e73\u6ed1\u808c\nB. \u6e1b\u7de9\u54b3\u55fd\nC. \u6291\u5236\u6162\u6027\u767c\u708e\u53cd\u61c9\nD. \u589e\u52a0\u547c\u5438\u9053\u7e96\u6bdb\u904b\u52d5\nE. \u589e\u52a0\u547c\u5438\u9053\u9ecf\u6db2\u5206\u6ccc\n": "(C)", "104-13.\n\u4e0b\u5217\u95dc\u65bc\u904e\u654f\u6027\u80ba\u708e(hypersensitivity pneumonitis)\u81e8\u5e8a\u8868\u5fb5\u7684\u6558\u8ff0\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\nA. \u6210\u56e0\u662f\u7576\u5177\u6709\u7279\u7570\u9ad4\u8cea\u7684\u4eba\uff0c\u5438\u5165\u904e\u654f\u6709\u6a5f\u6027\u7269\u8cea\u6642\u6240\u81f4\nB. \u53ef\u80fd\u51fa\u73fe\u767c\u51b7\u3001\u767c\u71b1\nC. \u5728\u63a5\u89f8\u904e\u654f\u539f\u5f8c\u7684\u4e00\u5230\u5169\u500b\u5c0f\u6642\u5167\u51fa\u73fe\u547c\u5438\u56f0\u96e3\u75c7\u72c0\nD. \u652f\u6c23\u7ba1\u80ba\u6ce1\u704c\u6d17\u6db2\u4e2d\u7684CD4\u8207CD8\u6dcb\u5df4\u7403\u7d30\u80de\u7684\u6bd4\u4f8b\u5e38\u5c0f\u65bc1\nE. \u652f\u6c23\u7ba1\u80ba\u6ce1\u704c\u6d17\u6db2\u4e2d\u80a5\u5927\u7d30\u80de\u7684\u91cf\u53ef\u80fd\u548c\u75be\u75c5\u56b4\u91cd\u5ea6\u6210\u6b63\u6bd4\n": "(C)", "104-14.\n\u4e0b\u5217\u4f55\u8005\u662f\u76ee\u524d\u570b\u969b\u9593\u505a\u55ae\u80ba\u80ba\u81df\u79fb\u690d\u6700\u5e38\u898b\u7684\u9069\u61c9\u75c7\uff1f\nA. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(COPD)\nB. \u56ca\u816b\u7e96\u7dad\u5316(cystic fibrosis)\nC. \u539f\u767c\u6027\u80ba\u7e96\u7dad\u5316(idiopathic pulmonary fibrosis)\nD. \u985e\u8089\u7624(sarcoidosis)\nE. \u539f\u767c\u6027\u80ba\u52d5\u8108\u9ad8\u58d3(idiopathic pulmonary hypertension)\n": "(A or C)", "104-15.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u963b\u585e\u6027\u547c\u5438\u7761\u7720\u4e2d\u6b62\u75c7\u6709\u95dc\u7684\u8a98\u767c\u56e0\u5b50\uff1f\nA. \u80a5\u80d6\nB. \u7537\u6027\nC. \u4e0b\u5df4\u8f03\u5c0f\nD. \u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\nE. \u9f3b\u606f\u8089\n": "(E)", "104-16.\n\u4e0b\u5217\u6709\u95dc\u539f\u767c\u81ea\u767c\u6027\u6c23\u80f8(primary spontaneous pneumothorax)\u7684\u63cf\u8ff0\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\nA. \u75c5\u60a3\u7121\u904e\u53bb\u80ba\u90e8\u75be\u75c5\nB. \u5e38\u662f\u80ba\u5c16\u7684bleb\u7834\u88c2\u6240\u81f4\nC. \u521d\u6b21\u767c\u751f\u5f8c\uff0c\u7d04\u670910%\u7684\u6a5f\u6703\u518d\u5fa9\u767c\nD. \u521d\u6b21\u767c\u751f\u7684\u4e00\u822c\u6cbb\u7642\u539f\u5247\u662fsimple aspiration\nE. \u75c5\u60a3\u5e38\u6709\u5438\u83f8\u53f2\n": "(C)", "104-17.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u5f8c\u7e31\u9694\u8154\u816b\u7624\u5e38\u898b\u7684\u539f\u56e0\uff1f\nA. neurogenic tumor\nB. meningocele\nC. gastroenteric cyst\nD. bronchogenic cyst\nE. esophageal diverticulum\n": "(D)", "104-18.\n\u4e0b\u5217\u95dc\u65bc\u539f\u767c\u6027\u80ba\u7e96\u7dad\u5316(idiopathic pulmonary fibrosis)\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5178\u578b\u7684\u75c5\u7406\u8b8a\u5316\u662fusual interstitial pneumonia\nB. \u5178\u578b\u7684\u9ad8\u89e3\u6790\u5ea6\u96fb\u8166\u65b7\u5c64\u8b8a\u5316\u662f\u9031\u908a\u4e0b\u80ba\u91ce\u7684\u8702\u7aa9\u72c0\u7dda\u689d\u5f71\u50cf\nC. \u5178\u578b\u7684\u80ba\u529f\u80fd\u8b8a\u5316\u662f\u4fb7\u9650\u578b\u6c23\u9ad4\u4ea4\u63db\u969c\u7919\nD. \u5438\u5165\u6027\u985e\u56fa\u9187\u662f\u85e5\u7269\u6cbb\u7642\u7684\u9996\u9078\nE. \u662f\u80ba\u81df\u79fb\u690d\u7684\u9069\u61c9\u75c7\u4e4b\u4e00\n": "(D)", "104-19.\n62\u6b72\u7537\u6027\uff0c\u904e\u53bb\u7121\u5438\u83f8\u53f2\uff0c\u6b64\u6b21\u56e0\u54b3\u55fd\u4e09\u500b\u6708\u90fd\u6c92\u6539\u5584\uff0c\u6545\u81f3\u9580\u8a3a\u5c31\u91ab\uff0c\u80f8\u90e8X\u5149\u6aa2\u67e5\u986f\u793a\u53f3\u5074\u6709\u4e2d\u91cf\u808b\u819c\u7a4d\u6db2\uff0c\u4ee5\u7d30\u91dd\u62bd\u5438\u5f8c\u6aa2\u9a57\u767c\u73fe\u808b\u819c\u7a4d\u6db2\u7684total protein\u70ba4.8 g/dL\uff0cLDH\u70ba298 U/L\uff0c\u540c\u6642\u75c5\u60a3\u8840\u6db2\u4e2d\u7684total protein\u70ba5.8 g/dL(\u6b63\u5e38\u7bc4\u570d\u70ba6.4 - 8.4 g/dL)\uff0cLDH\u70ba273 U/L(\u6b63\u5e38\u7bc4\u570d\u70ba131 - 250 U/L)\uff1b\u808b\u819c\u7a4d\u6db2\u4e2d\u7684\u767d\u8840\u7403\u7e3d\u6578\u70ba2300 /cumm\uff0c\u55dc\u4e2d\u6027\u7403\u70ba3%\uff0c\u6dcb\u5df4\u7403\u70ba97%\uff0c\u7d30\u80de\u5b78\u53ca\u6297\u9178\u6027\u67d3\u8272\u6aa2\u67e5\u7686\u70ba\u9670\u6027\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6700\u4e0d\u9069\u7576\uff1f\nA. \u6839\u64daLight's criteria\uff0c\u6b64\u808b\u819c\u7a4d\u6db2\u61c9\u70baexudate\nB. \u82e5\u7d30\u80de\u5b78\u6a19\u672c\u4e2d\u7684\u9593\u76ae\u7d30\u80de(methoselial cell)\u6bd4\u4f8b\u4e0d\u52303%\uff0c\u5247\u7d50\u6838\u6027\u808b\u819c\u7a4d\u6db2\u7684\u6a5f\u6703\u5f88\u5927\nC. \u56e0\u70ba\u8981\u5728\u808b\u819c\u7a4d\u6db2\u4e2d\u76f4\u63a5\u627e\u5230\u7d50\u6838\u83cc\u7684\u654f\u611f\u6027\u4e0d\u523010%\uff0c\u6240\u4ee5\u6297\u9178\u6027\u67d3\u8272\u6aa2\u67e5\u70ba\u9670\u6027\uff0c\u4e26\u4e0d\u80fd\u6392\u9664\u7d50\u6838\u6027\u808b\u819c\u7a4d\u6db2\u7684\u8a3a\u65b7\nD. \u56e0\u70ba\u8981\u5728\u808b\u819c\u7a4d\u6db2\u7d30\u80de\u5b78\u6aa2\u67e5\u4e2d\u767c\u73fe\u60e1\u6027\u7d30\u80de\u7684\u654f\u611f\u6027\u8d85\u904e90%\uff0c\u6240\u4ee5\u7d30\u80de\u5b78\u6aa2\u67e5\u70ba\u9670\u6027\uff0c\u61c9\u53ef\u6392\u9664\u60e1\u6027\u808b\u819c\u7a4d\u6db2\u7684\u8a3a\u65b7\nE. \u53ef\u8003\u616e\u505a\u808b\u819c\u5207\u7247\u4ee5\u5e6b\u52a9\u8a3a\u65b7\n": "(D)", "104-20.\n\u4e0b\u5217\u4f55\u8655\u6709\u54b3\u55fd\u63a5\u53d7\u9ad4(cough receptor)\uff1f (1)\u4e0a\u773c\u77bc\uff0c(2)\u978f\u819c\uff0c(3)\u984d\u982d\uff0c(4)\u53e3\u8154\uff0c(5)\u54bd\uff0c(6)\u5589\uff0c(7)\u5916\u8033\u9053\uff0c(8)\u98df\u9053\uff0c(9)\u7d30\u652f\u6c23\u7ba1\nA. (4)+(5)+(6)+(8)+(9)\nB. (2)+(5)+(6)+(8)+(9)\nC. (1)+(5)+(6)+(7)+(9)\nD. (5)+(6)+(7)+(8)+(9)\nE. (2)+(5)+(6)+(7)+(9)\n": "(D)", "104-21.\n\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u60c5\u6cc1\u5c0e\u81f4\u547c\u5438\u56f0\u96e3\u7684\u6a5f\u8f49\u548c\u547c\u5438\u529f(work of breath)\u589e\u52a0\u7121\u95dc\uff1f(1)\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\uff0c(2)\u6c23\u5598\uff0c(3)\u80ba\u52d5\u8108\u9ad8\u58d3\uff0c(4)\u8ca7\u8840\uff0c(5)\u5fc3\u56e0\u6027\u80ba\u6c34\u816b\uff0c(6)\u975e\u5fc3\u56e0\u6027\u80ba\u6c34\u816b\uff0c(7)\u9593\u8cea\u6027\u80ba\u75c5\uff0c(8)\u53bb\u689d\u4ef6\u5316(deconditioning)\nA. (4)+(6)+(8)\nB. (3)+(4)+(8)\nC. (2)+(5)+(7)\nD. (3)+(4)+(5)\nE. (1)+(2)+(7)\n": "(B)", "104-22.\n\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u539f\u56e0\u9020\u6210\u7684\u808b\u819c\u7a4d\u6db2\u901a\u5e38\u662ftransudate\uff1f(1)\u9b31\u8840\u6027\u5fc3\u8870\u7aed\uff0c(2)\u809d\u786c\u5316\uff0c(3)\u80ba\u6813\u585e\uff0c(4)\u85e5\u7269\uff0c(5)\u4e73\u7cdc\u80f8\uff0c(6)\u4e0a\u8154\u975c\u8108\u963b\u585e\uff0c(7)Dressler's syndrome\uff0c(8)Meigs' syndrome\nA. (1)+(2)+(3)+(6)\nB. (1)+(2)+(6)+(7)\nC. (1)+(3)+(5)+(6)\nD. (2)+(5)+(6)+(8)\nE. (1)+(2)+(5)+(6)\n": "(A)", "105-1.\n\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (chronic obstructive pulmonary disease\uff0cCOPD)\u7684\u7406\u5b78\u6aa2\u67e5\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u56b4\u91cd\u7684\u60a3\u8005\u6703\u51fa\u73fecachexia\uff0c\u6b64\u8207\u9ad4\u5167\u767c\u708e\u7269\u8ceaTGF-\u03b2\u5347\u9ad8\u6709\u95dc\u3002\nB. \u6775\u72c0\u6307(Clubbing of the digits)\u8207COPD\u7121\u95dc\uff0c\u5728COPD\u60a3\u8005\u8eab\u4e0a\u65b0\u767c\u73fe\u5230\u6775\u72c0\u6307\uff0c\u9808\u5c0b\u627e\u5176\u4ed6\u7684\u539f\u56e0\u3002\nC. \u6709\u4e9b\u60a3\u8005\u6703\u56e0\u70ba\u80ba\u90e8\u904e\u5ea6\u5145\u6c23(hyperinflation)\uff0c\u4f7f\u6a6b\u8188\u819c\u8b8a\u5e73\uff0c\u5728\u5438\u6c23\u6642\u808b\u9aa8\u4e0b\u7de3\u6703\u7570\u5e38\u5730\u5411\u5167\u79fb\u52d5(paradoxical inward movement)\uff0c\u7a31\u70baHoover\u2032s sign\u3002\nD. \u6709\u4e9b\u60a3\u8005\u6703\u56e0\u70bahyperinflation\uff0c\u5448\u73fe\u51fa\u6876\u72c0\u80f8(barrel chest) \u3002\nE. \u91cd\u5ea6\u60a3\u8005\u5e38\u63a1\"tripod\"\u5750\u59ff\uff0c\u4ee5\u5229\u8f14\u52a9\u547c\u5438\u808c(accessory respiratory muscle)\u7684\u4f7f\u7528\u3002\n": "(A)", "105-2.\n\u6709\u95dc\u9020\u6210\u4f4e\u8840\u6c27\u75c7 (hypoxemia)\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u9ad8\u6d77\u62d4(high altitude)\u5f15\u8d77hypoxemia\uff0c\u80ba\u6ce1-\u52d5\u8108\u6c27\u6c23\u58d3\u529b\u5dee\uff08P(A-a)O2\uff0cAlveolar-arterial oxygen tension gradient\uff09\u6703\u4e0a\u5347\nB. \u63db\u6c23\u91cf\u4e0d\u8db3(hypoventilation)\uff0c\u52d5\u8108\u8840\u4e2d\u7684\u4e8c\u6c27\u5316\u78b3\u58d3\u529b(PaCO2)\u6703\u5347\u9ad8\nC. \u9593\u8cea\u6027\u80ba\u75c5(interstitial lung disease)\u60a3\u8005\uff0c\u6c27\u6c23\u7684\u64f4\u6563\u7570\u5e38(diffusion limitation)\uff0c\u5438\u5165\u9ad8\u6fc3\u5ea6\u7684\u6c27\u6c23\u7121\u6cd5\u6539\u5584hypoxemia\nD. \u80ba\u6813\u585e(pulmonary embolism)\u6703\u9020\u6210\u5206\u6d41(shunt)\uff0c\u5c0e\u81f4hypoxemia\nE. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (COPD) \u60a3\u8005\uff0c\u6703\u56e0\u901a\u6c23\u8207\u8840\u6db2\u704c\u6d41\u4e0d\u5339\u914d(V/Q mismatch) \u9020\u6210\u4f4e\u8840\u6c27\uff0c\u6b64\u6642\u5438\u5165\u9ad8\u6fc3\u5ea6\u7684\u6c27\u6c23\u7121\u6cd5\u6539\u5584hypoxemia\n": "(B)", "105-3.\n\u95dc\u65bc\u963b\u585e\u578b\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7 (Obstructive Sleep Apnea/Hypopnea Syndrome\uff0cOSAHS)\uff0c\u4e0b\u5217\u54ea\u4e9b\u63cf\u8ff0\u662f\u6b63\u78ba\u7684\uff1f\r1. \u80a5\u80d6(obesity)\u8207\u7537\u6027\u70ba\u6700\u91cd\u8981\u7684\u5371\u96aa\u56e0\u5b50\r2. \u6a19\u6e96\u7684\u8a3a\u65b7\u65b9\u6cd5(gold standard)\u70ba overnight oximetry\r3. \u548c\u5fc3(\u8166)\u8840\u7ba1\u75be\u75c5\u3001\u4ee3\u8b1d\u6027\u75be\u75c5\u6709\u95dc\r4. \u5c0d\u5065\u5eb7\u9020\u6210\u7684\u4e0d\u5229\u5f71\u97ff\u662f\u900f\u904esleep fragmentation\u3001cortical arousal \u8207 chronic intermittent hypercapnia (increase in PaCO2)\u9020\u6210\r5. \u6301\u7e8c\u967d\u58d3\u547c\u5438\u5668(continuous positive airway pressure\uff0cCPAP) \u70ba\u6a19\u6e96\u7684\u6cbb\u7642\u65b9\u6cd5\r6. CPAP \u53ef\u4f7f\u8840\u58d3\u4e0b\u964d\u5e73\u5747\u9054\u5230 12~14 mmHg\nA. 2+3+6\nB. 2+3+5\nC. 1+3+6\nD. 1+3+5\nE. 1+5+6\n": "(D)", "105-4.\n\u80ba\u529f\u80fd\u6aa2\u67e5\u4e2d\u7684\u4e00\u6c27\u5316\u78b3\u7030\u6f2b\u91cf(DLCO\uff0cthe diffusion capacity of the lungs for carbon monoxide)\u662f\u6e2c\u91cfCO\u5f9e\u80ba\u6ce1\u64f4\u6563\u5165\u5fae\u8840\u7ba1\u7684\u80fd\u529b\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u932f\u8aa4:\nA. \u6e2c\u91cf\u6642\u82e5\u75c5\u60a3\u9589\u6c23\u4e0d\u8db3\u5341\u79d2\uff0c\u6e2c\u5f97\u7684\u6578\u503c\u53ef\u80fd\u6703\u504f\u4f4e\u3002\nB. \u5207\u9664\u80ba\u8449\u7684\u60a3\u8005\uff0c\u82e5\u5269\u9918\u80ba\u90e8\u662f\u5065\u5eb7\u7684\uff0c\u6e2c\u5f97\u7684DLCO\u96d6\u7136\u7d55\u5c0d\u503c\u53ef\u80fd\u504f\u4f4e\uff0c\u4f46\u6821\u6b63\u80ba\u6ce1\u63db\u6c23\u91cf(alveolar volume)\u5f8c\u5247\u6703\u6b63\u5e38\u3002\nC. \u53ef\u4ee5\u7528\u4f86\u76e3\u6e2c\u85e5\u7269\u6bd2\u6027\uff0c\u5982:Bleomycin\u3002\nD. \u80ba\u6c23\u816b(emphysema)\u8207\u6c23\u5598(asthma)\u6703\u4e0b\u964d\u3002\nE. \u904b\u52d5\u8207\u6025\u6027\u80ba\u51fa\u8840 (acute pulmonary hemorrhage)\u6703\u4e0a\u5347\n": "(D)", "105-5.\n45\u6b72\u7537\u6027\uff0c\u56e0\u547c\u5438\u4e0d\u9069\uff0c\u6aa2\u67e5\u51fa\u53f3\u5074\u808b\u819c\u7a4d\u6db2 (pleural effusion)\u3002\u808b\u819c\u7a4d\u6db2\u7d93\u62bd\u53d6\u5f8c\u5206\u6790\u7d50\u679c\u5982\u4e0b: \u9ec3\u8272, LDH: 180 U/L, total protein: 4 g/dL\u3002\u8840\u6e05(serum)\u7684\u6aa2\u9a57\u503c\u70ba: LDH: 200 U/L, total protein: 6.2 g/dL\u3002\u5247\u6b64\u75c5\u60a3\u7684\u75c5\u56e0\u6700\u4e0d\u53ef\u80fd\u662f:\nA. Pneumonia\nB. Hepatic hydrothorax\nC. Malignancy\nD. Methothelioma\nE. Pulmonary embolus\n": "(B)", "105-6.\n80\u6b72\u7537\u6027\u6709\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(chronic obstructive pulmonary disease\uff0cCOPD)\u8207\u5fc3\u8870\u7aed\u75c5\u53f2\uff0c\u4e00\u5468\u4f86\u547c\u5438\u56f0\u96e3\u4f86\u6025\u8a3a\uff0c\u5728\u6025\u8a3a\u6cbb\u7642\u4e09\u5929\u5f8c\u4f4f\u9662\u3002\u5230\u75c5\u623f\u6642\uff0c\u610f\u8b58\u6e05\u9192\uff0c\u8840\u58d3160/90 mmHg\uff0c\u5fc3\u8df3108/min\uff0c\u547c\u5438\u901f\u738720/min\u3002\u5728\u672a\u7528\u6c27\u6c23\u7684\u72c0\u614b\u4e0b\uff0c\u52d5\u8108\u6c23\u9ad4\u5206\u6790(arterial blood gas): pH =7.50, PaO2= 65 mmHg, PaCO2 =43 mmHg, HCO3= 35 mEq/L, SaO2 93%\u3002urine [Cl-] =10 mEq/L\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u6b63\u78ba?\nA. \u662f\u4ee3\u8b1d\u6027\u9e7c\u8840\u75c7(metabolic alkalosis)\u5408\u4f75\u547c\u5438\u9178\u8840\u75c7(respiratory acidosis)\nB. \u70ba\u6025\u6027\u547c\u5438\u8870\u7aed\nC. Oxygen-Hemoglobin Dissociation Curve\u5de6\u79fb\uff0c\u7d44\u7e54\u6216\u5668\u5b98\u5bb9\u6613\u7f3a\u6c27\u3002\nD. \u6613\u5408\u4f75\u9ad8\u8840\u9240\u75c7(hyperkalemia)\u3002\nE. \u5728\u6025\u8a3a\u4e00\u5b9a\u6709\u4f7f\u7528\u985e\u56fa\u9187(corticosteroid)\u6cbb\u7642\u3002\n": "(C)", "105-7.\n\u95dc\u65bc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(Acute respiratory distress syndrome\uff0cARDS)\uff0c\u4e0b\u5217\u54ea\u4e9b\u63cf\u8ff0\u662f\u932f\u8aa4\u7684\uff1f\nA. \u5fc5\u9808\u662f\u6025\u6027\u767c\u4f5c\uff08acute onset\uff09\u3001X \u5149\u70ba\u5169\u5074\u6d78\u6f64\u3001\u80ba\u5fae\u8840\u7ba1\u6954\u58d3( PCWP, pulmonary capillary wedge pressure)\u2266 18 mm Hg\u6216\u7121\u5de6\u5fc3\u623f\u58d3\u529b\u5347\u9ad8\u4e4b\u81e8\u5e8a\u8b49\u64da\u3002\nB. \u6839\u64daBerlin definition\uff0cPaO2 /FiO2 \u9700\u5c0f\u65bc 300 mm Hg\uff0c\u56b4\u91cd\u5ea6\u518d\u4f9dPaO2 /FiO2\u503c\u5340\u5206\u70ba\u8f15(200~300)\u3001\u4e2d(100~200)\u3001\u91cd\u5ea6(<100)\uff0c\u800c\u4e14\u4e0d\u5efa\u8b70\u4f7f\u7528acute lung injury\u9019\u500b\u540d\u8a5e\u3002\nC. \u5e38\u898b\u539f\u56e0\u70ba\u6557\u8840\u75c7(sepsis)\u3001\u80ba\u708e( pneumonia) \u3001\u55c6\u5165\u80c3\u5167\u7269(aspiration)\u3001\u5916\u50b7\u7b49\u3002\nD. \u5e38\u9808\u63d2\u7ba1\u53ca\u547c\u5438\u5668\u652f\u6301\u3002\u96a8\u6a5f\u5206\u6d3e\u7814\u7a76\u7684\u7d50\u679c\u5f37\u70c8\u5efa\u8b70\u4f7f\u7528\u4f4e\u6f6e\u6c23\u5bb9\u7a4d(low tidal volume)\u548c\u4f4e\u5410\u6c23\u672b\u967d\u58d3(low PEEP, positive end-expiratory pressure)\u3002\nE. \u96a8\u6a5f\u5206\u6d3e\u7814\u7a76\u7684\u7d50\u679c\u5f37\u70c8\u5efa\u8b70\u4f7f\u7528\u547c\u5438\u5668\u60a3\u8005\uff0c\u9664sedation\u4ee5\u5916\uff0c\u65e9\u671f\u7d66\u4e88cisatracurium besylate (early neuromuscular blockade)\u3002\u5c0d\u65bcsevere ARDS\u60a3\u8005\uff0c\u53ef\u589e\u52a0\u5b58\u6d3b\u7387\n": "(D)", "105-8.\n\u95dc\u65bc\u9811\u56fa\u578b\u6c23\u5598(Refractory Asthma)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u9996\u8981\u4e4b\u52d9\u70ba\u78ba\u8a8d\u75c5\u4eba\u7528\u85e5\u7684\u9075\u5f9e\u6027(complicance)\u8207\u6e1b\u5c11\u53ef\u80fd\u7684\u8a98\u767c\u56e0\u5b50(trigger factors)\nB. \u4f4e\u5291\u91cf theophylline \u5b8c\u5168\u6c92\u6548\uff0c\u4e0d\u5b9c\u5617\u8a66\nC. \u5927\u90e8\u5206\u7684\u75c5\u4eba\u9700\u8981\u53e3\u670d\u7684\u985e\u56fa\u9187\u6cbb\u7642(oral corticosteroid)\nD. Omalizumab\u5c0d\u65bc\u67d0\u4e9ballergic asthma\u60a3\u8005\uff0c\u5177\u6709\u7642\u6548\uff0c\u7279\u5225\u662f\u5f88\u983b\u7e41\u60e1\u5316\u767c\u4f5c\u60a3\u8005\nE. Anti-TNF (tumor necrosis factor) \u5c0d\u65bcsevere asthma\u60a3\u8005\u6cbb\u7642\u6548\u679c\u4e0d\u4f73\uff0c\u4e0d\u61c9\u4f7f\u7528\n": "(B)", "105-9.\n\u4e0b\u5217\u4f55\u8005\u5c0d\u65bc\u6cbb\u7642\u6c23\u5598\u6025\u6027\u767c\u4f5c(acute exacerbations)\uff0c\u6c92\u6709\u89d2\u8272\uff1f\nA. Systemic corticosteroids\nB. Supplemental oxygen\nC. Inhaled heliox\nD. IV magnesium sulfate (MgSO4)\nE. Antibiotics\n": "(E)", "105-10.\n35\u6b72\u5e74\u8f15\u5973\u6027\uff0c\u56e0\u5065\u6aa2\u7167\u4e86\u4e00\u5f35\u80f8\u90e8X\u5149\uff0c\u5982\u4e0b\u5716\u6240\u793a\uff0c\u6b64\u5916\uff0c\u60a3\u8005\u5728\u5c0f\u817f\u4e0a\u6709\u76ae\u819a\u75c5\u5146\uff0c\u7d93\u8a3a\u65b7\u70ba\u7d50\u7bc0\u6027\u7d05\u6591(erythema nodosum)\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u6558\u8ff0\u6b63\u78ba\r1. \u9700\u8981\u8f49\u4ecb\u773c\u79d1\u91ab\u5e2b\u9032\u884c\u773c\u775b\u7684\u8a55\u4f30\r2. \u8a72\u75be\u75c5\u7684\u5206\u671f\u9700\u8981\u9032\u4e00\u6b65\u4f7f\u7528\u96fb\u8166\u65b7\u5c64\u9032\u884c\u5206\u671f\r3. \u6240\u6709\u60a3\u8005\u5747\u9700\u63a5\u53d7\u6cbb\u7642\r4. \u8a72\u75be\u75c5\u5bb9\u6613\u9020\u6210\u591a\u91cd\u5668\u5b98\u4fb5\u72af\r5. \u6240\u6709\u60a3\u8005\u7684\u8a3a\u65b7\u5747\u9700\u8981\u75c5\u7406\u5207\u7247\u7684\u6aa2\u67e5\nA. 1+3+4+5\nB. 1+2+4\nC. 1+4\nD. 2+3\nE. 2+4+5\n": "(C)", "105-11.\n57\u6b72\u7537\u6027\uff0c\u53f3\u4e0a\u80ba\u8449\u816b\u7624\uff0c\u7d93\u8b49\u5be6\u70ba\u80ba\u817a\u764c\u3002\u96fb\u8166\u65b7\u5c64\u986f\u793a\uff0c\u8a72\u816b\u7624\u7d044\u516c\u5206\u5927\uff0c\u53f3\u4e0b\u80ba\u8449\u53e6\u6709\u4e00\u5c0f\u816b\u7624\u7d041.5\u516c\u5206\u5927\uff0c\u4e5f\u8b49\u5be6\u70ba\u540c\u4e00\u7d44\u7e54\u578b\u7684\u80ba\u817a\u764c\uff0c\u540c\u5074\u814b\u4e0b\u6dcb\u5df4\u7d50\u7d93\u5207\u7247\u8b49\u5be6\u70ba\u8f49\u79fb\uff0c\u9664\u6b64\u4e4b\u5916\u7121\u5176\u4ed6\u6dcb\u5df4\u7d50\u4fb5\u72af\uff0c\u4e5f\u7121\u5176\u4ed6\u5668\u5b98\u9060\u7aef\u8f49\u79fb\uff0c\u8acb\u554f\u6839\u64da\u7b2c\u4e03\u7248\u7684\u80ba\u764cTNM\u5206\u671f\u7cfb\u7d71\uff0c\u75c5\u60a3\u7684\u80ba\u817a\u764c\u5206\u671f\u70ba\uff1f\nA. T2aN1M0, stage IIB\nB. T2aN3M0, stage IIIB\nC. T3N1M0, stage IIIA\nD. T4N3M0, stage IIIB\nE. T4N0M1b, stage IV\n": "(E)", "105-12.\n71\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u70ba\u54b3\u55fd\u4e09\u5468\uff0c\u80f8\u90e8X\u5149\u610f\u5916\u767c\u73fe\u5de6\u80ba\u6709\u9670\u5f71\u3002\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u986f\u793a(\u5982\u5716\u793a)\u5de6\u4e0b\u8449\u6709\u4e00\u9846\u816b\u7624\u53ca\u53f3\u6c23\u7ba1\u524d\u6709\u4e00\u98461\u516c\u5206\u6dcb\u5df4\u7d50\uff0c\u982d\u90e8\u96fb\u8166\u65b7\u5c64\u53ca\u9aa8\u9abc\u6383\u63cf\u7686\u7121\u7570\u5e38\u3002\u8acb\u554f\u63a5\u4e0b\u4f86\u7684\u6aa2\u67e5\u4f55\u8005\u6700\u6709\u6548\u7387\uff0c\u53ef\u4ee5\u5728\u6700\u77ed\u7684\u6642\u9593\u5f97\u5230\u6cbb\u7642\u6240\u9700\u8981\u7684\u8cc7\u8a0a\uff1f\nA. \u5148\u505a\u96fb\u8166\u65b7\u5c64\u63a5\u7247\u6aa2\u67e5\u78ba\u8a8d\u70ba\u60e1\u6027\u5f8c\uff0c\u518d\u505a\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\uff0c\u6dcb\u5df4\u7d50\u6709\u7570\u5e38\u518d\u505a\u7e31\u8188\u8154\u93e1\u6dcb\u5df4\u53d6\u6a23\u3002\nB. \u5148\u505a\u96fb\u8166\u65b7\u5c64\u63a5\u7247\u6aa2\u67e5\u78ba\u8a8d\u70ba\u60e1\u6027\u5f8c\uff0c\u518d\u505a\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\uff0c\u6dcb\u5df4\u7d50\u6709\u7570\u5e38\u518d\u505a\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u7d93\u6c23\u7ba1\u6dcb\u5df4\u7d50\u62bd\u5438\u3002\nC. \u5148\u505a\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u5468\u908a\u816b\u7624\u5207\u7247\uff0c\u518d\u505a\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\u3002\u6dcb\u5df4\u7d50\u6709\u7570\u5e38\u518d\u505a\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u7d93\u6c23\u7ba1\u6dcb\u5df4\u7d50\u62bd\u5438\u3002\nD. \u5148\u505a\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u7d93\u6c23\u7ba1\u6dcb\u5df4\u7d50\u62bd\u5438\uff0c\u78ba\u8a8d\u70ba\u60e1\u6027\u816b\u7624\uff0c\u5982\u679c\u70ba\u826f\u6027\u540c\u6642\u505a\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u5468\u908a\u816b\u7624\u5207\u7247\u5f8c\uff0c\u518d\u8003\u616e\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\u3002\nE. \u5148\u505a\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\uff0c\u78ba\u8a8d\u7121\u5176\u4ed6\u8f49\u79fb\u518d\u505a\u96fb\u8166\u65b7\u5c64\u5207\u7247\u6aa2\u67e5\u3002\n": "(D)", "105-13.\n65\u6b72\u7537\u6027\u75c5\u4eba\u814e\u7d72\u7403\u814e\u708e\u9577\u671f\u6d17\u814e\uff0c\u6700\u8fd1\u56e0\u98df\u617e\u4e0d\u632f\u4f86\u9580\u8a3a\uff0c\u75f0\u6db2\u6aa2\u67e5\u767c\u73fe\u70ba\u958b\u653e\u6027\u80ba\u7d50\u6838\uff0c\u9ad4\u91cd\u7d0460\u516c\u65a4\uff0c\u6297\u7d50\u6838\u85e5\u7269\u8a72\u5982\u4f55\u7d66\u4e88\uff1f\r1. INH (100mg) \u6bcf\u59293\u9846\r2. RIF (150 mg) \u6bcf\u59294\u9846\r3. Rifater \u6bcf\u59295\u9846\r4. EMB (400mg) \u6bcf\u59292.5 \u9846\r5. PZA (500mg) \u6bcf\u59293\u9846\r6. EMB\u6d17\u814e\u5f8c2.5 \u9846\r7. PZA\u6d17\u814e\u5f8c3\u9846\u3002\nA. 1+2+3+4\nB. 1+2+6+7\nC. 3+6\nD. 1+2+4+7\nE. 1+2+5+6\n": "(B)", "105-14.\n\u5728\u56b4\u91cd\u6c23\u5598\u767c\u4f5c\u7015\u81e8\u547c\u5438\u8870\u7aed\u7684\u75c5\u4eba\u53ef\u4ee5\u8003\u616e\u4e0b\u5217\u54ea\u4e9b\u6cbb\u7642\uff1f\r1. Noninvasive Ventilator\r2. \u9810\u9632\u6027\u7684\u63d2\u7ba1\u6cbb\u7642\uff0c\u7279\u5225\u662fCO2 \u6b63\u5e38\u6216\u7a0d\u9ad8\u7684\u75c5\u4eba\r3. \u975c\u8108\u6ce8\u5c04 \u03b22 agonist\r4. \u5438\u5165\u5f0f\u526f\u4ea4\u611f\u795e\u7d93\u62ee\u6297\u5291\uff08anticholinergic\uff09\r5. \u975c\u8108\u6ce8\u5c04 Aminophylline\uff08\u8336\u9e7c\uff09\r6. \u975c\u8108\u6ce8\u5c04 anti IgE antibody \uff08Omalizumab\uff09\nA. 1+3+4+5\nB. 2+3+4+5\nC. 2+4+5+6\nD. 1+3+5+6\nE. 2+3+4+6\n": "(B)", "105-15.\n79\u6b72\u5973\u6027\uff0c\u5f9e\u4e0d\u62bd\u83f8\uff0c\u5c0f\u6642\u5019\u7121\u6c23\u5598\u75c5\u53f2\uff0c\u70ba\u5bb6\u5ead\u4e3b\u5a66\uff0c30\u6b72\u4ee5\u5f8c\uff0c\u5076\u723e\u6703\u6709\u547c\u5438\u56f0\u96e3\u7684\u60c5\u6cc1\uff0c\u7279\u5225\u662f\u5728\u611f\u5192\u5f8c\u75c7\u72c0\u52a0\u5287\uff0c\u5728\u4e00\u822c\u8a3a\u6240\u670d\u7528\u85e5\u7269\u5f8c\u5373\u6539\u5584\u3002\u95dc\u65bc\u547c\u5438\u56f0\u96e3\u7684\u60c5\u6cc1\u96a8\u8457\u5e74\u9f61\u589e\u52a0\u800c\u8d8a\u4f86\u8d8a\u56b4\u91cd\uff0c\u8fd1\u5e74\u4f86\u5e38\u6709\u5598\u9cf4\u8072\uff0c\u80ba\u529f\u80fd\u6aa2\u67e5\u986f\u793a FVC 65.7 %\uff0c FEV1 43.1%\uff0c FEV/FVC 54.3%\uff0c Bronchodilator test negative to Fenoterol 100 mcq 4puff\uff0c \u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5178\u578b\u7684 COPD\u61c9\u8a72\u7d66\u4e88long-acting muscarinic antagonist\nB. \u53ef\u4ee5\u662f\u9577\u671f\u7684Asthma\u7684\u7d50\u679c\nC. \u53ef\u4ee5\u662fAsthma COPD overlap syndrome\nD. \u53ef\u4ee5\u7e7c\u7e8c\u7d66\u4e88Inhaled corticosteroid\nE. \u8003\u616e\u80ba\u90e8\u5fa9\u5065\u53ca\u6d41\u611f\u80ba\u708e\u93c8\u7403\u83cc\u75ab\u82d7\n": "(A)", "105-16.\n\u80ba\u9ad8\u58d3\uff08Pulmonary Hypertension\uff09\u6839\u64da\u6700\u65b0\u7684\u5b9a\u7fa9\u5206\u70ba\u4e94\u985e\uff0c\u5176\u4e2d\u54ea\u4e00\u985e\u88ab\u885b\u798f\u90e8\u5065\u4fdd\u7f72\u8a02\u7fa9\u70ba\u7f55\u898b\u75be\u75c5\uff1f\nA. \u80ba\u52d5\u8108\u9ad8\u58d3\uff08Pulmonary Arterial Hypertension\uff09\nB. \u5de6\u5fc3\u75be\u75c5\u5f15\u8d77\u7684\u80ba\u9ad8\u58d3\nC. \u6162\u6027\u80ba\u75c5\u5f15\u8d77\u7684\u80ba\u9ad8\u58d3\nD. \u6162\u6027\u8840\u6813\u6216\u6813\u585e\u75be\u75c5\u9020\u6210\u7684\u80ba\u9ad8\u58d3\nE. \u4e0d\u660e\u6216\u591a\u91cd\u539f\u56e0\u4e4b\u80ba\u9ad8\u58d3\n": "(A)", "105-17.\n63\u6b72\u5973\u6027\u75c5\u4eba\u56e0\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u63db\u904e\u4e8c\u5c16\u74e3\u74e3\u819c\uff0c\u5fc3\u5f8b\u4e0d\u6574\u9577\u671f\u4f7f\u7528\u85e5\u7269\u3002\u56e0\u70ba\u5598\u7684\u60c5\u5f62\u52a0\u5287\uff0cCXR\u53ca\u96fb\u8166\u65b7\u5c64\u5982\u5716\u793a\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u662f\uff1f\nA. \u70ba\u5178\u578b\u7684 Interstitial Lung Disease\uff0c\u53ef\u4ee5\u662fidiopathic pulmonary fibrosis\u3002\nB. \u80ba\u90e8\u6709\u8a31\u591a\u5c0f\u9ede\uff0cMiliary TB\u7121\u6cd5\u6392\u9664\u3002\nC. X\u5149\u53ca\u96fb\u8166\u65b7\u5c64\u6709\u8a31\u591a\u7684\u7dda\u689d\uff0c\u53ef\u4ee5\u662fkerley line \u61c9\u70ba\u80ba\u6c34\u816b\u3002\nD. \u7121\u986f\u5f71\u5291\u809d\u81df\u537b\u660e\u986f\u8f03\u4eae\u8981\u8003\u616eAmiodarone \u9020\u6210\u7684 Interstitial Lung Disease\u3002\nE. \u6709\u8a31\u591a\u7684\u9ede\u8ddf\u7dda\uff0c\u61c9\u8003\u616e\u80ba\u764c\u5408\u4f75 lymphangitis carcinomatosis\u3002\n": "(D)", "105-18.\n\u5c0d\u65bc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4 (ARDS)\uff0c\u4e0b\u5217\u54ea\u4e00\u7a2e\u8655\u7f6e\u65b9\u5f0f\u5c0d\u65bc\u9810\u5f8c\uff08survival\uff09\u662f\u6c92\u6709\u5e6b\u52a9\u7684\uff1f\nA. \u4e00\u6c27\u5316\u6c2e\u7684\u5438\u5165\u4f7f\u7528\uff08inhaled NO\uff09\u3002\nB. \u4fef\u81e5\uff08prone position\uff09\u3002\nC. \u4f4e\u6f6e\u6c23\u91cf\u8a2d\u5b9a\uff08Low tidal volume\uff09\u3002\nD. \u9ad8\u5410\u6c23\u672b\u7aef\u6b63\u58d3\uff08High PEEP or open Lung\uff09\u3002\nE. \u65e9\u671f\u795e\u7d93\u808c\u8089\u963b\u65b7\uff08early Neuromuscular Blockade\uff09\u3002\n": "(A)", "105-19.\n57\u6b72\u6cb9\u6f06\u5de5\u56e0\u80f8\u60b6\u4f86\u91ab\u9662\u5c31\u8a3a\uff0c\u5fc3\u81df\u76f8\u95dc\u6aa2\u67e5\u7121\u554f\u984c\uff0cCXR\u5982\u5716\uff0c\u4ed4\u7d30\u8a62\u554f\u904e\u53bb\u7684\u8077\u696d\uff0c\u66fe\u5728\u62c6\u8239\u5ee0\u5de5\u4f5c\u5341\u591a\u5e74\uff0c\u5176\u4ed6\u5668\u5b98\u4e26\u7121\u8f49\u79fb\u7684\u8de1\u8c61\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\u80ba\u817a\u764c\u3002\nB. \u504f\u5149\u986f\u5fae\u93e1\u53ef\u4ee5\u770b\u5230\u7d44\u7e54\u5207\u7247\u5167\u7684\u7d50\u6676\u3002\nC. \u514d\u75ab\u7d44\u7e54\u67d3\u8272TTF-1 \u61c9\u70ba Negative\u3002\nD. \u53ef\u4ee5\u8003\u616e\u5916\u79d1\u5207\u9664\u3002\nE. \u7b2c\u4e00\u7dda\u7684\u5316\u5b78\u6cbb\u7642\u70ba\u611b\u5be7\u9054\uff08pemetrexed\uff09\u52a0\u9251\u91d1\u3002\n": "(A)", "105-20.\n\u5c0d\u65bc\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u4f4e\u901a\u6c23\u75c7\u5019\u7fa4\uff08obstructive sleep apnea hypopnea syndrome OSAHS\uff09\u4e0b\u5217\u4f55\u8005\u70ba\u662f \ufe56\nA. \u5e38\u4f75\u767c\u8840\u58d3\u3001\u5fc3\u81df\u3001\u8166\u8840\u7ba1\u75be\u75c5\uff0c\u4f46\u8207\u7cd6\u5c3f\u75c5\u7121\u95dc\u3002\nB. \u6771\u65b9\u4eba\u767c\u751f\u6b64\u75c5\u7684\u5e73\u5747BMI\u8f03\u897f\u65b9\u4eba\u70ba\u4f4e\uff0c\u4e3b\u8981\u662f\u907a\u50b3\u75be\u75c5\u9020\u6210\u3002\nC. \u8a3a\u65b7\u56b4\u91cdOSAHS\u7684\u6a19\u6e96\u662fApnea hypoxia index \uff08AHI\uff09\u226715 events\uff0fH\u3002\nD. OSAHS \u5728\u7761\u7720\u5feb\u901f\u52d5\u773c\u671f\uff08REM\uff09\u75c7\u72c0\u6700\u56b4\u91cd\u3002\nE. \u75c5\u4eba\u6700\u5e38\u62b1\u6028\u75b2\u7d2f\u3001\u7121\u6cd5\u96c6\u4e2d\u7cbe\u795e\u3002\n": "(D)", "105-21.\n\u5c0d\u65bc\u6557\u8840\u75c7\u7684\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e \ufe56\nA. Early goal directed therapy \u4e3b\u8981\u662f\u70ba\u4e86\u63d0\u4f9b\u8db3\u5920\u7684\u704c\u6d41\uff0c\u5efa\u8b70\u5728\u8840\u58d3\u4f4e\u7684\u75c5\u4eba\uff0c\u524d\u4e00\u5230\u5169\u5c0f\u6642\u7d66\u4e881~2\u5347\u7684Normal Saline\u3002\nB. \u8d8a\u5feb\u7d66\u4e88\u8db3\u5920\u4e14\u9069\u7576\u7684\u6297\u751f\u7d20\u662f\u63d0\u9ad8\u5b58\u6d3b\u7387\u7684\u6c7a\u5b9a\u56e0\u7d20\u3002\nC. \u63d0\u5347\u7d44\u7e54\u6c27\u6c23\u7684\u4f7f\u7528\u662f\u6cbb\u7642\u7684\u76ee\u7684\u4e4b\u4e00\uff0c\u56e0\u6b64\u5fc5\u9808\u7dad\u6301\u975c\u8108\u6c27\u542b\u91cf\uff08\u6c27\u6c23\u98fd\u548c\u5ea6\uff09>70%\u3002\nD. \u70ba\u4e86\u7dad\u6301\u8db3\u5920\u8840\u6db2\u704c\u6d41\u53ca\u907f\u514d\u80ba\u6c34\u816b\uff0c\u4e2d\u5fc3\u975c\u8108\u58d3\u8981\u7dad\u6301\u57288~12cm H2O \u3002\nE. \u76e1\u91cf\u7dad\u6301\u5c3f\u91cf\u57280.5ml\uff0fKg\u4ee5\u4e0a\uff0c\u5982\u679c\u5c3f\u91cf\u4e0d\u8db3\u53ef\u4ee5\u8003\u616e\u5229\u5c3f\u5291furosemide\u4f7f\u7528\u3002\n": "(C)", "105-22.\n\u5c0d\u65bcCOPD\u7684\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e\ufe56\nA. \u5c0d\u65bc\u904b\u52d5\u6703\u5598\u7684\u75c5\u4eba\uff0c\u904b\u52d5\u6642\u7d66\u4e88\u6c27\u6c23\u662f\u53ef\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\u3002\nB. \u5438\u5165\u6027\u985e\u56fa\u9187\u5c0d\u65bc\u6b7b\u4ea1\u7387\u7684\u964d\u4f4e\u4ecd\u6709\u722d\u8b70\uff0c\u5c0d\u65bc\u6025\u6027\u767c\u4f5c\u4e00\u5e74\u8d85\u904e\u5169\u6b21\u7684\u75c5\u4eba\uff0c\u53ef\u4ee5\u8003\u616e\u4f7f\u7528\u3002\nC. \u80ba\u90e8\u5fa9\u5065\u662f\u6cbb\u7642COPD\u91cd\u8981\u7684\u6cbb\u7642\u4e4b\u4e00\uff0c\u53ef\u4ee5\u6709\u6548\u964d\u4f4e\u4f4f\u9662\u7387\u3002\nD. \u9810\u9632\u6027\u7684\u6297\u751f\u7d20\u4f7f\u7528\uff0c\u7121\u6cd5\u964d\u4f4e\u6025\u6027\u767c\u4f5c\u7684\u6b21\u6578\uff0c\u4f46azithromycin\u4f3c\u4e4e\u53ef\u4ee5\u5ef6\u9577\u6025\u6027\u518d\u767c\u4f5c\u7684\u5929\u6578\u3002\nE. \u975e\u4fb5\u8972\u6027\u6b63\u58d3\u547c\u5438\u5668\u53ef\u4ee5\u5e6b\u5fd9COPD\u547c\u5438\u8870\u7aed\u7684\u75c5\u4eba\uff0c\u4f46\u610f\u8b58\u4e0d\u6e05\u6216\u75f0\u91cf\u592a\u591a\u7684\u75c5\u4eba\u4e0d\u5efa\u8b70\u4f7f\u7528\u3002\n": "(A)", "106-1.\n\u95dc\u65bc\u80ba\u90e8\u7684\u7406\u5b78\u6aa2\u67e5\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. Velcro crackles \u53ef\u898b\u65bc\u80ba\u7e96\u7dad\u5316(idiopathic pulmonary fibrosis, IPF) \u60a3\u8005\u3002\nB. Pulsus paradoxus \u51fa\u73fe\u5728\u963b\u585e\u6027\u80ba\u75c5(obstructive lung disease)\u60a3\u8005\u6642\uff0c\u662f\u4e00\u500b\u4e0d\u597d\u7684\u5fb5\u8c61\uff0c\u53ef\u80fd\u662f\u7015\u81e8\u547c\u5438\u8870\u7aed (impending respiratory failure)\u7684\u5fb5\u5146\u3002\nC. Egophony\u662f\u6307\u75c5\u4eba\u767c\u51fa\"AH\"\u7684\u8072\u97f3\uff0c\u7d93\u7531\u5be6\u8cea\u5316\u5340\u57df\u7684\u7570\u5e38\u50b3\u5c0e\uff0c\u91ab\u5e2b\u5728\u807d\u8a3a\u6642\u807d\u5230 \"EEE\"\u7684\u8072\u97f3\uff0c\u53ef\u898b\u65bc\u80ba\u708e (pneumonia)\u60a3\u8005\u3002\nD. Wheezes \u5e38\u898b\u65bc\u6c23\u5598( asthma)\u60a3\u8005\uff0c\u4f46\u5728\u9b31\u8840\u6027\u5fc3\u8870\u7aed (congestive heart failure)\u7684\u60a3\u8005\u4e5f\u53ef\u898b\u5230\u3002\nE. stridor\u662f\u5438\u6c23\u6642\u9ad8\u983b\u7684\u8072\u97f3\uff0c\u5e38\u70baupper airway obstruction\u7684\u8868\u73fe\u3002\n": "(C)", "106-2.\n\u95dc\u65bc\u547c\u5438\u529f\u80fd\u65b9\u9762\u7684\u6aa2\u67e5\uff0c\u4ee5\u4e0b\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4e00\u6c27\u5316\u78b3\u80ba\u64f4\u6563\u529b\u6aa2\u67e5(DLCO\uff0cdiffusion capacity of CO in lung)\u5728\u80ba\u6c23\u816b  (emphysema)\u7684\u60a3\u8005\u6703\u4e0b\u964d\uff0c\u5728\u6709\u5de6\u81f3\u53f3\u5fc3\u5167\u5206\u6d41(left-to-right intracardiac shunt)\u7684\u60a3\u8005\u6703\u4e0a\u5347\u3002\nB. \u80ba\u91cf\u8a08\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u8a66\u9a57 (spirometry with bronchodilator reversibility test)\u662f\u5728\u5438\u5165\u652f\u6c23\u7ba1\u64f4\u5f35\u5291(\u5982:albuterol\u6216ipratropium)\u7684\u524d\u5f8c\uff0c\u9032\u884c\u80ba\u91cf\u8a08(spirometry)\u7684\u6e2c\u8a66\u3002\u524d\u5f8c\u80ba\u529f\u80fd\u7684\u8b8a\u5316\u7a0b\u5ea6\uff0c\u7531\u65bc\u91cd\u73fe\u6027\u4e0d\u4f73\uff0c\u7121\u6cd5\u826f\u597d\u5730\u9810\u6e2c\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u6cbb\u7642\u7684\u9577\u671f\u6548\u679c\u3002\nC. \u547c\u6c23\u4e2d\u4e00\u6c27\u5316\u6c2e\u7684\u6fc3\u5ea6(fraction of exhaled nitric oxide, FeNO)\u662f\u55dc\u4f0a\u7d05\u6027\u7d30\u80de\u547c\u5438\u9053\u767c\u708e(Eosinophilic Airway Inflammation) \u7684\u6307\u6a19\uff0c\u53ef\u7528\u65bc\u9810\u6e2c\u547c\u5438\u9053\u963b\u585e\u5c0d\u985e\u56fa\u9187\u6cbb\u7642(corticosteroid)\u7684\u53cd\u61c9\u3002\nD. \u6e2c\u91cf\u6700\u5927\u547c\u5438\u58d3\u529b(maximal respiratory pressures)\u6709\u52a9\u65bc\u627e\u51fa\u808c\u8089\u7121\u529b(muscle weakness)\u5c0e\u81f4\u7684\u4fb7\u9650\u6027\u901a\u6c23\u969c\u7919(restrictive ventilator impairment)\u75c5\u60a3\uff0c\u4e5f\u5bb9\u6613\u5340\u5206\u808c\u8089\u7121\u529b\u8207\u6e2c\u8a66\u914d\u5408\u5ea6\u4e0d\u4f73(poor test performance)\u7684\u60a3\u8005\u3002\nE. \u6fc0\u767c\u8a66\u9a57(provocation test)\u662f\u6e2c\u91cf\u6c23\u9053\u904e\u5ea6\u53cd\u61c9(airway hyperresponsiveness)\u53ef\u7528methacholine\u6216\u51b7\u7a7a\u6c23\u6216\u8eab\u9ad4\u523a\u6fc0(physical stimuli)\u3002\n": "(D)", "106-3.\n\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(chronic obstructive pulmonary disease, COPD)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8a3a\u65b7COPD\u4e00\u5b9a\u9700\u8981\u80ba\u91cf\u8a08(spirometry)\u8207\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u8a66\u9a57 (bronchodilator reversibility test)\u3002\nB. \u8f15\u5ea6\u5230\u4e2d\u5ea6\u7684COPD\u60a3\u8005\uff0c\u82e5\u6709\u547c\u5438\u9053\u9ad8\u53cd\u61c9\u6027(airway hyperresponsiveness\uff0cAHR)\uff0c\u53ef\u4ee5\u9810\u6e2c\u80ba\u529f\u80fd\u6703\u52a0\u901f\u4e0b\u964d\uff0c\u7279\u5225\u662f\u6301\u7e8c\u5438\u83f8\u8005\u3002\nC. \u5408\u4e4e\u6162\u6027\u652f\u6c23\u7ba1\u708e(chronic bronchitis)\u5b9a\u7fa9\u7684\u60a3\u8005\u90fd\u5c6c\u65bcCOPD\u3002\nD. Centriacinar emphysema\u4e3b\u8981\u5f71\u97ffrespiratory bronchiole\uff0c\u5e38\u898b\u65bc\u03b11-antitrypsin deficiency\u60a3\u8005\u3002\nE. \u80ba\u6c23\u816b(emphysema)\u662f\u75c5\u7406\u8a3a\u65b7\uff0c\u800c\u6162\u652f\u6c23\u7ba1\u708e(chronic bronchitis)\u70ba\u81e8\u5e8a\u8a3a\u65b7\u3002\n": "(D)", "106-4.\n\u80ba\u529f\u80fd\u6aa2\u67e5\u7684\u6c23\u6d41\u5bb9\u7a4d\u95dc\u4fc2(flow-volume volume/loop)\u8207\u75be\u75c5\u7684\u914d\u5c0d(\u5982\u5716)\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1a(X\u8ef8\u70ba\u5bb9\u7a4d\uff0cY\u8ef8\u70ba\u6c23\u6d41\uff0cY\u8ef8\u6b63\u5411\u70ba\u5410\u6c23\u3001\u8ca0\u5411\u70ba\u5438\u6c23, TLC:total lung capacity, RV: residual volume)\nA. \u8072\u5e36\u9ebb\u75fa(vocal cord paralysis)\uff0c\u9020\u6210\u547c\u5438\u9053\u963b\u585e(variable extra-thoracic obstruction)\u3002\nB. \u5fa9\u767c\u6027\u591a\u8edf\u9aa8\u708e(relapsing polychondritis)\uff0c\u9020\u6210\u547c\u5438\u9053\u963b\u585e(variable intra-thoracic obstruction)\u3002\nC. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(chronic obstructive pulmonary disease, COPD)\u9020\u6210\u7684\u963b\u585e\u6027\u901a\u6c23\u969c\u7919(obstructive ventilatory impairment)\u3002\nD. \u80ba\u7e96\u7dad\u5316(pulmonary fibrosis)\u9020\u6210\u7684\u4fb7\u9650\u6027\u901a\u6c23\u969c\u7919(restrictive ventilatory impairment)\u3002\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(A)", "106-5.\n\u75c5\u60a3\u80f8\u90e8X\u5149\u7247\u8207\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u5982\u5716\uff0c \u4ee5\u4e0b\u8a3a\u65b7\u4f55\u8005\u6700\u70ba\u53ef\u80fd:\nA. Small cell lung cancer\nB. Septic emboli\nC. Sarcoidosis\nD. Bronchiolitis obliterans organizing pneumonia\nE. Pulmonary fibrosis\n": "(B)", "106-6.\n\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (chronic obstructive pulmonary disease\uff0cCOPD)\u7684\u8a55\u4f30\u8207\u6cbb\u7642\uff0c\u4e0b\u5217\u90a3\u4e9b\u63cf\u8ff0\u932f\u8aa4\uff1f(1) 2011-2016\u5e74\u4fee\u8a02\u4e4bGOLD (Global Initiative for Chronic Obstructive Lung Disease) COPD guideline\uff0c\u9664\u4e86FEV1 (forced expiratory volume in one second\uff0c\u7528\u529b\u547c\u6c23\u4e00\u79d2\u91cf)\u4e4b\u5916\uff0c\u52a0\u5165\u4e86\u524d\u4e00\u5e74\u6025\u6027\u60e1\u5316(acute exacerbation)\u767c\u4f5c\u6b21\u6578\u8207\u81e8\u5e8a\u75c7\u72c0\uff0c\u5c07\u75c5\u60a3\u5206\u70baABCD\u56db\u985e\u3002\u6b64\u5206\u985e\u65b9\u5f0f\u6bd4FEV1\u66f4\u80fd\u9810\u6e2c\u75c5\u60a3\u7684\u6b7b\u4ea1\u7387\u8207\u6025\u6027\u60e1\u5316\u7684\u98a8\u96aa\uff1b(2) GOLD 2017 COPD guideline\uff0c\u4f9d\u7167\u75c5\u60a3\u524d\u4e00\u5e74\u6025\u6027\u60e1\u5316(acute\r\nexacerbation)\u767c\u4f5c\u6b21\u6578\u8207\u81e8\u5e8a\u75c7\u72c0\u4f86\u5efa\u8b70\u6cbb\u7642\u7684\u85e5\u7269\uff0c\u4e0d\u5fc5\u518d\u8003\u616eFEV1\uff1b(3) \u4ee5\u5438\u5165\u6027\u7528\u85e5\u800c\u8a00\uff0c\u9577\u6548\u578b\u7684\u4e59\u578b\u81f4\u6548\u5291(long-acting beta2-agonist\uff0cLABA) \u8207\u5438\u5165\u6027\u985e\u56fa\u9187(ICS) \u7684\u7d44\u5408\uff0c\u6bd4LABA\u8207\u9577\u6548\u578b\u7684\u6bd2\u8548\u9e7c\u62ee\u6297\u5291(long-acting anti-muscarinic antagonist\uff0cLAMA)\u7684\u7d44\u5408\u66f4\u80fd\u6e1b\u5c11\u60e1\u5316\u7684\u98a8\u96aa\uff1b(4) LABA/LAMA\u7684\u7d44\u5408\u8207LABA/ICS\u7684\u7d44\u5408\uff0c\u5169\u8005\u80ba\u708e\u4f75\u767c\u75c7\u767c\u751f\u7684\u6bd4\u4f8b\u6709\u986f\u8457\u5dee\u7570\uff1b(5)\u91dd\u5c0dC\u985e\u7684\u75c7\u72c0\u8f15\u4f46\u662f\u60e1\u5316\u98a8\u96aa\u9ad8\u7684COPD\u75c5\u60a3\uff0cGOLD 2017 COPD guideline\u5efa\u8b70\u512a\u5148\u8003\u616e\u4f7f\u7528LABA\u6cbb\u7642\u3002\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(5)\nE. (1)+(4)+(5)\n": "(D)", "106-7.\n\u95dc\u65bc\u63db\u6c23\u63a7\u5236(ventilatory control)\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. heyne-Stokes\u547c\u5438\u7d04\u4f54\u547c\u5438\u4e2d\u6b62\u75c7(sleep apnea)\u60a3\u8005\u76845~10%\uff0c\u5728\u6c92\u6709\u5fc3\u8870\u7aed(heart failure)\u60a3\u8005\u8eab\u4e0a\uff0c\u4e26\u4e0d\u5e38\u898b\u3002\nB. Hypoventilation syndrome\u5b9a\u7fa9\u70ba\u7f3a\u4e4f\u8db3\u5920\u7684\u901a\u6c23\u91cf\u4ee5\u7dad\u6301\u6b63\u5e38\u52d5\u8108\u8840\u4e2dCO2\u5206\u58d3(PaCO2)\u3002\u6700\u5e38\u898b\u7684\u60c5\u5f62\u70ba\u56b4\u91cd\u7684\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (chronic obstructive pulmonary disease\uff0cCOPD)\u6216\u75c5\u614b\u80a5\u80d6(morbid obesity)\u3002\nC. Central congenital hypoventilation syndrome\u4e4b\u524d\u88ab\u7a31\u70baOndine curse\uff0c\u662f\u7b2c\u56db\u5c0d\u67d3\u8272\u9ad4\u4e0a\u7684PHOX2B\u57fa\u56e0\u767c\u751f\u7a81\u8b8a\uff0c\u9020\u6210\u5c0dCO2\u7684\u901a\u6c23\u53cd\u61c9\u4e0d\u8db3\u3002\nD. \u5973\u6027\u3001PaCO2\u57fa\u790e\u503c\u8f03\u9ad8\u3001\u5fc3\u623f\u64b2\u52d5(atrial flutter)\u90fd\u662fCheyne-Stokes\u547c\u5438\u7684\u5371\u96aa\u56e0\u5b50\u3002\nE. 90% \u7684obesity-hypoventilation syndrome\u60a3\u8005\u5408\u4f75\u6709\u963b\u585e\u578b\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7( obstructive sleep apnea)\u3002\n": "(D)", "106-8.\n\u95dc\u65bc\u963b\u585e\u578b\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7 (Obstructive Sleep Apnea/Hypopnea Syndrome\uff0cOSAHS)\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\nA. GOLD 2017 COPD guideline\u5c07OSAHS\u7d0d\u5165COPD\u7684\u5171\u75c5\u75c7\u4e4b\u4e00\u3002\nB. \u5408\u4f75\u6709COPD\u8207OSAHS\u7684\u60a3\u8005\uff0c\u6bd4\u53ea\u6709\u55ae\u4e00\u75be\u75c5\u7684\u60a3\u8005\u9810\u5f8c\u8f03\u5dee\uff0c\u767d\u5929\u4e5f\u66f4\u5bb9\u6613\u767c\u751f\u80ba\u9ad8\u58d3(pulmonary hypertension)\u3002\nC. 2016\u5e74\u5927\u578b\u7684\u96a8\u6a5f\u5206\u6d3e\u5be6\u9a57SAVE study\u8b49\u5be6\u6301\u7e8c\u967d\u58d3\u6cbb\u7642(continuous positive airway pressure\uff0cCPAP)\u53ef\u4ee5\u9810\u9632\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u767c\u751f\u3002\nD. OSAHS\u5c0d\u5065\u5eb7\u9020\u6210\u7684\u4e0d\u5229\u5f71\u97ff\u662f\u900f\u904echronic intermittent hypoxemia \u8207sleep fragmentation\u6240\u9020\u6210\nE. \u4ee5\u9023\u7e8c\u967d\u58d3\u547c\u5438\u5668\u6cbb\u7642(CPAP)\u6cbb\u7642overlap syndnome\u53ef\u4ee5\u6539\u5584COPD\u9810\u5f8c\n": "(C)", "106-9.\n\u95dc\u65bc\u6c23\u5598 (asthma)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5438\u5165methacholin\u6216histamine\u6703\u9020\u6210\u652f\u6c23\u7ba1\u6536\u7e2e(bronchoconstriction)\u7a31\u70ba\u547c\u5438\u9053\u904e\u5ea6\u53cd\u61c9\u6027(airway hyperresponsiveness\uff0cAHR)\u3002\u9019\u662f\u6c23\u5598(asthma)\u7684\u7279\u5fb5\uff0c\u4f46\u5728\u5f88\u591aCOPD\u60a3\u8005\u8eab\u4e0a\u4e5f\u53ef\u898b\u5230\u3002\nB. \u547c\u6c23\u4e2d\u4e00\u6c27\u5316\u6c2e\u7684\u6fc3\u5ea6(fraction of exhaled nitric oxide, FeNO)\u5df2\u88ab2017 GINA (Global Initiative for Asthma) guideline \u5efa\u8b70\u53ef\u4ee5\u7528\u4f86\u5f15\u5c0e\u6cbb\u7642asthma (FENO-guided treatment)\u3002\nC. \u5c0d\u65bc\u540c\u6642\u6709\u6162\u6027\u9f3b\u7ac7\u708e(chronic rhinosinusitis)\u7684\u60a3\u8005\uff0c\u6cbb\u7642\u9f3b\u7ac7\u708e\u50c5\u80fd\u6539\u5584\u9f3b\u5b50\u548c\u547c\u5438\u9053\u7684\u75c7\u72c0\uff0c\u5c0d\u65bcasthma outcome\u4e26\u7121\u5e6b\u52a9\u3002\nD. Asthma with obesity\u662fasthma\u7684\u8868\u73fe\u578b(phenotype)\u4e4b\u4e00\uff0c\u6709\u8f03\u660e\u986f\u7684\u547c\u5438\u9053\u75c7\u72c0\uff0c\u4f46\u5f88\u5c11\u55dc\u4f0a\u7d05\u6027\u547c\u5438\u9053\u767c\u708e(eosinophilic airway inflammation)\u3002\nE. \u6c23\u5598\u75c5\u4eba\u7684\u8a55\u4f30\u4e2d\u5305\u62ec\u5171\u75c5\u5982\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7(obstructive sleep apnea)\u3002\n": "(BorC)", "106-10.\n\u95dc\u65bc\u6c23\u5598 (asthma)\u8a55\u4f30\u8207\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u75c7\u72c0\u662f\u5426\u63a7\u5236\u8981\u8a55\u4f30\u65e5\u591c\u9593\u75c7\u72c0\u3001\u662f\u5426\u9700\u8981\u7de9\u89e3\u7528\u85e5(reliever)\u548c\u6709\u6c92\u6709\u56e0\u70ba\u6c23\u5598\u65e5\u5e38\u7684\u6d3b\u52d5\u53d7\u9650\u3002\nB. \u6bcf\u5468\u767d\u5929\u767c\u4f5c\u5169\u6b21\u4ee5\u4e0a\u5c31\u5fc5\u9808\u8981\u898f\u5f8b\u7684controller(\u5438\u5165\u6027\u985e\u56fa\u9187)\u6cbb\u7642\u3002\nC. \u6c23\u5598\u63a7\u5236\u4e0d\u4f73\u6700\u5e38\u898b\u7684\u539f\u56e0\u662f\u7528\u85e5\u7684compliance\u4e0d\u597d\uff0c\u7279\u5225\u662f\u5438\u5165\u6027\u985e\u56fa\u9187\u3002\nD. \u6c23\u5598\u5b8c\u5168\u63a7\u52363\u500b\u6708\u5f8c\uff0c\u53ef\u4ee5\u505c\u7528controller\u6cbb\u7642\u3002\nE. \u5728\u6c23\u5598\u75c5\u4eba\u7684\u8a55\u4f30\u61c9\u5305\u62ec\u5171\u75c5\u5982\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7(obstructive sleep apnea)\n": "(D)", "106-11.\n80\u6b72\u7537\u6027\u6709\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(chronic obstructive pulmonary disease\uff0cCOPD)\uff0c\u547c\u5438\u56f0\u96e3\u3001\u54b3\u55fd\u6709\u9ec3\u75f0\u5df2\u6301\u7e8c\u4e00\u5468\uff0c\u5f8c\u4f86\u610f\u8b58\u8b8a\u5dee\u88ab\u9001\u5230\u6025\u8a3a\u3002\u5728\u6025\u8a3a\u6642\u6aa2\u67e5\u986f\u793a\uff0c\u610f\u8b58E1V1M3\uff0c\u8840\u58d3102/62 mmHg\uff0c\u5fc3\u8df3118/min\uff0c\u547c\u5438\u901f\u738712/min\uff0c\u80ba\u90e8\u6709\u660e\u986f\u6d78\u6f64\uff0cKUB\u5448\u73febowel loop dilatation\uff0c\u5c3f\u91cf\u6709\u6e1b\u5c11\u3002\u7121\u8178\u8815\u52d5\u97f3\uff0c\u7121\u8179\u819c\u708e\u7684\u5fb5\u8c61\u3002\u5728\u672a\u7528\u6c27\u6c23\u7684\u72c0\u614b\u4e0b\uff0c\u52d5\u8108\u6c23\u9ad4\u5206\u6790(arterial blood gas): pH =7.2, PaO2= 65 mmHg, PaCO2 =60 mmHg, HCO3= 18 mEq/L, SaO2 93%\u3002\u8840\u6e05\u4e2d[Na+]=140 mmol/L, [K+] = 2.8 mmol/L , [Cl-] =96 mmol/L, [BUN]=36 mg/dL, [Creatinin] =1.6\r\nmg/dL\u3002\u4ee5\u4e0b\u54ea\u4e9b\u63cf\u8ff0\u6216\u8655\u7f6e\u662f\u6b63\u78ba\u7684\uff1a\r\n(1) \u75c5\u60a3\u7684\u72c0\u614b\u662f\u4ee3\u8b1d\u6027\u9178\u8840\u75c7(metabolic acidosis)\u5408\u4f75\u547c\u5438\u9178\u8840\u75c7(respiratory acidosis)\u3002\r\n(2) \u70baCOPD\u5408\u4f75\u6025\u6027\u547c\u5438\u8870\u7aed\uff0c\u61c9\u512a\u5148\u4f7f\u7528\u975e\u4fb5\u8972\u6027\u96d9\u76f8\u967d\u58d3\u547c\u5438\u5668(bi-level positive airway pressure\uff0cBiPAP)\u3002\r\n(3) \u70ba\u9ad8\u9670\u96e2\u5b50\u9593\u9699(Anion Gap)\u4e4b\u9178\u8840\u75c7\uff0c\u53ef\u80fd\u6709\u6557\u8840\u75c7\u5408\u4f75\u4f11\u514b\u5728\u9032\u884c\u3002\r\n(4) \u6613\u6709\u5fc3\u5ba4\u6027\u5fc3\u640f\u904e\u901f(ventricular tachycardia)\u767c\u751f\u3002\r\n(5) \u6709\u8178\u963b\u585e\u7684\u5fb5\u8c61\uff0c\u61c9\u6703\u8a3a\u5916\u79d1\u91ab\u5e2b\u9032\u884c\u6025\u8a3a\u624b\u8853\u3002\nA. (1)+(2)+(3)\nB. (3)+(4)+(5)\nC. (1)+(3)+(4)\nD. (1)+(2)+(5)\nE. (1)+(3)+(5)\n": "(C)", "106-12.\n70\u6b72\u4e4b\u7537\u6027\u75c5\u4eba\uff0c\u4e00\u5929\u5169\u5305\u83f8\u3002\u6700\u8fd1\u5341\u5e74\u4f86\u5e38\u6709\u75f0\u53ca\u54b3\u55fd\uff0c\u6700\u8fd1\u4e00\u5e74\u4f86\u4e26\u6709\u904b\u52d5\u5f8c\u547c\u5438\u56f0\u96e3\u4e4b\u75c7\u72c0\u3002\u5c31\u8a3a\u6642\u7406\u5b78\u6aa2\u67e5\u7d50\u679c\u5982\u4e0b\uff1a\u8840\u58d3\u53ca\u8108\u640f\u6b63\u5e38\uff0c\u547c\u5438\u6bcf\u5206\u941822\u6b21\uff0c\u7121\u767c\u7d3a\u73fe\u8c61\uff0c\u80f8\u5ed3\u4e4b\u524d\u5f8c\u5f91\u8f03\u6b63\u5e38\u589e\u52a0\u3002\u53e9\u8a3a\u6642\u5448\u793a\u300c\u904e\u5ea6\u56de\u97ff\u300d\u4e4b\u73fe\u8c61\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u4e4b\u90e8\u4efd\u7d50\u679c\u5982\u4e0b\uff1apH7.36\uff0cPaO2 74mmHg\uff0cPaCO2 58mmHg\u3002\u75c5\u4eba\u70ba\u4ec0\u9ebc\u89ba\u5f97\u5598?\nA. \u56e0\u70ba\u8840\u6db2\u6c27\u6c23\u6fc3\u5ea6\u4e0d\u5920 (PaO2 74mmHg)\nB. \u56e0\u70ba\u8840\u6db2\u9178\u9e7c\u503c\u8d85\u904e\u6b63\u5e38\u503c\nC. \u56e0\u70ba\u4e8c\u6c27\u5316\u78b3\u6fc3\u5ea6\u592a\u9ad8 (PaCO2 58mmHg)\nD. \u80f8\u5ed3\u4e4b\u524d\u5f8c\u5f91\u589e\u52a0\uff0c\u547c\u5438\u808c\u7121\u6cd5\u6709\u6548\u904b\u4f5c\nE. \u54b3\u55fd\u75f0\u592a\u591a\u6240\u4ee5\u89ba\u5f97\u5598\n": "(C)", "106-13.\n\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(COPD\u7c21\u7a31\u80ba\u963b\u585e)\u75c5\u4eba\u80ba\u529f\u80fd\u6aa2\u67e5FVC 3600\u6beb\u5347\uff08\u9810\u6e2c\u503c3880\u6beb\u5347\uff09\uff0cFEV1 2160\u6beb\u5347\uff08\u9810\u6e2c\u503c3100\u6beb\u5347\uff09\u76ee\u524d\u75c5\u60c5\u7121\u986f\u8457\u8b8a\u5316\uff0c\u6b64\u6642\u75c5\u4eba\u6700\u4e0d\u9700\u8981\u7684\u6cbb\u7642\u70ba\u4f55?\nA. \u80ba\u708e\u93c8\u7403\u83cc\u75ab\u82d7\u53ca\u6d41\u611f\u75ab\u82d7\nB. \u6212\u83f8\nC. \u5438\u5165\u578b\u6c23\u7ba1\u64f4\u5f35\u5291\nD. \u80ba\u5fa9\u539f(\u80ba\u5fa9\u5065)\nE. \u53e3\u670d\u6297\u751f\u7d20\n": "(E)", "106-14.\n77\u6b72\u7537\u6027\u8001\u7159\u69cd\u4e00\u59291\u81f32\u5305\u83f8\uff0c\u8d85\u904e50\u5e74\uff0c\u56e0\u70ba\u8116\u5b50\u6478\u5230\u4e00\u9846\u6dcb\u5df4\u7d50\u4f86\u5230\u91ab\u9662\u3002\u4e00\u7cfb\u5217\u7684\u6aa2\u67e5\u767c\u73fe\u70ba\u5206\u5316\u4e0d\u597d\u7684\u80ba\u817a\u764c\uff0c\u5177\u6709KRAS Mutation\uff0c\u6709\u9aa8\u9abc\u53ca\u76ae\u4e0b\u7684\u8f49\u79fb\uff0c\u75c5\u4eba\u8a62\u554f\u514d\u75ab\u6cbb\u7642\u7684\u53ef\u80fd\u6027\uff0c\u4ee5\u4e0b\u4f55\u8005\u70ba\u662f\uff1f(1)\u5efa\u8b70\u505a\u751f\u7269\u6a19\u8a8c\u7d30\u80de\u7a0b\u5f0f\u6b7b\u4ea1-\u914d\u9ad41 (PD-L1)\u514d\u75ab\u7d44\u7e54\u67d3\u8272\uff0c\u816b\u7624\u7d30\u80de\u67d3\u8272\u8d85\u904e50%\uff0c\u53ef\u4ee5\u8003\u616e\u7b2c\u4e00\u7dda\u4f7f\u7528\uff1b(2)\u62bd\u83f8\u7684\u75c5\u4eba\u5c0d\u65bc\u514d\u75ab\u6cbb\u7642\u6548\u679c\u8f03\u597d\uff1b(3)KRAS Mutation \u5c0d\u65bc\u514d\u75ab\u6cbb\u7642\u6548\u679c\u8f03\u597d\uff1b(4)\u514d\u75ab\u6cbb\u7642\u5728\u80ba\u817a\u764c\u7684\u75c5\u4eba\u4e5f\u6709\u5e6b\u52a9\uff0c\u4f46\u8207\u5316\u7642\u7684\u5dee\u7570\uff0c\u8f03\u9c57\u72c0\u7d30\u80de\u764c\u4e0d\u660e\u986f\uff1b(5)\u80ba\u764c\u7684\u514d\u75ab\u6cbb\u7642\u6cd5\u662f\u5c07\u75c5\u4eba\u7684 T \u7d30\u80de\u5206\u96e2\u51fa\u4f86\u8207\u6297\u539f\u4e00\u8d77\u57f9\u990a\u5f8c\u518d\u6ce8\u5c04\u56de\u53bb\u3002\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(4)\nC. (1)+(2)+(3)\nD. (1)+(2)+(4)\nE. (1)+(2)\n": "(B)", "106-15.\n\u4e0b\u5217\u5c0d\u53f0\u7063\u80ba\u764c\u7684\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f(1)\u53f0\u7063\u5973\u6027\u80ba\u817a\u764c\uff0c\u62bd\u83f8\u7684\u6bd4\u4f8b\u4e0d\u523010%\uff1b(2)\u7537\u6027\u75c5\u4eba\u6700\u5e38\u898b\u7684\u662f\u9c57\u72c0\u7d30\u80de\u764c\uff1b(3)\u8207\u5c0f\u7d30\u80de\u80ba\u764c\u76f8\u8f03\uff0c\u9c57\u72c0\u7d30\u80de\u764c\u8207\u62bd\u83f8\u7684\u95dc\u806f\u6027\u66f4\u9ad8\uff1b(4)\u81fa\u7063\u80ba\u764c\u7684\u7537\u5973\u6bd4\u4f8b\u76f8\u8f03\u897f\u65b9\u570b\u5bb6\uff0c\u5973\u6027\u80ba\u764c\u6bd4\u4f8b\u504f\u9ad8\uff1b(5)\u56e0\u70ba\u6a19\u9776\u85e5\u7269\u53ca\u514d\u75ab\u6cbb\u7642\u7684\u767c\u5c55\uff0c\u80ba\u764c\u7684\u9810\u5f8c\u6bd4\u80c3\u764c\u53ca\u8178\u764c\u597d\u3002\nA. (1+)(3)+(4)\nB. (2)+(3)+(5)\nC. (1)+(3)+(5)\nD. (3)+(4)+(5)\nE. (2)+(4)+(5)\n": "(B)", "106-16.\n72\u6b72\u5973\u6027\u80a1\u9aa8\u9aa8\u6298\u958b\u5200\u4f4f\u9662\uff0c\u4e09\u5929\u5f8c\u7a81\u767c\u5598\uff0c\u7406\u5b78\u6aa2\u67e5\u5448\u73fe\u5fc3\u8df3\u6bcf\u5206\u9418120\u4e0b\uff0c\u547c\u5438\u6bcf\u5206\u941825\u6b21\uff0c\u8840\u6c27\u6fc3\u5ea694%(Room air)\uff0c\u6c92\u6709\u767c\u71d2\uff0c\u5fc3\u80ba\u6aa2\u67e5\u7121\u7570\u5e38\u3002\u5fc3\u96fb\u5716\u986f\u793a\u7ac7\u6027\u5fc3\u8df3\u904e\u901f(sinus tachycardia)\uff0c\u52d5\u8108\u8840\u6aa2\u67e5:\u9178\u9e7c\u503c7.52\uff0c\u4e8c\u6c27\u5316\u78b3\u5206\u58d3 (PaCO2)25mmHg\uff0c\u4e0b\u4e00\u6b65\u8a72\u505a\u751a\u9ebc\u6aa2\u67e5\u6216\u6cbb\u7642\uff1f\nA. \u5b89\u6170\u75c5\u4eba\u5598\u662f\u9aa8\u6298\u6b63\u5e38\u75c5\u7a0b\nB. \u7d66\u4e88\u93ae\u5b9a\u5291\nC. \u5b89\u6392\u5fc3\u81df\u8d85\u97f3\u6ce2\nD. \u5b89\u6392\u96fb\u8166\u65b7\u5c64\u80ba\u8840\u7ba1\u9020\u5f71\nE. \u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u6c23\u7ba1\u767c\u708e\n": "(D)", "106-17.\n32\u6b72\u5973\u6027\u88ab\u8a3a\u65b7\u70ba\u4e2d\u5ea6\u6301\u7e8c\u6027\u6c23\u5598\u3002\u4e09\u500b\u6708\u4f86\u6c23\u5598\u63a7\u5236\u826f\u597d\uff0c\u77ed\u6548\u6c23\u7ba1\u64f4\u5f35\u5291\u4e00\u9031\u4f7f\u7528\u4e0d\u5230\u4e00\u6b21\uff0c\u4e00\u500b\u6708\u665a\u4e0a\u6703\u56e0\u6c23\u5598\u9192\u4f86\u5169\u6b21\uff0c\u904b\u52d5\u6642\u4e0d\u6703\u53d7\u5230\u9650\u5236\u3002\u76ee\u524d\u7528\u85e5\u5305\u62ec\u5438\u5165\u985e\u56fa\u9187 fluticasone 50 ug/puff 2puff\u4e00\u5929\u5169\u6b21\uff0c\u9577\u6548\u6c23\u7ba1\u64f4\u5f35\u5291salmeterol 50 ug/puff\u4e00\u5929\u5169\u6b21\uff0cFEV1 \u76ee\u524d\u70ba83% predict value\uff0c\u63a5\u4e0b\u4f86\u8a72\uff1f\nA. \u52a0\u4e0a\u767d\u4e09\u70ef\u62ee\u6297\u5291(leukotriene antagonist) montelukast 10mg \u6bcf\u5929\u4e00\u6b21\nB. \u964d\u4f4e\u5438\u5165\u6027\u985e\u56fa\u9187 fluticasone \u523050ug/puff 1puff\u4e00\u5929\u4e00\u6b21\nC. \u505c\u6b62\u5438\u5165\u6027\u985e\u56fa\u9187\u4f7f\u7528\nD. \u505c\u6b62\u9577\u6548\u6c23\u7ba1\u64f4\u5f35\u5291 salmeterol \u4f7f\u7528\nE. \u7dad\u6301\u76ee\u524d\u6cbb\u7642\n": "(D)", "106-18.\n\u5168\u4e16\u754c\u9020\u6210\u652f\u6c23\u7ba1\u64f4\u5f35\u6700\u5e38\u898b\u7684\u539f\u56e0\uff1f\nA. \u56ca\u6027\u7e96\u7dad\u5316 cystic fibrosis\nB. \u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\nC. \u80ba\u7d50\u6838\nD. \u5206\u679d\u687f\u83cc\u611f\u67d3(MAC infection)\nE. \u514d\u75ab\u7403\u86cb\u767d\u7f3a\u4e4f\u75c7\n": "(C)", "106-19.\n\u80ba\u7d50\u6838\u7684\u63a7\u5236\u6700\u91cd\u8981\u7684\u5c31\u662f\u53ca\u6642\u6aa2\u6e2c\uff0c\u4e26\u63d0\u4f9b\u6709\u6548\u7684\u77ed\u671f\u6cbb\u7642\u3002\u9032\u4e00\u6b65\u7684\u9810\u9632\u662f\u627e\u51fa\u6f5b\u4f0f\u7d50\u6838\u611f\u67d3\u7684\u7fa4\u7d44\u4e26\u7d66\u4e88\u6cbb\u7642\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u662f\uff1f(1)\u75be\u75c5\u7ba1\u5236\u7f72\u5df2\u57282016\u5e74\u63a8\u52d5\u5168\u5e74\u9f61\u5c64\u6f5b\u4f0f\u7d50\u6838\u5168\u90fd\u6cbb\u8a08\u756b\uff1b(2)\u6f5b\u4f0f\u7d50\u6838\u7684\u5075\u6e2c\uff0c\u4e94\u6b72\u4ee5\u4e0a\u4ee5\u7d50\u6838\u83cc\u76ae\u819a\u6e2c\u9a57(TST)\u70ba\u4e3b\uff0c\u4e94\u6b72\u4ee5\u4e0b\u4ee5\u4e19\u578b\u5e72\u64fe\u7d20\u91cb\u653e\u8a66\u9a57(IGRA)\u70ba\u4e3b\uff1b(3)\u9700\u505aCXR \uff0c\u6392\u9664\u80ba\u90e8\u6709\u6d3b\u52d5\u6027\u80ba\u7d50\u6838\uff1b(4)\u6cbb\u7642\u7684\u8655\u65b9\u572812\u6b72\u4ee5\u4e0b\u53ef\u4ee5\u8003\u616e9\u500b\u6708\u7684 Isoniazid \u62163\u500b\u6708\u7684 Isoniazid \u52a0 Rifapentine\uff1b(5)\u5efa\u8b70\u4ee5\u90fd\u6cbb\u8a08\u756b\u7d66\u85e5(Directly Observed Treatment Short-Course\uff0cDOTS)\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(4)+(5)\nD. (1)+(3)+(4)\nE. (3)+(4)+(5)\n": "(B)", "106-20.\n62\u6b72\u7537\u6027 COPD\u5728\u9580\u8a3a\u8ffd\u8e64\u6cbb\u7642\u3002\u5728\u4e00\u6b21\u91cd\u611f\u5192\u5f8c\uff0c\u75c5\u4eba\u89ba\u5f97\u8d8a\u4f86\u8d8a\u5598\uff0c\u54b3\u55fd\u52a0\u5287\uff0c\u5408\u4f75\u5c11\u8a31\u9ec3\u75f0\uff0c\u56e0\u6b64\u4f86\u5230\u6025\u8a3a\u3002\u672a\u767c\u4f5c\u6642\uff0c\u6700\u5f8c\u4e00\u6b21\u7684\u80ba\u529f\u80fdFEV1 42%\u3002\u5728\u6025\u8a3a\uff0c\u4e8c\u6c27\u5316\u78b3\u5206\u58d3 (PaCO2)78mmHg\uff0c\u75c5\u4eba\u5448\u73feaccessory muscle use \u53ca\u8f15\u5fae\u795e\u667a\u4e0d\u6e05\uff0c\u5169\u5074\u7030\u6f2b\u6027\u5598\u9cf4\u97f3\uff0c\u80f8\u90e8X\u5149\u7121\u80ba\u708e\u8de1\u8c61\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u61c9\u8a72\u505a\u751a\u9ebc\u53ef\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\uff1f\nA. \u4f7f\u7528\u975e\u4fb5\u8972\u6027\u6b63\u58d3\u547c\u5438\u5668\nB. \u63d2\u7ba1\u4f7f\u7528\u547c\u5438\u5668\nC. \u7d66\u4e88\u5ee3\u6548\u6027\u6297\u751f\u7d20\nD. \u975c\u8108\u6ce8\u5c04\u985e\u56fa\u9187\nE. \u589e\u52a0\u6c23\u7ba1\u64f4\u5f35\u5291\u7684\u5291\u91cf\n": "(A)", "106-21.\n57\u6b72\u7537\u6027\uff0c\u5e74\u8f15\u6642\u505a\u904e\u7164\u7926\u5de5\u5341\u591a\u5e74\u3002\u6700\u8fd1\u56e0\u70ba\u5598\u3001\u54b3\u52a0\u5287\u4f86\u91ab\u9662\u6c42\u8a3a\uff0c\u4e0b\u5217\u54ea\u7a2e\u75be\u75c5\u8207\u4ed6\u7684\u8077\u696d\u7121\u95dc\uff1f\nA. \u80ba\u764c\nB. \u80ba\u7d50\u6838\nC. \u6162\u6027\u80ba\u963b\u585e\u6027\u80ba\u75be\nD. \u5875\u80ba\u75c7\nE. \u9593\u76ae\u7624(mesothelioma)\n": "(E)", "106-22.\n\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\uff0c\u4e0b\u5217\u54ea\u4e00\u500b\u6558\u8ff0\u70ba\u975e\uff1f\nA. \u6709\u4e9b\u75c5\u4eba\u53ef\u80fd\u5f9e\u5c0f\u5c31\u6709\u6253\u547c\u7684\u554f\u984c\uff0c\u800c\u9ad4\u91cd\u589e\u52a0\u5247\u6703\u52a0\u901f\u75be\u75c5\u9032\u884c\u3002\nB. \u4e3b\u8981\u7684\u5371\u96aa\u56e0\u5b50\u70ba\u5973\u6027\u53ca\u80a5\u80d6\nC. \u96a8\u8457\u5e74\u7d00\u589e\u52a0\uff0c\u767c\u75c5\u7684\u6a5f\u6703\u4e5f\u589e\u52a0\nD. \u5e38\u4f34\u96a8\u5fc3\u8840\u7ba1\u75be\u75c5\u53ca\u4ee3\u8b1d\u75be\u75c5\nE. \u8a3a\u65b7\u9700\u8981\u9760\u904e\u591c\u591a\u5c0e\u7761\u7720\u76e3\u6e2c(overnight polysomnography)\n": "(B)", "107-1.\n\u95dc\u65bc\u80ba\u764c\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u54ea\u4e9b\u662f\u6b63\u78ba\u7684\uff1f (1). \u80ba\u764c\u514d\u75ab\u7d44\u7e54\u67d3\u8272\uff0cP63 \u4ee5\u53ca cytokeratin 5/6 \u662f\u967d\u6027\uff0c\u800cthyroid transcription factor-1 (TTF-1)\u662f\u9670\u6027\uff0c\u901a\u5e38\u6703\u8a3a\u65b7\u70ba \u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c (squamous cell carcinoma) (2). \u5728\u7b2c\u56db\u671f\u80ba\u764c\u7684\u6cbb\u7642\uff0c\u9a45\u52d5\u57fa\u56e0\u7a81\u8b8a (driver mutation)\u662f\u6c7a\u5b9a\u6a19\u9776\u6cbb\u7642\u6548\u679c\u7684\u91cd\u8981\u56e0\u5b50\uff0c\u4f46\u5176\u4ed6\u5171\u540c\u51fa\u73fe\u7684\u7a81\u8b8a (concurrent mutation)\u4e5f\u6703\u5f71\u97ff\u6a19\u9776\u6cbb\u7642\u7684\u6548\u679c (3). \u7b2c\u56db\u671f\u80ba\u817a\u764c\u7684\u6cbb\u7642\uff0c\u9808\u57f7\u884c\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4(epidermal growth factor receptor(EGFR)) \u7a81\u8b8a\u53caALK\uff08anaplastic lymphoma kinase\uff09\u57fa\u56e0\u8f49\u7f6e(translocation)\r\u7b49\u57fa\u56e0\u6aa2\u6e2c\u4ee5\u5916\uff0c\u514d\u75ab\u7d44\u7e54\u67d3\u8272\u6e2c\u5b9aPD-L1\u8868\u73fe\u91cf\uff0c\u4e5f\u662f\u6c7a\u5b9a\u85e5\u7269\u6cbb\u7642\u7684\u6839\u64da (4). EGFR \u7a81\u8b8a\u967d\u6027\u4e4b\u80ba\u817a\u764c\u75c5\u60a3\u4f7f\u7528erlotinib \u4e00\u5e74\u5f8c\u7522\u751f\u6297\u85e5\u6027\uff0c\u518d\u6b21\u816b\u7624\u5207\u7247\u767c\u73feEGFR T790M\u7a81\u8b8a\uff0c\u53ef\u4ee5\u4f7f\u7528afatinib\u4f86\u6cbb\u7642\u6297\u85e5\u7684\u816b\u7624 (5). \u7b2c\u56db\u671f\u80ba\u817a\u764c\uff0c\u6709\u57fa\u56e0\u7a81\u8b8a\u4e14\u4f7f\u7528\u9069\u5408\u6a19\u9776\u6cbb\u7642\u7684\u75c5\u60a3\uff0c\u6bd4\u6c92\u6709\u57fa\u56e0\u7a81\u8b8a\u7684\u75c5\u60a3\uff0c\u5b58\u6d3b\u8f03\u9577\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(3)+(5)\nC. (1)+(2)+(4)+(5)\nD. (2)+(3)+(5)\nE. (1)+(4)+(5)\n": "(B)", "107-2.\n\u95dc\u65bc\u9ad8\u6d77\u62d4\u75be\u75c5(high altitude illness)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u9ad8\u6d77\u62d4\u75be\u75c5\u767c\u751f\u539f\u56e0\uff0c\u662f\u56e0\u70ba\u9ad8\u5c71\u4e0a\u6c27\u6c23\u6fc3\u5ea6\u8f03\u4f4e\nB. \u6025\u6027\u9ad8\u5c71\u75c5(acute mountain sickness; AMS)\uff0c\u56e0\u7f3a\u6c27\u51fa\u73fe\u982d\u75db\u3001\u982d\u6688\u3001\u75b2\u5026\u3001\u5641\u5fc3\u3001\u5614\u5410\u7b49\u975e\u7279\u7570\u6027\u75c7\u72c0\nC. \u9ad8\u6d77\u62d4\u8166\u6c34\u816b(high-altitude cerebral edema; HACE)\u7684\u75c7\u72c0\u5305\u62ec\u56b4\u91cd\u982d\u75db\u3001\u55dc\u7761\u3001\u610f\u8b58\u4e0d\u6e05\u3001\u6b65\u614b\u4e0d\u7a69\u3001\u751a\u81f3\u660f\u8ff7\nD. \u722c\u5347\u7684\u901f\u5ea6\u53ca\u4ee5\u524d\u767c\u751f\u904e\u9ad8\u6d77\u62d4\u75be\u75c5\uff0c\u662f\u9ad8\u6d77\u62d4\u75be\u75c5\u767c\u751f\u7684\u91cd\u8981\u98a8\u96aa\u56e0\u5b50(risk factors)\nE. acetazolamide \u53ef\u4ee5\u7528\u4f86\u9810\u9632\u9ad8\u5c71\u75c5\n": "(A)", "107-3.\n\u95dc\u65bc\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\uff08obstructive sleep apnea syndrome\uff09\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\u662f\u6700\u5e38\u898b\u7684\u7761\u7720\u547c\u5438\u969c\u7919\uff08sleep-disordered breathing\uff09\uff0c\u7279\u5fb5\u662f\u54bd\u90e8\u7684\u547c\u5438\u9053\uff0c\u5728\u7761\u7720\u6642\u53cd\u8986\u963b\u585e\nB. \u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\u6700\u4e3b\u8981\u7684\u98a8\u96aa\u56e0\u5b50\uff08risk factors\uff09\u662f\u80a5\u80d6\u548c\u7537\u6027\nC. \u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\u6703\u589e\u52a0\u51a0\u72c0\u52d5\u8108\u5fc3\u81df\u75c5\u3001\u5fc3\u5f8b\u4e0d\u6574\u3001\u5fc3\u81df\u8870\u7aed\u3001\u4e2d\u98a8\u53ca\u7cd6\u5c3f\u75c5\u7684\u98a8\u96aa\nD. \u6574\u665a\u7684\u7761\u7720\u591a\u9805\u751f\u7406\u6aa2\u67e5(overnight polysomnogram) \u662f\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\u7684\u6a19\u6e96\u6aa2\u67e5\nE. \u6574\u665a\u7684\u7761\u7720\u591a\u9805\u751f\u7406\u6aa2\u67e5\uff0c\u767c\u73fe\u75c5\u60a3\u547c\u5438\u4e2d\u6b62\u6307\u6578\uff08apnea- hypopnea index\uff0cAHI\uff09\u5927\u65bc15\u6642\uff0c\u9700\u518d\u52a0\u4e0a\u591c\u9593\u547c\u5438\u969c\u7919\uff08nocturnal breathing disturbances \uff09\u6216\u767d\u5929\u55dc\u7761\u3001\u75b2\u5026\u7b49\u75c7\u72c0\uff0c\u624d\u80fd\u8a3a\u65b7\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\n": "(E)", "107-4.\n\u95dc\u65bc\u80f8\u817a\u7624(thymoma)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7d04\u4e00\u534a\u7684\u80f8\u817a\u7624\uff0c\u8a3a\u65b7\u6642\u4e26\u7121\u81e8\u5e8a\u75c7\u72c0\nB. \u80f8\u817a\u7624\u53ef\u6709\u816b\u7624\u4f34\u751f\u75c7\u5019\u7fa4(parapneoplastic syndrome)\uff0c\u5305\u62ec\u91cd\u75c7\u808c\u7121\u529b(myasthenia gravis)\uff0c\u7d14\u7d05\u8840\u7403\u518d\u751f\u4e0d\u826f (pure red cell aplasia)\uff0c\u4f4e\u4e19\u578b\u7403\u86cb\u767d\u8840\u75c7(hypogammaglobulinemia) \u7b49\nC. \u4f34\u6709\u91cd\u75c7\u808c\u7121\u529b\u7684\u80f8\u817a\u7624\u75c5\u60a3\uff0c\u5176\u9810\u5f8c\u6bd4\u7121\u91cd\u75c7\u808c\u7121\u529b\u7684\u80f8\u817a\u7624\u75c5\u60a3\u4f86\u5f97\u5dee\nD. \u80f8\u817a\u7624\u5c6c\u65bc\u653e\u5c04\u7dda\u6cbb\u7642\u654f\u611f(radiation sensitive)\u816b\u7624\uff0c\u56e0\u6b64\u653e\u5c04\u7dda\u6cbb\u7642\u5ee3\u6cdb\u4f7f\u7528\u65bc\u6cbb\u7642\u80f8\u817a\u7624\nE. \u5b8c\u5168\u624b\u8853\u5207\u9664\u662f\u6cbb\u7652\u80f8\u817a\u7624\u6700\u4f73\u7684\u65b9\u5f0f\n": "(C)", "107-5.\n\u95dc\u65bc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(Acute respiratory distress syndrome,ARDS)\u7684\u80ba\u4fdd\u8b77\u547c\u5438\u5668\u7b56\u7565(lung-protective ventilator strategies)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6f6e\u6c23\u5bb9\u7a4d(tidal volume; TV)\u3000\u8a2d\u5b9a10 mL/kg\u7406\u60f3\u9ad4\u91cd\uff08ideal body weight\uff1bIBW\uff09\uff0c\u4ee5\u907f\u514d\u80ba\u6ce1\u584c\u9677\nB. \u9ad8\u539f\u58d3(plateau pressure)\u6700\u597d\u5c0f\u65bc30 cmH2O\nC. \u4e0d\u5b9c\u4f7f\u7528\u5410\u6c23\u672b\u7aef\u6b63\u58d3(positive end expiratory pressure)\uff0c\u4ee5\u514d\u9020\u6210\u547c\u5438\u5668\u5c0e\u81f4\u7684\u80ba\u640d\u50b7(ventilator-induced lung injury)\nD. \u589e\u52a0CO2 \u6392\u9664\u91cf\uff0c\u4ee5\u514d\u7522\u751f\u547c\u5438\u6027\u9178\u4e2d\u6bd2\uff08repiratory acidosis\uff09\nE. \u7d66\u4e88100% \u6c27\u6c23\n": "(B)", "107-6.\n\u95dc\u65bc\u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2(carbon monoxide poisoning)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u54ea\u4e9b\u662f\u6b63\u78ba\u7684\uff1f (1). \u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790(arterial blood gas)\u6642\uff0c\u52d5\u8108\u8840\u6c27\u5206\u58d3\uff08arterial PaO2\uff09\u503c\u4e0b\u964d (2). \u8108\u640f\u8840\u6c27\u98fd\u548c\u5ea6\u5206\u6790(pulse oximetry)\uff0c\u6c27\u98fd\u548c\u5ea6\uff08oxygen saturation\uff09\u6b63\u5e38 (3). \u91cd\u5ea6\u5438\u83f8\u8005\uff0c\u5176\u78b3\u6c27\u8840\u7d05\u86cb\u767d\uff08carboxyhemoglobin\uff09 \u6e2c\u5f9712%\uff0c\u53ef\u8a3a\u65b7\u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2 (4). \u6cbb\u7642\u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2\u75c5\u60a3\uff0c\u7d66\u4e88\u6c27\u6c23\u6cbb\u7642\uff0c\u6fc3\u5ea6\u4e0d\u5b9c\u8d85\u904e60%\uff0c\u4ee5\u514d\u9020\u6210\u6c27\u4e2d\u6bd2\uff08oxygen toxicity\uff09(5). \u6cbb\u7642\u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2\u75c5\u60a3\uff0c\u8981\u6ce8\u610f\u6025\u6027\u5fc3\u808c\u7f3a\u6c27\uff08acute myocardial ischemia\uff09\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (2)+(5)\n": "(E)", "107-7.\n\u95dc\u65bc\u808b\u819c\u7a4d\u6db2(pleural effusion)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u54ea\u4e9b\u662f\u6b63\u78ba\u7684\uff1f (1). \u808b\u819c\u7a4d\u6db2\u5e38\u898b\u7684\u539f\u56e0\u70ba\uff1b\u5fc3\u81df\u8870\u7aed (heart failure)\u3001\u80ba\u708e\u53ca\u60e1\u6027\u816b\u7624 (2). \u7576\u808b\u819c\u7a4d\u6db2\u8d85\u904e\u534a\u500b\u80f8\u5ed3\u6642\uff0c\u56e0\u70ba\u9ad8\u5ea6\u61f7\u7591\u60e1\u6027\u816b\u7624\u6240\u9020\u6210\uff0c\u6240\u4ee5\u76f4\u63a5\u505a\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\uff0c\u4ee5\u770b\u6e05\u695a\u7a4d\u6db2\u5167\u7684\u816b\u7624  (3).\u3000adenosine deaminase <40 IU/L\uff0c\u8981\u8003\u616e\u7d50\u6838\u6027\u80f8\u819c\u708e(tuberculosis pleuritis) (4). \u808b\u819c\u7a4d\u6db2\u4e4b\u8840\u6bd4\u5bb9\uff08hematocrit\uff09\u9054\u8840\u6db2\u4e4b\u8840\u6bd4\u5bb9\u768450%\u4ee5\u4e0a\uff0c\u8981\u8003\u616e\u8840\u80f8\uff08hemothorax\uff09(5). \u5c3f\u80f8\uff08urinothorax\uff09\u662f\u5c6c\u65bcexudate\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(4)+(5)\nD. (2)+(3)+(5)\nE. (3)+(4)+(5)\n": "(C)", "107-8.\n\u95dc\u65bc\u80ba\u9ad8\u58d3(pulmonary hypertension)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u80ba\u9ad8\u58d3\u7684\u5b9a\u7fa9\u70ba\uff1a\u65bc\u4f11\u606f\u72c0\u614b\uff0c\u5e73\u5747\u80ba\u52d5\u8108\u58d3\u5927\u65bc25\u6beb\u7c73\u6c5e\u67f1\nB. \u80ba\u52d5\u8108\u58d3\u529b\u53ef\u7d93\u7531\u7f6e\u5165\u80ba\u52d5\u8108\u5c0e\u7ba1(pulmonary artery catheter)\u76f4\u63a5\u6e2c\u5f97\uff0c\u6216\u8005\u85c9\u7531\u7d93\u80f8\u524d\u5fc3\u81df\u8d85\u97f3\u6ce2\u4f30\u7b97\nC. \u80ba\u81df\u8840\u6813\u52d5\u8108\u5167\u819c\u5207\u9664\u8853\uff08pulmonary thromboendarterectomy\uff09\u662f\u6cbb\u7642\u6162\u6027\u8840\u7ba1\u6813\u585e\u9020\u6210\u4e4b\u80ba\u52d5\u8108\u9ad8\u58d3(chronic thromboembolic pulmonary hypertension; CTEPH)\u7684\u65b9\u6cd5\nD. CTEPH \u8a3a\u65b7\u5e38\u4f7f\u7528\u80ba\u90e8\u704c\u6d41\u901a\u6c23\u6838\u91ab\u6383\u63cf (lung perfusion/ventilation scan)\nE. portopulmonary hypertension\u662f\u5c6c\u65bc\u809d\u80ba\u75c7\u5019\u7fa4(hepatopulmonary syndrome)\n": "(E)", "107-9.\n62\u6b72\u7537\u6027\uff0c\u662f\u4f4d\u8001\u83f8\u69cd(\u83f8\u9f61\u8d85\u904e30\u5305\u5e74)\uff0c\u4e3b\u8a34\u54b3\u55fd\u3001\u8d70\u5e73\u8def\u6703\u5598(\u6162\u6162\u8d70\u9084\u662f\u9700\u8981\u505c\u4e0b\u4f86\u4f11\u606f)\u3001\u6709\u6642\u6709\u5598\u9cf4\u8072(wheezing)\uff0c \u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u5169\u5074\u547c\u5438\u8072\u6e1b\u4f4e\u53ca\u5410\u6c23\u672b\u7aef\u5598\u9cf4\u8072\u3002\u80ba\u529f\u80fd\u6aa2\u67e5\uff1aFEV1 \u662f\u9810\u6e2c\u503c\u768465%\u3001FEV1/FVC 65%\u3002\u6839\u64da\u76ee\u524d\u7684\u6cbb\u7642\u6307\u5f15\uff0c\u4e0b\u5217\u54ea\u9805\u6cbb\u7642\u6700\u9069\u7576\uff1f\nA. \u5438\u5165\u578b\u985e\u56fa\u9187\u53ca\u80ba\u90e8\u5fa9\u5065\nB. \u9700\u8981\u6642\u4f7f\u7528\u77ed\u6548\u578b\u7684\u4e59\u578b\u81f4\u6548\u5291( short-acting beta2-agonist, SABA) \u53ca\u80ba\u90e8\u5fa9\u5065\nC. \u9577\u6548\u578b\u7684\u6bd2\u8548\u9e7c\u62ee\u6297\u5291(long-acting muscarinic antagonist, LAMA) \u53ca\u80ba\u90e8\u5fa9\u5065\nD. phosphodiesterase-4 inhibitor\u53ca\u80ba\u90e8\u5fa9\u5065\nE. \u975c\u8108\u6ce8\u5c04 aminophyline\u53ca\u80ba\u90e8\u5fa9\u5065\n": "(C)", "107-10.\n31\u6b72\u5973\u6027\uff0c\u5f9e\u5c0f\u5c31\u88ab\u8a3a\u65b7\u6c23\u5598\uff0c\u9577\u5927\u5f8c\u75c7\u72c0\u6539\u5584\u3002\u4f46\u6bcf\u5e74\u90fd\u6703\u767c\u4f5c\uff0c\u6700\u8fd1\u534a\u5e74\u8f03\u5e38\u611f\u5230\u80f8\u60b6\u53ca\u6c23\u4fc3\uff0c\u5230\u8a3a\u6240\u5c31\u8a3a\u5f8c\uff0c\u91ab\u5e2b\u7d66\u4e88\u77ed\u6548\u578b\u7684\u4e59\u578b\u81f4\u6548\u5291( short-acting beta2-agonist\uff0cSABA)\uff0c\u4f46\u5979\u5076\u800c\u624d\u7528\u3002\u6703\u56e0\u70ba\u5598\u534a\u591c\u9192\u4f86\uff0c\u7d04\u6bcf\u5468\u4e00\u6b21\u5230\u4e8c\u6b21\uff0c\u4f86\u5230\u4f60\u7684\u8a3a\u9593\u3002\u80ba\u529f\u80fd\u6aa2\u67e5\uff1aFEV1 \u662f\u9810\u6e2c\u503c\u768470%\u3001FEV1/FVC 75%\uff0c\u652f\u6c23\u7ba1\u64f4\u5f35\u8a66\u9a57(bronchodilator test) FEV1 \u6539\u558416%\u3002\u6839\u64da\u76ee\u524d\u7684\u6cbb\u7642\u6307\u5f15\uff0c\u4e0b\u5217\u54ea\u9805\u6cbb\u7642\u6700\u9069\u7576?\nA. \u5438\u5165\u578b\u985e\u56fa\u9187 +\u9577\u6548\u578b\u7684\u4e59\u578b\u81f4\u6548\u5291( long-acting beta2-agonist\uff0cLABA)\nB. \u9577\u6548\u578b\u7684\u6bd2\u8548\u9e7c\u62ee\u6297\u5291(long-acting muscarinic antagonist, LAMA)\nC. \u53e3\u670d\u985e\u56fa\u9187 +\u53e3\u670d\u4e59\u578b\u81f4\u6548\u5291\nD. omalizumab\nE. \u767d\u4e09\u70ef\u62ee\u6297\u5291(leukotriene antagonist) montelukast 10mg \u6bcf\u5929\u4e00\u6b21\n": "(A)", "107-11.\n31\u6b72\u5973\u6027\uff0c\u7121\u75c7\u72c0\uff0c\u5065\u5eb7\u6aa2\u67e5\u80f8\u90e8X\u5149\u5982\u5716\u6240\u793a\uff0c\u5b89\u6392\u96fb\u8166\u65b7\u5c64\u5982\u5716\u6240\u793a\uff0c\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\u4f55?\nA. Sarcoidosis\nB. Lymphoma\nC. Lung cancer\nD. Esophageal cancer\nE. Bronchogenic cyst\n": "(A)", "107-12.\n68\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u83f8\u9f6150\u5e74\uff0c\u54b3\u55fd\u3001\u5598\u52a0\u5287\u4f86\u5230\u9580\u8a3a\uff0cCXR\u986f\u793a\u5de6\u5074\u816b\u7624\u5408\u4f75\u7a4d\u6c34\uff0c\u5207\u7247\u6aa2\u67e5\u53ca\u62bd\u6c34\u6aa2\u67e5\u78ba\u8a8d\u662f\u80ba\u817a\u764c\u5408\u4f75\u60e1\u6027\u808b\u819c\u7a4d\u6c34\u3002\u57fa\u56e0\u6aa2\u6e2c\u70baKRAS\u7a81\u8b8a\uff0cPD-L1\u67d3\u827260%\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u6cbb\u7642\u6548\u679c\u6700\u597d\nA. \u6a19\u9776\u85e5\u7269\u6cbb\u7642\nB. \u514d\u75ab\u6cbb\u7642\nC. \u5316\u5b78\u6cbb\u7642 + \u6a19\u9776\u6cbb\u7642\nD. \u5316\u5b78\u6cbb\u7642\nE. \u514d\u75ab\u6cbb\u7642 + \u6a19\u9776\u6cbb\u7642\n": "(B)", "107-13.\n\u52a0\u8b77\u75c5\u623f\u4e2d\u8d85\u97f3\u6ce2\u53ef\u4ee5\u7528\u4f86\uff1a(1). \u8a55\u4f30\u8840\u7ba1\u5167\u9ad4\u6db2\u91cf (2). \u8a55\u4f30\u808b\u819c\u7a4d\u6db2 (3). \u5e6b\u5fd9 central line insertion (4). \u8a55\u4f30\u6c23\u80f8\u7bc4\u570d (5). \u8a55\u4f30\u5fc3\u5305\u819c\u7a4d\u6db2\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(4)+(5)\nC. (1)+(2)+(3)+(5)\nD. (2)+(4)+(5)\nE. (2)+(3)+(4)+(5)\n": "(C)", "107-14.\n\u4e0b\u5217\u5c0d\u6162\u6027\u963b\u585e\u6027\u80ba\u75be COPD \u7684\u6cbb\u7642\u4f55\u8005\u70ba\u5c0d\uff1f\nA. \u6839\u64da NEJM \u6700\u65b0\u7684\u7814\u7a76, triple therapy LABA + LAMA + ICS \u6bd4 Dual therapy LABA + LAMA \u53ef\u4ee5\u964d\u4f4e\u6025\u6027\u767c\u4f5c\u7684\u6b21\u6578\uff0c\u6240\u4ee5\u91cd\u5ea6COPD \u7684\u75c5\u4eba\u90fd\u61c9\u8a72\u63a5\u53d7 triple therapy\nB. phosphodiesterase-4 inhibitor roflumilast \u53ef\u4ee5\u7528\u4f86\u6cbb\u7642\u4ee5\u6162\u6027\u6c23\u7ba1\u708e\u8868\u73fe\u70ba\u4e3b\u7684\u56b4\u91cdCOPD\u75c5\u4eba\nC. \u9577\u6548\u6c23\u7ba1\u64f4\u5f35\u5291\u53ef\u4ee5\u6539\u5584\u75c5\u4eba\u75c7\u72c0\uff0c\u589e\u52a0FEV1\uff0c\u964d\u4f4e\u6025\u6027\u767c\u4f5c\u6b21\u6578\u53ca\u964d\u4f4e\u6b7b\u4ea1\u7387\nD. \u5438\u5165\u6027\u85e5\u5291\u662f\u6cbb\u7642COPD\u7684\u9996\u9078\u85e5\u7269\uff0c\u5982\u679c\u75c5\u4eba\u6cbb\u7642\u6548\u679c\u4e0d\u4f73\uff0c\u8003\u616e\u76f4\u63a5\u63db\u85e5\nE. COPD\u6025\u6027\u767c\u4f5c\u9700\u8981\u4f4f\u9662\u6cbb\u7642\uff0c\u907f\u514d\u4f75\u767c\u75c7\u767c\u751f\n": "(B)", "107-15.\n70 \u6b72\u5973\u6027\u56e0\u70ba\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4\uff08ARDS\uff09\u4f4f\u9032\u52a0\u8b77\u75c5\u623f\uff0c\u5979\u56e0\u70ba\u5de6\u817f\u5927\u817f\u9aa8\u6298\uff0c\u525b\u525b\u63a5\u53d7\u624b\u8853\u3002\u624b\u8853\u76f8\u7576\u6210\u529f\uff0c\u8853\u4e2d\u63a5\u53d7PRBC 2U\uff0c\u8eab\u9ad8150cm\uff0c\u9ad4\u91cd80Kg\uff0c\u624b\u8853\u5b8c\u5f8c\u547c\u5438\u5668\u7121\u6cd5\u79fb\u9664\uff0c\u4e14\u6c27\u6c23\u9700\u8981\u91cf\u9010\u6f38\u589e\u52a0\uff0cPEEP 15 cmH2O \u4e14plateau pressure \u8d8a\u4f86\u8d8a\u9ad8\u3002\u8eab\u9ad4\u6aa2\u67e5\u9664\u4e86\u5169\u5074\u4e0b\u80ba\u91ce\u6709\u5438\u6c23\u671f\u56c9\u97f3\uff0c\u5fc3\u8df3\u8f03\u5feb\uff0c\u4e26\u7121\u5176\u5b83\u767c\u73fe\uff0c\u6700\u6709\u53ef\u80fd\u9020\u6210ARDS\u7684\u539f\u56e0\u70ba\u4f55 ?\nA. \u547c\u5438\u5668\u9020\u6210\u7684\u80ba\u640d\u50b7\nB. \u80a5\u80d6\u5f15\u8d77\u7684\u547c\u5438\u529f\u80fd\u4f4e\u4e0b\uff08hypoventilation syndrome\uff09\nC. \u8f38\u8840\u9020\u6210\u7684\u80ba\u640d\u50b7\nD. \u80ba\u6813\u585e\nE. \u5438\u5165\u6027\u80ba\u708e\n": "(D)", "107-16.\n71\u6b72\u7537\u6027\u56e0\u70ba\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (COPD) \u6025\u6027\u767c\u4f5c\u63d2\u7ba1\u5165\u52a0\u8b77\u75c5\u623f\uff0c\u5728\u7d66\u4e88\u985e\u56fa\u9187\u3001\u6c23\u7ba1\u64f4\u5f35\u5291\u53ca\u6297\u751f\u7d20\u5f8c\uff0c\u75c5\u60c5\u9010\u6f38\u6539\u5584\u3002\u4e94\u5929\u5f8c\u5617\u8a66\u62d4\u7ba1\u4f46spontaneous breathing trial (SBT) \u5931\u6557\u3002\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab\u6b63\u5e38\uff0c\u8840\u58d3132/85\u6beb\u7c73\u6c5e\u67f1\uff0c\u5fc3\u738775/min\uff0c\u547c\u5438\u97f3\u5169\u5074\u7686\u4e0b\u964d\u3002\u5728SBT\u5f8c\u75c5\u4eba\u770b\u8d77\u4f86\u6709\u9ede\u5026\u6020\u3002\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u4f73\uff1f\nA. \u7e7c\u7e8c\u547c\u5438\u5668\u4f7f\u7528\u76f4\u5230SBT \u6210\u529f\u518d\u62d4\u7ba1\nB. \u76f4\u63a5\u62d4\u7ba1\u6539\u7528\u6b63\u58d3\u975e\u4fb5\u8972\u6027\u547c\u5438\u5668\uff08bilevel noninvasive positive pressure ventilation\uff09\nC. \u76f4\u63a5\u62d4\u7ba1\u7d66\u4e88\u8db3\u5920\u6c27\u6c23\nD. \u5efa\u8b70\u6c23\u5207\nE. \u547c\u5438\u5668full support \u8b93\u75c5\u4eba\u4f11\u606f\uff0c\u5f85\u75c5\u4eba\u8212\u670d\u518d\u91cd\u65b0\u812b\u96e2\u8a13\u7df4\n": "(B)", "107-17.\n83\u6b72\u5973\u6027\u56e0\u70ba\u5598\u4f86\u9580\u8a3a\u5c31\u8a3a\uff0c\u9664\u4e86\u9ad8\u8840\u58d3\u53ca\u5076\u800c\u5fc3\u5f8b\u4e0d\u6574\u5916\uff0c\u6c92\u6709\u5176\u4ed6\u75be\u75c5\u3002\u6700\u8fd1\u66fe\u88ab\u8a3a\u65b7\u6709\u5fc3\u8870\u7aed\u3002\u80f8\u90e8X\u5149\u986f\u793a\u5de6\u5074\u55ae\u5074\u5927\u91cf\u7a4d\u6db2\u3002\u62bd\u6c34\u6aa2\u67e5\u7b26\u5408\u6ef2\u6db2\uff08exudate\uff09\uff0c\u7d30\u83cc\u57f9\u990a\u7121\u7d30\u83cc\uff0c\u4f46\u7d50\u6838\u83cc\u57f9\u990a\u9577\u51faMycobacterium tuberculosis\uff0c\u4ee5\u4e0b\u8655\u7f6e\u4f55\u8005\u6b63\u78ba\uff1a(1). \u653e\u7f6e\u80f8\u7ba1\u5f15\u6d41\uff0c\u907f\u514d\u81bf\u80f8\u60e1\u5316 (2). \u958b\u59cb\u56db\u5408\u4e00\u6cbb\u7642 (3). \u7167\u6703\u5916\u79d1\u505a\u525d\u812b\u8853(decortication) (4). \u653e\u7f6e\u8c6c\u5c3e\u578b\u5c0e\u7ba1\u5f15\u6d41 (5). \u80f8\u8154\u7a7f\u523a\u8853\u55ae\u6b21\u5f15\u6d41\nA. (1)+(2)+(3)\nB. (2)+(3)\nC. (2)+(4)\nD. (2)+(5)\nE. (2)+(3)+(4)\n": "(D)", "107-18.\n49\u6b72\u75c5\u4eba\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (COPD) \u4ee5\u652f\u6c23\u7ba1\u708e\u4f86\u8868\u73fe\u5e38\u6709\u9ec3\u75f0\u3002\u6578\u5468\u524d\u958b\u59cb\u75f0\u91cf\u589e\u52a0\uff0c\u4f86\u6025\u8a3a\u524d\u54b3\u4e86\u7d04 100ml \u7684\u9bae\u8840\u3002\u8eab\u9ad4\u6aa2\u67e5\u9664\u4e86\u8f15\u5fae\u7684\u5598\u9cf4\u8072\u5916\uff0c\u6c92\u6709\u5176\u4ed6\u7570\u5e38\uff0c\u62bd\u8840\u6aa2\u67e5 WBC\u3001 PT\u3001PTT\u3001Platelet\u3001Hb\u3001BUN\u3001Cre\u3001ALT\u5168\u90e8\u6b63\u5e38\uff0c\u9664\u4e86CXR\u5728\u5de6\u4e0b\u80ba\u8449\u6709\u4e9b\u6bdb\u73bb\u7483\u72c0\u7684\u6d78\u6f64\u3002\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u986f\u793a\u5c40\u90e8\u7684\u6bdb\u73bb\u7483\u6d78\u6f64\u5728\u5de6\u4e0b\u8449  \u3002\u8acb\u554f\u63a5\u4e0b\u4f86\u61c9\u8a72\u505a\u751a\u9ebc\uff1f\nA. \u96fb\u8166\u65b7\u5c64\u5f15\u5c0e\u5207\u7247\nB. \u7d66\u4e88\u6297\u751f\u7d20 ciprofloxacin\nC. \u80ba\u90e8\u9ad8\u89e3\u50cf\u5ea6\u96fb\u8166\u65b7\u5c64\nD. \u652f\u6c23\u7ba1\u93e1\u6aa2\u67e5\nE. \u8840\u6db2\u57f9\u990a\n": "(D)", "107-19.\n75\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(COPD)\u6025\u6027\u767c\u4f5c\u63d2\u7ba1\u9032\u52a0\u8b77\u75c5\u623f\u3002\u5728ICU\u7d66\u4e88\u93ae\u975c\u5291\u53ca\u547c\u5438\u5668\u652f\u6301\u3002\u958b\u59cb\u7684\u5c16\u5cf0\u5438\u6c23\u58d3\u529b\uff08Peak inspiratory pressure\uff09\u70ba30 cmH2O\uff0c\u9ad8\u539f\u671f\u58d3\u529b15 cmH2O\u3002\u4e00\u500b\u5c0f\u6642\u5f8c\uff0c\u5c16\u5cf0\u5438\u6c23\u58d3\u529b\u70ba42 cmH2O\uff0c\u9ad8\u539f\u671f\u58d3\u529b26 cmH2O\uff0c FiO2 0.5\uff0cSaturation 90%\u3002\u8eab\u9ad4\u6aa2\u67e5\u5f8c\u6c92\u6709\u767c\u71d2\uff0c\u8840\u58d3100/60 mmHg\uff08\u5728\u6025\u8a3a\u70ba150/100 mmHg\uff09\uff0c\u5fc3\u8df3110/min\uff0c\u547c\u5438\u6b21\u657830/min\uff0c\u9838\u975c\u8108\u6012\u5f35\uff0c\u5fc3\u97f3\u8f03\u5c0f\u8072\uff0c\u547c\u5438\u97f3\u5c0d\u7a31\u4f46\u5c0f\u8072\u3002\u4ee5\u4e0b\u54ea\u7a2e\u60c5\u6cc1\u6700\u80fd\u89e3\u91cb\u75c5\u4eba\u6c23\u9053\u58d3\u529b\u7684\u8b8a\u5316\uff1f\nA. \u75f0\u591a\uff0c\u75f0\u584a\u5361\u4f4f\nB. \u6c23\u7ba1\u5167\u7ba1\u6298\u5230\nC. \u93ae\u975c\u5291\u904e\u91cf\nD. \u6c23\u80f8\nE. \u81ea\u767c\u6027\u5410\u6c23\u6027\u6b63\u58d3(Auto PEEP)\n": "(E)", "107-20.\n75\u6b72\u7537\u6027\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5severe emphysema group D\uff0c\u8f15\u5fae\u7684\u6d3b\u52d5\u5c31\u5bb9\u6613\u5598\u3002\u5e73\u6642\uff08Ambient air\uff09\u7684\u8840\u6c27\u6fc3\u5ea6\u70ba 90%\uff0c\u5076\u723e\u6389\u5230 88%\u4ee5\u4e0b\uff0c\u4f46\u5f88\u5feb\u5c31\u56de\u523090%\uff0c\u904b\u52d5\u6642\u8840\u6c27\u6fc3\u5ea6\u7d04\u70ba 88\u223c90%\uff0c\u5076\u723e\u6389\u5230 88%\u4ee5\u4e0b\uff0c\u5bb6\u5c6c\u8a62\u554f\u9700\u4e0d\u9700\u8981\u4f7f\u7528\u6c27\u6c23\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u4e0d\u9700\u9577\u671f\u4f7f\u7528\uff0c\u56e0\u70ba\u4e0d\u6703\u5f71\u97ff\u4f4f\u9662\u5929\u6578\nB. \u4e0d\u9700\u9577\u671f\u4f7f\u7528\uff0c\u56e0\u70ba\u4e0d\u6703\u5f71\u97ff\u6b7b\u4ea1\u7387\nC. \u9808\u9577\u671f\u4f7f\u7528\uff0c\u6703\u964d\u4f4e\u6b7b\u4ea1\u7387\nD. \u8003\u616e\u8840\u6c27\u6fc3\u5ea6\u4f4e\u65bc88% \u6642\u518d\u4f7f\u7528\nE. \u4e0d\u9700\u9577\u671f\u4f7f\u7528\uff0c\u4e0d\u6703\u5f71\u97ff\u80ba\u529f\u80fd\n": "(C)", "107-21.\n71\u6b72\u7537\u6027\u8001\u83f8\u69cd\uff0c\u4e00\u5929\u4e00\u5305\u83f8\u5df2\u7d9350\u5e74\uff0c\u62b1\u6028\u75f0\u591a\uff0c\u8d70\u8def\u6703\u5598\uff0c\u54b3\u55fd\u52a0\u5287\uff0c\u9580\u8a3a\u91ab\u5e2b\u5b89\u6392\u80ba\u529f\u80fd\u6aa2\u67e5\uff0cFVC 3600\u6beb\u5347\uff08\u9810\u6e2c\u503c3880\u6beb\u5347\uff09\uff0cFEV1  2160\u6beb\u5347\uff08\u9810\u6e2c\u503c3100\u6beb\u5347\uff09\uff0c\u4e26\u958b\u59cb\u7d66\u4e88tiotropium\uff08spiriva respimat\uff09\u3002\u75c7\u72c0\u96d6\u6709\u6539\u5584\uff0c\u4f46\u4ecd\u5e38\u6709\u5598\u54b3\u7684\u60c5\u5f62\u3002\u9580\u8a3a\u91ab\u5e2b\u8003\u616e\u6539\u8b8a\u8655\u65b9\uff0c\u4e0b\u5217\u4f55\u8005\u6703\u512a\u5148\u8003\u616e\uff1f\nA. \u7dad\u6301\u5438\u5165\u578b\u9577\u6548\u6297\u81bd\u9e7c\u85e5\u7269\uff0c\u589e\u52a0\u4f4e\u5291\u91cf\u53e3\u670d\u985e\u56fa\u9187\nB. \u7dad\u6301\u5438\u5165\u578b\u9577\u6548\u6297\u81bd\u9e7c\u85e5\u7269\uff0c\u52a0\u5438\u5165\u578b\u77ed\u6548\u03b22 agonist (LAMA + SABA)\nC. \u8003\u616e\u5438\u5165\u578b\u9577\u6548\u6297\u81bd\u9e7c\u85e5\u7269\uff0c\u52a0\u5438\u5165\u578b\u985e\u56fa\u9187\uff08LAMA+ICS\uff09\nD. \u5438\u5165\u578b\u9577\u6548\u6297\u81bd\u9e7c\u85e5\u7269\uff0c\u52a0\u5438\u5165\u578b\u9577\u6548\u03b22 agonist (LAMA + LABA)\nE. \u5438\u5165\u578b\u9577\u6548\u03b22 agonist\uff0c\u52a0\u5438\u5165\u578b\u985e\u56fa\u9187 (LABA + ICS)\n": "(D)", "107-22.\n\u6709\u95dc\u80ba\u764c\uff0c\u4e0b\u5217\u54ea\u500b\u63cf\u8ff0\u662f\u932f\u8aa4\uff1f\nA. \u5728\u53f0\u7063\u80ba\u764c\u7684\u75c5\u4eba\uff0c\u76f8\u8f03\u4e16\u754c\u5176\u4ed6\u570b\u5bb6\uff0c\u5973\u6027\u6709\u8f03\u9ad8\u7684\u6bd4\u4f8b\nB. \u53f0\u7063\u7537\u6027\u75c5\u4eba\u9c57\u72c0\u7d30\u80de\u764c\u7684\u4eba\u6578\u6bd4\u80ba\u817a\u764c\u4f86\u7684\u9ad8\nC. \u5728\u53f0\u7063\uff0c\u5973\u6027\u80ba\u817a\u764c\u5438\u83f8\u6bd4\u4f8b\u751a\u4f4e\nD. \u7f8e\u570b\u6709\u4e00\u7a2e\u8da8\u52e2\u5c31\u662f\u80ba\u817a\u764c\u6bd4\u4f8b\u589e\u52a0\uff0c\u7279\u5225\u662f\u5e74\u8f15\u5973\u6027\u4e0d\u62bd\u83f8\u7684\u65cf\u7fa4\nE. \u5c0f\u7d30\u80de\u80ba\u764c\u8207\u5438\u83f8\u9ad8\u5ea6\u76f8\u95dc\n": "(B)", "108-1.\n\u6709\u95dc\u963f\u65af\u5339\u9748\u654f\u611f\u578b\u6c23\u5598(Aspirin-sensitive asthma)\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba? (1)\u901a\u5e38\u5148\u767c\u751f\u904e\u654f\u6027\u9f3b\u708e(Perennial rhinitis)\u8207\u9f3b\u606f\u8089(Nasal polyps)\u4e4b\u75c5\u5fb5\uff1b(2)\u963f\u65af\u5339\u9748\u654f\u611f\u578b\u6c23\u5598\u6bd4\u8f03\u4e0d\u6703\u88ab\u75c5\u6bd2\u611f\u67d3\u5f15\u767c\u6025\u6027\u767c\u4f5c (Exacerbations of asthma)\uff1b(3)\u963f\u65af\u5339\u9748\u654f\u611f\u578b\u6c23\u5598\u5e38\u5e38\u5728\u540c\u4e00\u5bb6\u5ead\u4e2d\u6703\u6709\u591a\u4f4d\u6210\u54e1\u767c\u751f\uff1b(4)cyclooxygenase 1 (COX-1) \u6291\u5236\u5291\u8f03COX-2 \u6291\u5236\u5291\u5bb9\u6613\u5f15\u767c\u963f\u65af\u5339\u9748\u654f\u611f\u578b\u6c23\u5598\uff1b(5)\u6cbb\u7642\u6548\u679c\u4ee5\u6297\u767d\u4e09\u70ef\u7d20(Antileukotrienes)\u8f03\u4f73\uff0c\u5438\u5165\u6027\u985e\u56fa\u9187 (Inhaled corticosteroids)\u4e0d\u5efa\u8b70\u4f7f\u7528\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(2)+(4)\nD. (1)+(4)\nE. (3)+(4)+(5)\n": "(D)", "108-2.\n\u6709\u95dc\u5438\u5165\u6027\u80ba\u708e(Aspiration pneumonia)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4? (1)\u81f4\u75c5\u7684\u83cc\u7a2e\u5728\u6700\u8fd1\u9019\u5e7e\u5e74\u4f86\uff0c\u53ad\u6c27\u83cc(Anaerobes)\u7684\u91cd\u8981\u6027\u6f38\u6f38\u9ad8\u65bc\u597d\u6c27\u83cc(aerobes)\uff1b(2)\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(Chronic obstructive pulmonary disease)\u662f\u5176\u4e2d\u4e00\u500b\u5371\u96aa\u56e0\u5b50\uff1b(3)\u7ba1\u704c\u98f2\u98df(Tube feeding)\u5f88\u5b89\u5168\uff0c\u53ef\u4ee5\u907f\u514d\u541e\u56a5\u529f\u80fd\u4e0d\u4f73\u7684\u75c5\u60a3\u767c\u751f\u5438\u5165\u6027\u80ba\u708e\uff1b(4)\u53ea\u6709\u5728\u5438\u5165\u5927\u91cf\u8207\u9178\u6027\u7684\u80c3\u5bb9\u7269(Gastric contents)\u6642\uff0c\u624d\u5bb9\u6613\u767c\u751fChemical pneumonitis\uff1b(5)\u4f86\u81ea\u793e\u5340(Community -acquired)\u7684\u75c5\u60a3\u767c\u751f\u5438\u5165\u6027\u80ba\u708e\uff0c\u53ef\u8003\u616e\u7d66\u4e88ampicillin\u2013sulbactam,\rcarbapenem (ertapenem), \u6216fluoroquinolone (levofloxacin or moxifloxacin)\u7684\u6cbb\u7642\nA. (1)+(2)+(3)\nB. (1)+(3)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (3)+(4)\n": "(B)", "108-3.\n\u6709\u95dc\u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316(Idiopathic Pulmonary Fibrosis, IPF)\u4e4b\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba? (1)\u80ba\u529f\u80fd\u6aa2\u67e5\u7d50\u679c\u901a\u5e38\u5448\u73fe\u4e00\u6c27\u5316\u78b3\u80ba\u7030\u6563\u91cf(Diffusing capacity of the lung for carbon monoxide, DLco)\u964d\u4f4e\uff1b(2)\u5371\u96aa\u56e0\u5b50\u5305\u62ec\u9ad8\u9f61, \u7537\u6027\u8207\u62bd\u83f8\u7b49\uff1b(3)\u8a3a\u65b7IPF\u4ee5\u81e8\u5e8a\u8207\u80ba\u90e8\u9ad8\u89e3\u50cf\u5ea6\u96fb\u8166\u65b7\u5c64\u6383\u63cf(HRCT\uff0cHigh Resolution Computed Tomography )\u70ba\u4e3b\uff0c\u4e0d\u4e00\u5b9a\u9700\u8981\u9032\u884c\u80ba\u5207\u7247Lung biopsy)\u6aa2\u67e5\uff1b(4)IPF\u60a3\u8005\u4e0d\u5efa\u8b70\u63a5\u53d7\u80ba\u79fb\u690d(Lung transplantation)\u624b\u8853\uff0c\u56e0\u70ba\u6709\u5f88\u9ad8\u7684\u6bd4\u4f8b\u6703\u5fa9\u767c\uff1b(5)\u4f7f\u7528Nintedanib \u6216 Pirfenidone\u6cbb\u7642IPF\uff0c\u7121\u6cd5\u964d\u4f4e\u6b7b\u4ea1\u7387\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(2)+(5)\nD. (2)+(3)+(4)\nE. (3)+(4)+(5)\n": "(A)", "108-4.\n\u95dc\u65bc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(Acute respiratory distress syndrome, ARDS)\u7684\u67cf\u6797\u5b9a\u7fa9(Berlin definition)\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u5f9e\u5371\u96aa\u56e0\u5b50\u7684\u66b4\u9732\u5230ARDS\u7684\u767c\u751f\u70ba7\u5929\u5167\nB. \u5f71\u50cf\u5b78\u8a3a\u65b7\u5305\u62ec\u80f8\u90e8X\u5149\u6216\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\nC. \u9700\u5b8c\u5168\u6392\u9664\u5fc3\u81df\u8870\u7aed\u6216Volume overload\nD. \u91cd\u5ea6ARDS\u5b9a\u7fa9\u70ba PaO2/FiO2 \u2266 100 mmHg\nE. \u53d6\u6d88\u6025\u6027\u80ba\u640d\u50b7(Acute lung injury, ALI)\u4e00\u8a5e\n": "(C)", "108-5.\n\u4e0b\u5217\u6709\u95dc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(Acute respiratory distress syndrome, ARDS)\u7684\u6cbb\u7642\u4f55\u8005\u6709\u8aa4?\nA. \u53ca\u65e9\u627e\u5230\u4e26\u6cbb\u7642\u9020\u6210ARDS\u7684\u75c5\u56e0\nB. \u547c\u5438\u5668\u4f7f\u7528\u4f4e\u6f6e\u6c23\u91cf(Tidal volume, 6ml/kg)\uff0c\u4ee5\u6e1b\u5c11\u547c\u5438\u5668\u5c0e\u81f4\u80ba\u640d\u50b7(Ventilator-induced lung injury)\nC. \u4fef\u81e5\u59ff(Prone position)\u53ef\u6e1b\u5c11\u4e2d\u91cd\u5ea6ARDS\u60a3\u8005(PaO2/FiO2 < 120 mmHg)\u4e4b\u6b7b\u4ea1\u7387\nD. \u9ad4\u5916\u819c\u6c27\u5408(Extracorporeal Membrane Oxygenation\uff0cECMO)\u7684\u65e9\u671f\u4f7f\u7528\uff0c\u53ef\u6539\u5584\u56b4\u91cdARDS\u60a3\u8005\u7684\u5b58\u6d3b\u7387\nE. \u4e0d\u5efa\u8b70\u5e38\u898f\u4f7f\u7528\u985e\u56fa\u9187(Glucocorticoids)\n": "(D)", "108-6.\n\u4e0b\u5217\u4f55\u8005\u975e\u6557\u8840\u6027\u4f11\u514b(Septic shock)\u6216\u6557\u8840\u75c7(Sepsis)\u7684\u6700\u65b0\u5b9a\u7fa9(Sepsis-3)?\nA. \u7591\u4f3c\u6216\u78ba\u8a3a\u75c5\u83cc\u611f\u67d3(Suspected or documented infection)\nB. \u51fa\u73fe\u5927\u65bc\u6216\u7b49\u65bc\u5169\u9805\u5168\u8eab\u6027\u708e\u6027\u53cd\u61c9\u75c7\u5019\u7fa4\u8981\u7d20(Systemic inflammatory response syndrome criteria)\nC. \u51fa\u73fe\u5927\u65bc\u6216\u7b49\u65bc\u5169\u9805\u76f8\u7e7c\u5668\u5b98\u8870\u7aed\u8a55\u5206(Sequential organ failure assessment, SOFA, point)\nD. \u9700\u4f7f\u7528\u8840\u7ba1\u589e\u58d3\u5291(Vasopressor)\u4ee5\u7dad\u6301\u5e73\u5747\u52d5\u8108\u8840\u58d3\u226765 mmHg\nE. \u5728\u7d66\u4e88\u9069\u7576\u8f38\u6db2\u6cbb\u7642\u60c5\u6cc1\u4e0b\uff0c\u8840\u6f3f\u4e73\u9178(Serum lactate)\u4ecd>2.0 mmol/L\n": "(B)", "108-7.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u5c6c\u65bc\u9ecf\u6db2\u963b\u585e\u6027\u80ba\u75be\u75c5(Muco-obstructive lung diseases)?\nA. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(Chronic obstructive pulmonary disease)\nB. \u6c23\u5598(Asthma)\nC. \u56ca\u72c0\u7e96\u7dad\u5316 (Cystic fibrosis)\nD. \u5148\u5929\u6027\u7e96\u6bdb\u904b\u52d5\u7570\u5e38\u75c7(Primary ciliary dyskinesia)\nE. \u975e\u56ca\u72c0\u7e96\u7dad\u5316\u652f\u6c23\u7ba1\u64f4\u5f35\u75c7(Non\u2013cystic fibrosis bronchiectasis)\n": "(B)", "108-8.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u975e\u4fb5\u8972\u6027\u547c\u5438\u5668(Noninvasive ventilation)\u7684\u4f7f\u7528\u7981\u5fcc(Contraindication)\nA. \u5fc3\u8df3\u6216\u547c\u5438\u505c\u6b62(Cardiac or respiratory arrest)\nB. \u56b4\u91cd\u8178\u80c3\u9053\u51fa\u8840(Severe gastrointestinal bleeding)\nC. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316(Chronic obstructive pulmonary disease with acute exacerbation)\nD. \u4e0a\u547c\u5438\u9053\u963b\u585e(Upper airway obstruction)\nE. \u8840\u6db2\u52d5\u529b\u4e0d\u7a69\u5b9a(Hemodynamic instability)\n": "(C)", "108-9.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u6ffe\u51fa\u6027\u808b\u819c\u7a4d\u6c34(Transudative pleural effusion) \u5f62\u6210\u4e4b\u75c5\u56e0?\nA. \u814e\u75c5\u75c7\u5019\u7fa4(Nephrotic syndrome)\nB. \u80ba\u584c\u9677(Atelectasis)\nC. \u4e0a\u8154\u975c\u8108\u963b\u585e(Superior vena cava obstruction)\nD. \u80ba\u6813\u585e(Pulmonary embolism)\nE. \u809d\u786c\u5316(Cirrhosis)\n": "(D)", "108-10.\n\u4e0b\u5217\u6709\u95dcParapneumonic effusions\u4e4b\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u662f\u6700\u5e38\u898b\u9020\u6210\u6ef2\u51fa\u6027\u808b\u819c\u7a4d\u6db2(Exudative pleural effusions)\u7684\u539f\u56e0\nB. \u6700\u91cd\u8981\u7684\u6cbb\u7642\u662f\u7d66\u4e88\u9069\u7576\u7684\u6297\u751f\u7d20(Antibiotics)\nC. \u9662\u5167\u611f\u67d3(Hospital-acquired infection)\u6b7b\u4ea1\u7387\u9ad8\u65bc\u793e\u5340\u611f\u67d3(Community-acquired infection)\nD. \u81bf\u80f8(empyema)\u5efa\u8b70\u4f7f\u752816-French\u4ee5\u4e0a\u7684\u80f8\u7ba1(Chest tube)\u6216\u8c6c\u5c3e\u5df4\u5c0e\u7ba1(Pigtail catheter)\u5f15\u6d41\nE. \u82e5\u51fa\u73fe\u8154\u5ba4\u5316\u808b\u819c\u7a4d\u6db2(Loculated pleural fluid)\u5c31\u8981\u8003\u616e\u7167\u6703\u80f8\u8154\u5916\u79d1\u9032\u884c\u5f71\u50cf\u8f14\u52a9\u80f8\u8154\u93e1\u624b\u8853(Video-assisted thoracoscopic surgery , VATS)\n": "(D)", "108-11.\n\u4e0b\u5217\u6709\u95dc\u7f8e\u570b\u570b\u5bb6\u80ba\u764c\u7be9\u6aa2\u8a66\u9a57(The National Lung Screening Trial, NLST)\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u63a5\u53d7\u7be9\u6aa2\u7684\u9ad8\u5371\u96aa\u65cf\u7fa4\u5fc5\u9808\u7b26\u540855-74\u6b72\u4e14\u5438\u83f8\u53f2\u5927\u65bc30\u5305\u83f8-\u5e74(Pack-year )\uff0c\u800c\u6212\u83f8\u8005\u5247\u9700\u6212\u83f8\u5341\u4e94\u5e74\u5167\nB. \u8a66\u9a57\u7d44\u4f7f\u7528\u4f4e\u5291\u91cf\u80f8\u90e8\u96fb\u8166\u65b7\u7be9\u6aa2, \u4e0d\u9700\u6253\u986f\u5f71\u5291\nC. \u5c0d\u7167\u7d44\u70ba\u4f7f\u7528\u80f8\u90e8X\u5149\u7be9\u6aa2\nD. \u8a66\u9a57\u7d44\u7684\u5047\u967d\u6027\u7387(False-positive rate)\u4f4e\u65bc\u5c0d\u7167\u7d44\nE. \u8a66\u9a57\u7d44\u76f8\u8f03\u65bc\u5c0d\u7167\u963b\u53ef\u964d\u4f4e\u80ba\u764c\u6b7b\u4ea1\u738720%\n": "(D)", "108-12.\n\u7b2c\u4e09\u671f\u7121\u6cd5\u63a5\u53d7\u624b\u8853\u5207\u9664\u4e4b\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u60a3\u8005(Unresectable non-small-cell lung cancer), \u5728\u9032\u884c\u5b8c\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642(Concurrent chemoradiotherapy, CCRT)\u5f8c\uff0c\u4e0b\u5217\u4f55\u7a2e\u6cbb\u7642\u53ef\u5ef6\u9577\u75c5\u60a3\u6574\u9ad4\u5b58\u6d3b(Overall survival)\nA. \u5bc6\u5207\u8ffd\u8e64\uff0c\u4e0d\u9700\u8ffd\u52a0\u4efb\u4f55\u6cbb\u7642\nB. \u978f\u56fa\u6027\u5316\u5b78\u6cbb\u7642(Consolidation chemotherapy)\u56db\u500b\u7642\u7a0b\nC. \u6a19\u9776\u6cbb\u7642(Targeted therapy)\u4f7f\u7528\u4e00\u5e74\nD. \u65bd\u6253Pembrolizumab\u4e00\u5e74\nE. \u65bd\u6253Durvalumab\u4e00\u5e74\n": "(E)", "108-13.\n18\u6b72\u5e74\u8f15\u7537\u6027\uff0c\u5065\u5eb7\u72c0\u6cc1\u826f\u597d\uff0c\u5728\u6253\u7403\u6642\u7a81\u767c\u6027\u5598\u53ca\u80f8\u60b6\uff0c\u4f86\u5230\u6025\u8a3a\uff0c\u521d\u6b65\u8a3a\u65b7\u7591\u4f3c\u6c23\u80f8\uff0c\u4f60\u9810\u671f\u6703\u6709\u90a3\u4e9b\u767c\u73fe(1)\u80f8\u90e8 X-ray \u770b\u5230pleural line\uff1b(2)\u807d\u8a3a\u60a3\u5074\u547c\u5438\u97f3\u4e0b\u964d\uff1b(3)\u6263\u8a3a\u60a3\u5074\u6fc1\u97f3(dullness)\u660e\u986f\uff1b(4)\u89f8\u8a3a\u5169\u5074\u5c0d\u7a31\u64f4\u5f35\uff1b(5)\u80f8\u8154\u8d85\u97f3\u6ce2\u60a3\u5074\u770b\u4e0d\u5230\u808b\u819c\u6ed1\u52d5\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(4)\nC. (1)+(2)+(3)\nD. (1)+(2)+(3)+(5)\nE. (1)+(2)+(5)\n": "(E)", "108-14.\n40\u6b72\u5973\u6027\uff0c\u5c0f\u6642\u5019\u6709\u6c23\u5598\u75c5\u53f2\uff0c\u9ad8\u4e2d\u4e4b\u5f8c\u5f88\u9577\u4e00\u6bb5\u6642\u9593\u6c92\u6709\u767c\u4f5c\uff0c10\u5e74\u524d\uff0c\u6c23\u5598\u518d\u5ea6\u767c\u4f5c\uff0c\u9019\u5e7e\u5e74\u63a7\u5236\u4e0d\u4f73\u3002\u5df2\u7d93\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187+\u9577\u6548\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291\uff0c\u5438\u5165\u578b\u9577\u6548\u6297\u81bd\u9e7c\u85e5\u7269\uff0c\u767d\u4e09\u70ef\u7d20\u53d7\u9ad4\u62ee\u6297\u5291\u53ca\u53e3\u670d\u985e\u56fa\u9187\uff0c\u4e0b\u5217\u4f55\u8005\u5c0d\u5979\u53ef\u80fd\u6703\u6709\u5e6b\u52a9\u3002(1)\u6aa2\u8996\u5438\u85e5\u7684\u6b63\u78ba\u6027\uff1b(2)\u627e\u51fa\u904e\u654f\u539f\uff0c\u4e26\u9060\u96e2\u904e\u654f\u539f\uff1b(3)\u6aa2\u67e5IgE\uff0c\u8003\u616e\u4f7f\u7528\u6297IgE\u7403\u86cb\u767d\u6297\u9ad4\uff1b(4)\u589e\u52a0\u53e3\u670d\u985e\u56fa\u9187\u7684\u5291\u91cf\uff1b(5)\u5982\u679c\u8840\u6db2\u53ca\u75f0\u6db2\u55dc\u9178\u6027\u767d\u8840\u7403\u589e\u52a0\uff0c\u53ef\u4ee5\u8003\u616e\u6297IL-5\u85e5\u7269\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(4)+(5)\nC. (1)+(3)+(4)+(5)\nD. (1)+(2)+(3)+(5)\nE. (2)+(3)+(4)+(5)\n": "(D)", "108-15.\n80\u6b72\u7537\u6027\u8001\u83f8\u69cd\u9ad8\u8840\u58d3\u898f\u5247\u670d\u85e5\uff0c\u56e0\u70ba\u54b3\u55fd\u3001\u5598\u4f86\u9580\u8a3a\u8a55\u4f30\u3002\u80f8\u90e8X-ray\u986f\u793a\u5169\u5074\u4e0b\u80ba\u91ce\u6709\u7db2\u72c0\u9670\u5f71\uff0c\u80ba\u529f\u80fd\u6aa2\u67e5 FVC 79 % of prediction\uff0c FEV1 82% of prediction\uff0cFEV1/FVC 75%\uff0cDLCO 56% of prediction\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. \u6c23\u5598\nB. \u80ba\u6c23\u816b\nC. \u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316\nD. \u6162\u6027\u652f\u6c23\u7ba1\u708e\nE. \u652f\u6c23\u7ba1\u64f4\u5f35\n": "(C)", "108-16.\n\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u7684\u75c5\u4eba\u5728\u8a3a\u6240\u8ffd\u8e64\u6642\uff0c\u82e5\u6709\u6025\u6027\u767c\u4f5c\uff0c\u91ab\u5e2b\u901a\u5e38\u6703\u4f7f\u7528\u6297\u751f\u7d20\u53ca\u985e\u56fa\u9187\uff0c\u7279\u5225\u662f\u75c5\u4eba\u5598\u3001\u75f0\u91cf\u589e\u52a0\u3001\u75f0\u8b8a\u9ec3\u3002\u4e0b\u5217\u54ea\u4e00\u7a2e\u5feb\u901f\u6aa2\u67e5\uff0c\u53ef\u4ee5\u5e6b\u52a9\u8a3a\u6240\u91ab\u5e2b\u6e1b\u5c11\u6297\u751f\u7d20\u7684\u4f7f\u7528\uff1f\nA. Interleukin-1\u03b2 (IL-1\u03b2)\nB. Tumor necrotic factor alpha (TNF-\u03b1)\nC. C-reactive protein (CRP)\nD. Procalcitonin\nE. Ferritin\n": "(C)", "108-17.\n88\u6b72\u7537\u6027\u56e0\u81bd\u7d50\u77f3\uff0c\u4f4f\u9662\u958b\u5200\u3002\u8853\u5f8c\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u767c\u4f5c\uff0c\u4e0b\u5217\u90a3\u4e00\u9805\u4e0d\u662f\u6025\u6027\u767c\u4f5c\u7684\u75c7\u72c0\u6216\u5fb5\u5019 (symptoms or signs)\nA. \u5410\u6c23\u6642\u547c\u5438\u97f3\u964d\u4f4e\u6216\u807d\u4e0d\u5230\nB. \u75f0\u91cf\u8b8a\u591a\nC. \u547c\u5438\u6b21\u6578\u589e\u52a0\nD. \u55ae\u5074\u547c\u5438\u97f3\u964d\u4f4e\nE. \u5438\u6c23\u53ca\u5410\u6c23\u6642\uff0c\u80f8\u5ed3\u8b8a\u5316\u4e0d\u660e\u986f\n": "(D)", "108-18.\n88\u6b72\u7537\u6027\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u767c\u4f5c\uff0c\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790(ABG)\u986f\u793apH7.30, CO2 80mmHg\uff0c\u4e0b\u5217\u54ea\u7a2e\u8655\u7f6e\u5c0d\u4ed6\u6700\u597d?\nA. \u6c23\u7ba1\u63d2\u7ba1\uff0c\u958b\u59cb\u4f7f\u7528\u547c\u5438\u5668(\u6a5f\u68b0\u901a\u6c23mechanical ventilation)\nB. \u975e\u4fb5\u8972\u6027\u901a\u6c23(non-invasive ventilation, NIV)\nC. \u7acb\u5373\u7d66\u4e88\u9577\u6548\u652f\u6c23\u7ba1\u64f4\u5f35\u5291(Long-acting bronchodilator)\nD. \u6297\u751f\u7d20(antibiotic)\nE. \u4eba\u5de5\u6025\u6551\u7526\u9192\u7403\u7d66\u6c27 (AMBU Bagging)\n": "(B)", "108-19.\n90\u6b72\u5973\u6027\u56e0\u70ba\u767c\u71d2\u4f86\u5230\u6025\u8a3a\uff0c\u5c3f\u6db2\u6aa2\u67e5\u986f\u793a\u81bf\u5c3f\uff0c\u8840\u58d3\u4e0d\u7a69\u5b9a\uff0c\u5408\u4f75\u814e\u529f\u80fd\u53d7\u640d\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e?\nA. \u6557\u8840\u75c7Sepsis \u5b9a\u7fa9\u662f\u78ba\u5b9a\u6216\u7591\u4f3c\u611f\u67d3\u6e90\u5408\u4f75SOFA score \u22672\nB. \u6557\u8840\u75c7\u4f11\u514bseptic shock\uff0c\u5247\u662f\u6557\u8840\u75c7\u9700\u5347\u58d3\u85e5(vasopressor)\u4f7f\u7528\u53ca\u4e73\u9178(lactate) >2 mmol/L\nC. \u8d8a\u65e9\u7d66\u4e88\u6709\u6548\u7684\u6297\u751f\u7d20\uff0c\u9810\u5f8c\u8d8a\u597d\nD. \u5c0e\u5c3f\u7ba1\u4f7f\u7528\uff0c\u5f15\u6d41\u5c3f\u6db2\nE. Norepinephrine \u662f\u9996\u9078\u7684\u5347\u58d3\u85e5(vasopressor)\n": "(D)", "108-20.\n35\u6b72\u7537\u6027\uff0c\u8eab\u9ad8172\u516c\u5206\uff0c\u9ad4\u91cd110\u516c\u65a4\uff0c\u56e0\u70ba\u7d93\u5e38\u5728\u767d\u5929\u6253\u778c\u7761\uff0c\u665a\u4e0a\u7761\u89ba\u6642\u6253\u547c\u8072\u8b93\u592a\u592a\u7121\u6cd5\u5165\u7761\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e?\nA. \u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\u662f\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u66ab\u505c/\u4f4e\u901a\u6c23\u7d9c\u5408\u75c7(Obstructive sleep apnea/hypopnea syndrome)\u7684\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\nB. \u75c5\u4eba\u7761\u7720\u54c1\u8cea\u4e0d\u4f73\uff0c\u5e38\u5e38\u56e0\u7f3a\u6c27\u800c\u9192\u4f86\nC. \u4e0b\u984e\u7a81\u51fa\u662f\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\nD. \u8a3a\u65b7\u4e3b\u8981\u9760\u904e\u591c\u7684\u591a\u5c0e\u7761\u7720\u5716 (overnight polysomnogram)\nE. \u5e38\u5408\u4f75\u5fc3\u81df\u3001\u8166\u8840\u7ba1\u53ca\u4ee3\u8b1d\u75be\u75c5\n": "(C)", "108-21.\n\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e?\nA. \u80ba\u764c\u57281900\u5e74\u4ee5\u524d\u70ba\u7f55\u898b\u75be\u75c5\nB. \u5c0f\u7d30\u80de\u80ba\u764c\u3001\u9c57\u72c0\u7d30\u80de\u764c\u7684\u6bd4\u4f8b\u9010\u5e74\u6e1b\u5c11\u662f\u5168\u4e16\u754c\u5171\u901a\u7684\u8da8\u52e2\nC. \u4e0d\u62bd\u83f8\u5973\u6027\u80ba\u817a\u764c\u7684\u4eba\u6578\u5927\u65bc\u62bd\u83f8\u5973\u6027\u80ba\u817a\u764c\u7684\u4eba\u6578\u662f\u5404\u500b\u5730\u5340\u4e00\u81f4\u7684\u73fe\u8c61\nD. \u7537\u6027\u80ba\u764c\u4eba\u6578\u53ca\u4f54\u4eba\u53e3\u6bd4\u4f8b\u8f03\u5973\u6027\u80ba\u764c\u4eba\u6578\u53ca\u4f54\u4eba\u53e3\u6bd4\u4f8b\u9ad8\u662f\u5168\u4e16\u754c\u4e00\u81f4\u7684\u73fe\u8c61\nE. \u53f0\u7063\u5973\u6027\u80ba\u764c\u4f54\u80ba\u764c\u7684\u6bd4\u4f8b\u9060\u9ad8\u65bc\u4e16\u754c\u5e73\u5747\u503c\n": "(C)", "108-22.\n\u80ba\u7d50\u6838\u7684\u63a7\u5236\u6700\u91cd\u8981\u7684\u5c31\u662f\u53ca\u6642\u6aa2\u6e2c\uff0c\u53ca\u63d0\u4f9b\u6709\u6548\u7684\u77ed\u671f\u6cbb\u7642\u3002\u9032\u4e00\u6b65\u7684\u9810\u9632\u662f\u627e\u51fa\u6f5b\u4f0f\u7d50\u6838\u611f\u67d3\u7684\u7fa4\u7d44\u4e26\u7d66\u4e88\u6cbb\u7642\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u662f? (1)\u75be\u75c5\u7ba1\u5236\u7f72\u5df2\u57282016\u5e74\u63a8\u52d5\u5168\u5e74\u9f61\u5c64\u6f5b\u4f0f\u7d50\u6838\u5168\u90fd\u6cbb\u8a08\u756b\uff1b(2)\u6f5b\u4f0f\u7d50\u6838\u7684\u5075\u6e2c\uff0c\u4e94\u6b72\u4ee5\u4e0a\u4ee5\u7d50\u6838\u83cc\u76ae\u819a\u6e2c\u9a57(TST)\u70ba\u4e3b\uff0c\u4e94\u6b72\u4ee5\u4e0b\u4ee5\u4e19\u578b\u5e72\u64fe\u7d20\u91cb\u653e\u8a66\u9a57(IGRA)\u70ba\u4e3b\uff1b(3)\u9700\u505aCXR \uff0c\u6392\u9664\u80ba\u90e8\u6709\u6d3b\u52d5\u6027\u80ba\u7d50\u6838\uff1b(4)\u7d50\u6838\u83cc\u76ae\u819a\u6e2c\u9a57(TST)\u5e38\u53d7\u975e\u7d50\u6838\u5206\u679d\u687f\u83cc(NTM)\u7684\u5e72\u64fe\uff1b(5)\u5efa\u8b70\u4ee5\u90fd\u6cbb\u8a08\u756b\u7d66\u85e5(Directly Observed Treatment Short-Course\uff0cDOTS)\u3002\nA. (1)+(2)+(3)+(4)\nB. (1)+(3)+(4)+(5)\nC. (2)+(3)+(4)+(5)\nD. (1)+(2)+(4)+(5)\nE. (2)+(4)+(5)\n": "(B)", "109-23.78\u6b72\u8001\u83f8\u69cd \uff0cCOPD\u8a3a\u65b7\u5df2\u7d93\u597d\u5e7e\u5e74 \uff0c\u56e0\u70ba\u80ba\u529f\u80fd\u4e0d\u4f73\u53ca\u54b3\u5598 \uff0c\u9577\u671f\u4f7f\u7528\u5438\u5165\u578b\u6c23\u7ba1\u64f4\u5f35\u5291 \u3002\u4e0d\u5e78\u7684\u662f\u5de6\n\u4e0a\u80ba\u8449\u767c\u73fe\u4e00\u9846\u816b\u7624 \uff0c\u5207\u7247\u8b49\u5be6\u662f\u9c57\u72c0\u7d30\u80de\u764c \uff0c\u6c92\u6709\u6dcb\u5df4\u7d50\u53ca\u9060\u7aef\u8f49\u79fb \uff0c\u5916\u79d1\u91ab\u5e2b\u60f3\u8981\u958b\u5200\u5207\u9664 \uff0c\u4f60\u6703\u5efa\n\u8b70\u54ea\u7a2e\u6aa2\u67e5\u4f86\u8a55\u4f30\u8853\u5f8c\u7684\u80ba\u529f\u80fd \uff1f   \nA.\u96fb\u8166\u65b7\u5c64\nB.\u6838\u78c1\u5171\u632f\nC.\u652f\u6c23\u7ba1\u93e1\nD.\u80ba\u81df\u8840\u6d41\u704c\u6ce8\u6383\u63cf\nE.\u80f8\u90e8\u8d85\u97f3\u6ce2\n": "[D]", "109-24.\u5e74\u8f15\u5973\u6027\u5728\u5065\u6aa2\u6642\u80f8\u90e8 X-ray \u6709\u7591\u4f3c\u816b\u7624\u7684\u9670\u5f71 \uff0c\u65bc\u662f\u4f86\u5230\u5927\u91ab\u9662\u9580\u8a3a\u9032\u4e00\u6b65\u6aa2\u67e5 \u3002\u5979\u807d\u670b\u53cb\u8aaa\u6838\u78c1\u5171\u632f\n\u6aa2\u67e5\u6bd4\u8f03\u6602\u8cb4 \u3001\u6bd4\u8f03\u7cbe\u5bc6 \uff0c\u65bc\u662f\u8981\u6c42\u5b89\u6392\u80f8\u90e8\u6838\u78c1\u5171\u632f\u6aa2\u67e5 \uff0c\u4e0b\u5217\u4f55\u8005\u8aaa\u660e\u662f\u4e0d\u5408\u7406\u7684 \uff1f   \nA.\u6838\u78c1\u5171\u632f\u5c0d\u65bc\u80ba\u81df\u7684\u89e3\u6790\u5ea6\u6bd4\u96fb\u8166\u65b7\u5c64\u4f73\uff0c\u53ef\u4ee5\u7528\u4f86\u6aa2\u6e2c\u80ba\u816b\u7624\nB.\u96fb\u8166\u65b7\u5c64\u5728\u80ba\u81df\u7684\u89e3\u6790\u5ea6\u6bd4\u6838\u78c1\u5171\u632f\u597d\nC.\u5c0d\u65bc\u80f8\u8154\u5165\u53e3\u816b\u7624\uff08pancoast tumor\uff09\u6838\u78c1\u5171\u632f\u6709\u8f03\u4f73\u7684\u89e3\u6790\u5ea6\nD.\u80ba\u52d5\u975c\u8108\u7578\u578b\uff0c\u6838\u78c1\u5171\u632f\u80fd\u63d0\u4f9b\u8db3\u5920\u7684\u8a0a\u606f\nE.\u810a\u690e\u6216\u795e\u7d93\u6839\u7684\u4fb5\u72af\uff0c\u6838\u78c1\u5171\u632f\u7684\u89e3\u6790\u5ea6\u6bd4\u96fb\u8166\u65b7\u5c64\u4f73\n": "[A]", "109-25.\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u652f\u6c23\u7ba1\u93e1\u642d\u914d\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u5e45\u5c04\u578b\u5fae\u5c0f\u63a2\u982d\u6aa2\u67e5\u53ef\u4ee5\u53d6\u5f97\u80ba\u5468\u908a\u7684\u816b\u7624\u7d44\u7e54 \uff0c\u8a3a\u65b7\u6e96\u78ba\u7387\u4f9d\u64cd\u4f5c\u8005\u7684\n\u7d93\u9a57\u6709\u6240\u4e0d\u540c\nB.\u80f8\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u53ef\u4ee5\u8a55\u4f30\u80ba\u9580\u9644\u8fd1\u7684\u75c5\u8b8a\nC.\u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u53d6\u6a23\u6aa2\u67e5\uff0c\u7e31\u8188\u8154\u93e1\u4ecd\u7136\u662f\u6a19\u6e96\u65b9\u5f0f\nD.\u808b\u819c\u8154\u93e1\u53ef\u4ee5\u7528\u4f86\u8a55\u4f30\u808b\u819c\u75c5\u8b8a\uff0c\u4e0d\u9700\u8981\u9032\u958b\u5200\u623f\u5168\u8eab\u9ebb\u9189\nE.\u65e9\u671f\u7684\u6c23\u7ba1\u9ecf\u819c\u75c5\u8b8a\u53ef\u4ee5\u7528\u87a2\u5149\u652f\u6c23\u7ba1\u93e1\u6aa2\u6e2c\n": "[B]", "109-26.59\u6b72\u7537\u6027\u56e0\u70ba\u4e45\u54b3\u4e0d\u7652 \u3001\u5927\u91cf\u7684\u9ec3\u75f0\u4f86\u9580\u8a3a\u5c31\u8a3a \u3002\u80f8\u90e8X\u5149\u6709 Tram tracks sign \uff0c\u56de\u9867\u75c5\u53f2 \uff0c\u4ed6\u6709\u6162\u6027\u9f3b\n\u7ac7\u708e\uff0c\u53cd\u8986\u767c\u4f5c \uff0c\u7d50\u5a5a\u6578\u5341\u5e74\u819d\u4e0b\u7121\u5b50 \uff0c\u4e0b\u5217\u8a3a\u65b7\u4f55\u8005\u6700\u6709\u53ef\u80fd \uff1f   \nA.\u56ca\u6027\u7e96\u7dad\u5316\uff08cystic fibrosis\uff09\nB.\u80ba\u6c23\u816b\uff08emphysema\uff09\nC.\u6c23\u5598\uff08asthma\uff09\nD.\u652f\u6c23\u7ba1\u64f4\u5f35\uff0c\u7e96\u6bdb\u904b\u52d5\u969c\u7919\u75c7\u5019\u7fa4\uff08dyskinetic cilia syndrome\nE.\u975e\u7d50\u6838\u5206\u679d\u687f\u83cc\uff08NTM\uff09\u611f\u67d3\n": "[D]", "109-27.\u4e0b\u5217\u75be\u75c5\u7684\u80ba\u529f\u80fd\u8868\u73fe\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u80a5\u80d6\uff1a\u80f8\u58c1\u7570\u5e38\u5c0e\u81f4\u901a\u6c23\u53d7\u9650\uff08ventilatory restriction\uff09\nB.\u91cd\u75c7\u808c\u7121\u529b\uff1a\u547c\u5438\u808c\u7121\u529b\u5c0e\u81f4\u901a\u6c23\u53d7\u9650\uff08ventilatory restriction\uff09   \nC.\u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316 \uff08idiopathic pulmonary fibrosis\uff09\uff1a \u80ba\u6ce1\u58c1\u8b8a\u539a \u3001\u56de\u5f48\u529b\uff08elastic recoil \uff09\u589e\u52a0\u5c0e\u81f4\u6c23\n\u6d41\u963b\u585e\nD.\u6c23\u5598\u767c\u4f5c\uff1a\u6c23\u9053\u76f4\u5f91\u6e1b\u5c0f\u5c0e\u81f4\u6c23\u6d41\u963b\u585e\nE.\u56b4\u91cd\u80ba\u6c23\u816b\uff08emphysema\uff09\u80ba\u6ce1\u58c1\u7834\u58de\u3001\u56de\u5f48\u529b\u4e0b\u964d\u5c0e\u81f4\u6c23\u6d41\u963b\u585e\n": "[C]", "109-28.\u95dc\u65bc\u7d50\u6838\u75c5\u85e5\u7269\u526f\u4f5c\u7528\u7684\u8655\u7406\u539f\u5247 \uff0c\u4e0b\u5217\u54ea\u4e9b\u6558\u8ff0\u662f\u6b63\u78ba\u7684 \uff1f\n(1) \u8840\u4e2d\u5c3f\u9178\u589e\u9ad8\u6642 \uff0c\u540c\u6642\u670d\u7528allopurinol \uff0c\u964d\u5c3f\u9178\u6548\u679c\u901a\u5e38\u5f88\u986f\u8457\n(2) \u56e0\u56b4\u91cd\u76ae\u819a\u526f\u4f5c\u7528\u800c\u4e2d\u65b7\u6cbb\u7642\u8005 \uff0c\u5f85\u526f\u4f5c\u7528\u6d88\u5931\u5f8c \uff0c\u61c9\u8003\u616e\u7531\u4f4e\u5291\u91cf\u81f3\u9ad8\u5291\u91cf\u9010\u4e00\u52a0\u5165\u6297\u7d50\u6838\u85e5\u7269\n(3) \u56b4\u91cd\u526f\u4f5c\u7528\u6642 \uff0c\u4f8b\u5982\u809d\u708e \u3001\u56b4\u91cd\u8996\u529b\u6a21\u7cca \u3001\u56b4\u91cd\u8840\u7403\u964d\u4f4e \u3001\u56b4\u91cd\u76ae\u819a\u526f\u4f5c\u7528\u6642 \uff0c\u61c9\u540c\u6642\u505c\u6b62\u6240\u6709\u6297\u7d50\n\u6838\u85e5\u7269\u6cbb\u7642 \n(4) \u8178\u80c3\u4e0d\u9069 \u3001\u76ae\u75b9\u3001\u6414\u7662\u3001\u95dc\u7bc0\u75e0\u75db\u7b49\u526f\u4f5c\u7528 \uff0c\u901a\u5e38\u5728\u670d\u7528\u6297\u7d50\u6838\u85e5\u7269\u5169\u5468\u5f8c\u6703\u81ea\u7136\u6e1b\u8f15 \u3002\u56e0\u6b64\uff0c\u82e5\u75c7\n\u72c0\u4e0d\u56b4\u91cd \uff0c\u61c9\u7d66\u4e88\u75c5\u4eba\u9069\u7576\u885b\u6559 \u3001\u5fc3\u7406\u6cbb\u7642 \uff0c\u5fc5\u8981\u6642\u7d66\u4e88\u85e5\u7269\u75c7\u72c0\u6cbb\u7642\u5373\u53ef   \nA.(1)+(2)+(3)+(4)\nB.(1)+(2)+(3)\nC.(1)+(2)+(4)\nD.(1)+(3)+(4)\nE.(2)+(3)+(4)\n": "[E]", "109-29.54\u6b72\u7537\u6027\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u53f2 \uff0c\u65e5\u524d\u8207\u570b\u5916\u56de\u4f86\u7684\u670b\u53cb\u804a\u5929\u559d\u5496\u5561 \uff0c\u6578\u65e5\u5f8c\u56e0\u70ba\u547c\u5438\u9053\u75c7\u72c0\u5408\u4f75\u767c\u71d2 \uff0c\u4f86\n\u91ab\u9662\u6025\u8a3a \u3002\u80f8\u90e8X -ray \u986f\u793a\u5169\u5074\u80ba\u6d78\u6f64 (\u6bdb\u73bb\u7483\u72c0\u70ba\u4e3b )\uff0c\u8840\u6c27\u98fd\u548c\u5ea6 <90%\uff0c\u7acb\u523b\u88ab\u9001\u9032\u52a0\u8b77\u75c5\u623f\u9694\n\u96e2\u300224\u5c0f\u6642\u5167 \uff0c\u80ba\u6d78\u6f64\u8b8a\u56b4\u91cd \uff0c\u63a5\u53d7\u6c23\u7ba1\u63d2\u7ba1\u53ca\u958b\u59cb\u547c\u5438\u5668\u4f7f\u7528 \u3002\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u5c0d\u65bc\u75c5\u4eba\u6709\u5e6b\u52a9 \uff1f\n(1) \u70ba\u78ba\u4fdd\u8db3\u5920\u8840\u6c27\u6fc3\u5ea6 \uff0c\u547c\u5438\u5668\u6f6e\u6c23\u5bb9\u7a4d\u898110 ml /kg  \u4ee5\u4e0a\n(2) \u547c\u5438\u5668\u5410\u6c23\u672b\u671f\u6b63\u58d3 (PEEP)\u6108\u4f4e\u8d8a\u597d\n(3) \u4fef\u81e5\u901a\u6c23 (Prone Positioning )\u53ef\u4ee5\u964d\u4f4e\u6c27\u6c23\u9700\u6c42\u91cf\n(4) \u7d66\u4e88\u93ae\u975c\u53ca\u795e\u7d93\u808c\u8089\u963b\u65b7\u5291\n(5) \u6c34\u5206\u9650\u5236 (fluid restriction )   \nA.(1)+(2)+(3)+(4)+(5)\nB.(2)+(3)+(4)+(5)\nC.(3)+(4)+(5)\nD.(1)+(3)+(4)+(5)\nE.(1)+(2)+(3)\n": "[C]", "109-30.72\u6b72\u6d77\u8ecd\u9000\u4f11\u8f2a\u6a5f\u58eb\u5b98\u9577 \uff0c\u9577\u5e74\u5728\u8ecd\u8266\u8f2a\u6a5f\u623f\u5de5\u4f5c \u3002\u6700\u8fd1\u56e0\u70ba\u5598 \uff0c\u5728\u9580\u8a3a\u5c31\u8a3a \uff0c\u80f8\u90e8X\u5149\u7570\u5e38\uff0c\u65bc\u662f\u63a5\u53d7\n\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u5982\u9644\u5716 \uff0c\u4e0b\u5217\u4f55\u8005\u6558\u8ff0\u70ba\u662f \uff1f\n(1) \u96fb\u8166\u65b7\u5c64\u986f\u793a\u70ba\u80f8\u819c\u6591 \uff08pleural plaques \uff09\n(2) \u8207\u5de5\u4f5c\u74b0\u5883\u606f\u606f\u76f8\u95dc\n(3) \u4e0d\u6703\u5f15\u8d77\u80ba\u764c\n(4) \u8207\u80f8\u8154\u9593\u76ae\u7624\u9ad8\u5ea6\u76f8\u95dc\n(5) \u62bd\u7159\u5c0d\u65bc\u764c\u75c7\u7684\u767c\u751f\u7387\u4e0d\u6703\u6709\u52a0\u6210\u6548\u679c   \nA.(1)+(2)+(3)\nB.(2)+(3)+(4)\nC.(3)+(4)+(5)\nD.(1)+(2)+(4)\nE.(1)+(2)+(5)   \n": "[D]", "109-31.40\u6b72\u7537\u6027\u56e0\u70ba\u55dc\u7761 \u3001\u6ce8\u610f\u529b\u7121\u6cd5\u96c6\u4e2d \uff0c\u670b\u53cb\u5efa\u8b70\u4ed6\u4f86\u7761\u7720\u547c\u5438\u66ab\u505c \uff08sleep apnea \uff09\u9580\u8a3a\u3002\u8eab\u9ad4\u6aa2\n\u67e5BMI>30\uff0c\u8116\u5b50\u77ed\uff0c\u4e0b\u5df4\u5167\u7e2e \uff0c\u4f3c\u4e4e\u70ba\u5178\u578bobstractive sleep apnea/ Hypopnea \nsyndrome \uff08OSAHS\uff09\u7684\u75c5\u4eba\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u975e \uff1f   \nA.OSAHS\u5e38\u5408\u4f75\u5176\u4ed6\u6162\u6027\u75be\u75c5\uff0c\u4f8b\u5982\uff1a\u5fc3\u8840\u7ba1\u75be\u75c5\u3001\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u7b49\nB.\u53ef\u4ee5\u5f9e\u75c7\u72c0\u53ca\u75c5\u53f2\u4f86\u8a3a\u65b7\nC.\u5f97\u5230OSAHS\u7684\u75c5\u4eba\u5bb9\u6613\u82f1\u5e74\u65e9\u901d\nD.\u75c5\u4eba\u56e0\u7761\u7720\u54c1\u8cea\u4e0d\u4f73\uff0c\u9577\u671f\u7f3a\u6c27\uff0c\u5bb9\u6613\u9020\u6210\u795e\u7d93\u529f\u80fd\u7684\u9000\u5316\nE.\u6301\u7e8c\u6c23\u9053\u6b63\u58d3\u547c\u5438\u5668\u6cbb\u7642\u662f\u76ee\u524d\u7684\u4e3b\u6d41\n": "[B]", "109-32.18\u6b72\u7537\u6027\u7121\u7279\u6b8a\u75be\u75c5\uff0c\u67d0\u5929\u5728\u6253\u7c43\u7403\u6642\u7a81\u7136\u80f8\u75db\u3001\u80f8\u60b6\u4f86\u5230\u6025\u8a3a\u3002\u80f8\u90e8 X\u5149\u5982\u9644\u5716\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u662f\uff1a    \nA.\u597d\u767c\u5e74\u8f15\u7537\u6027\u8eab\u6750\u77ee\u80d6\nB.\u5e38\u662f\u6162\u6027\u80ba\u90e8\u75be\u75c5\u5f15\u8d77\nC.\u6cbb\u7642\u9996\u9078\u662f\u958b\u5200\nD.\u8207\u62bd\u83f8\u95dc\u4fc2\u5bc6\u5207\nE.\u6cbb\u7642\u6210\u529f\u5f8c\u5e7e\u4e4e\u4e0d\u6703\u5fa9\u767c\n": "[D]", "109-33.72\u6b72\u7537\u6027\u8001\u7159\u69cd\u4e00\u5929\u5169\u5305\u83f8\u81f3\u5c1130 \u5e74\uff0c\u6709\u7cd6\u5c3f\u75c5 \u3001\u9ad8\u8840\u58d3\uff0c\u63a5\u53d7\u53e3\u670d\u85e5\u7269\u6cbb\u7642 \uff0c\u4f46\u9806\u5f9e\u6027\u4e0d\u4f73 \u3002\u6162\u6027\u963b\n\u585e\u6027\u80ba\u75c5\u5df2\u670910\u5e74\u6b77\u53f2 \uff0c\u96d6\u7136\u4f7f\u7528\u5438\u5165\u578b\u9577\u6548\u578b\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291 \uff08LABA\uff09\u53ca\u9577\u6548\u578b\u6297\u81bd\u9e7c\n\u5291\uff08LAMA\uff09\uff0c \u4f46\u5e38\u5e38\u56e0\u70ba\u80ba\u708e\u5408\u4f75\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316\u4f4f\u9662 \u3002\u6700\u8fd1\u65b0\u82f1\u683c\u862d\u96dc\u8a8c\u767c\u8868\u4e00\u7bc7\u5927\u578b\u7814\n\u7a76\uff0c\u8a8d\u70ba\u52a0\u4e0a\u5438\u5165\u578b\u985e\u56fa\u9187\u53ef\u4ee5\u6e1b\u5c11\u60e1\u5316\u6b21\u6578 \uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u662f \uff1a   \nA.\u5438\u5165\u578b\u985e\u56fa\u9187\u6703\u589e\u52a0\u80ba\u708e\u6a5f\u6703\uff0c\u4e0d\u9069\u5408\u6b64\u4f4d\u75c5\u4eba\nB.\u4f4e\u5291\u91cf\u985e\u56fa\u9187\u5c0d\u65bc\u964d\u4f4e\u6025\u6027\u767c\u4f5c\u66f4\u6709\u5e6b\u52a9\uff0c\u61c9\u8a72\u4f7f\u7528\u4f4e\u5291\u91cf\u5438\u5165\u578b\u985e\u56fa\u9187\nC.\u56e0\u70ba\u7cd6\u5c3f\u75c5\u63a7\u5236\u4e0d\u4f73\uff0c\u4f7f\u7528\u4f4e\u5291\u91cf\u5438\u5165\u578b\u985e\u56fa\u9187\u5373\u53ef\nD.\u4f7f\u7528\u9ad8\u5291\u91cf\u5438\u5165\u578b\u985e\u56fa\u9187\u53ca\u9577\u6548\u578b\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291\u6548\u679c\u6700\u4f73\nE.\u4f7f\u7528\u9ad8\u5291\u91cf\u5438\u5165\u578b\u985e\u56fa\u9187\u53ca\u9577\u6548\u578b\u6297\u81bd\u9e7c\u5291\u6700\u597d\n": "[A]", "109-34.71\u6b72\u7537\u6027\u6709\u5438\u7159\u53f2 \uff0c\u4e00\u5929\u4e00\u530530 \u5e74\uff0c\u6212\u4e8620\u5e74\u3002\u6700\u8fd1\u56e0\u70ba\u8d70\u8def\u6703\u5598 \u3001\u54b3\u55fd\u52a0\u91cd\u4f86\u5230\u9580\u8a3a \u3002\u80ba\u529f\u80fd\u6aa2\u67e5\u986f\n\u793a\u4fb7\u9650\u6027\u80ba\u529f\u80fd\u7f3a\u640d \uff08restrictive deficit\uff09\uff0c \u80f8\u90e8 X\u5149\u9ad8\u5ea6\u61f7\u7591\u80ba\u7e96\u7dad\u5316 \u3002\u4e0b\u5217\u4f55\u8005\u70ba\u975e \uff1f   \nA.\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u662f\u5fc5\u8981\u7684\u6aa2\u67e5\nB.\u5fc5\u9808\u6392\u9664\u7d50\u7de0\u7d44\u7e54\u75be\u75c5\uff08connective tissue disease\uff09\u9020\u6210\u7684\u80ba\u7e96\u7dad\u5316\nC.\u5207\u7247\u6aa2\u67e5\u662f\u5fc5\u8981\u7684\uff0c\u5373\u4f7f\u662f\u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316\u4e5f\u5fc5\u9808\u5207\u7247\u8b49\u5be6\nD.\u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316\uff0c\u76ee\u524d\u5df2\u6709\u6297\u7e96\u7dad\u5316\u7642\u6cd5\uff08pirfenidone \u53canintedanib\uff09\nE.\u514d\u75ab\u6291\u5236\u53ef\u80fd\u6703\u589e\u52a0\u6b7b\u4ea1\u7387\n": "[C]", "109-35.\u975e\u4fb5\u8972\u6027\u547c\u5438\u5668 \uff08noninvasive ventilator, NIV \uff09\u4e0d\u9069\u5408\u7528\u65bc\u4e0b\u5217\u54ea\u4e9b\u75c5\u4eba \uff1f\n(1) \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u767c\u4f5c\u5408\u4f75\u4e8c\u6c27\u5316\u78b3\u84c4\u7a4d\n(2) \u795e\u7d93\u808c\u8089\u75be\u75c5\u6240\u5c0e\u81f4\u7684\u6162\u6027\u547c\u5438\u8870\u7aed\n(3) \u610f\u8b58\u4e0d\u6e05\u7121\u6cd5\u5408\u4f5c\n(4) \u5fc3\u808c\u6897\u585e\u5408\u4f75\u80ba\u6c34\u816b\n(5) \u4f11\u514b\u7684\u75c5\u4eba   \nA.(1)+(2)+(3)+(4)+(5)\nB.(1)+(3)+(4)+(5)\nC.(2)+(3)+(4)   \nD.(1)+(3)+(4)\nE.(3)+(4)+(5)\n": "[E]", "109-36.\u6162\u6027\u963b\u585e\u6027\u80ba\u75be\u75c5COPD (Chronic Obstructive Pulmonary Disease )\u60a3\u8005\u5728\u4e0b\u5217\u54ea\u4e9b\u60c5\u6cc1\u6703\u53ef\u8003\u616e\u52a0\u4e0a\u5438\n\u5165\u6027\u985e\u56fa\u9187 (inhaled glucocorticoid )\u7684\u6cbb\u7642\uff1f\n(1) \u7576\u60a3\u8005\u540c\u6642\u6709\u6c23\u5598 (asthma)\u4e4b\u75c5\u53f2\n(2) \u7576\u60a3\u8005\u4e00\u5e74\u5167\u6709\u5169\u6b21\u6216\u4ee5\u4e0a\u6162\u6027\u963b\u585e\u6027\u80ba\u75be\u75c5\u6025\u6027\u767c\u4f5c\u4e4b\u75c5\u53f2\n(3) \u7576\u60a3\u8005\u4e00\u5e74\u5167\u6709\u4e00\u6b21\u6216\u4ee5\u4e0a\u6162\u6027\u963b\u585e\u6027\u80ba\u75be\u75c5\u6025\u6027\u767c\u4f5c\u9700\u8981\u4f4f\u9662\u4e4b\u75c5\u53f2\n(4) \u8840\u6db2\u55dc\u9178\u6027\u767d\u8840\u7403\u8a08\u7b97 (eosinophil count )\u5927\u65bc150/mm3\n(5) \u7576\u60a3\u8005\u4e0d\u9069\u5408\u4f7f\u7528\u9577\u6548\u578b\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u6642\u53ef\u55ae\u7368\u4f7f\u7528   \nA.(1)+(2)+(4)\nB.(1)+(3)+(4)\nC.(1)+(2)+(3)+(4)\nD.(1)+(2)+(3)+(5)\nE.(1)+(2)+(3)+(4)+(5)\n": "[C]", "109-37.\u738b\u5148\u751f40\u6b72\u6709\u6c23\u5598 (asthma)\u75c5\u53f2\uff0c\u5e73\u6642\u4e0d\u898f\u5247\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187 (inhaled corticosteroid, ICS )\u3002\u6700\u8fd1\u591c\u54b3\n\u4ee5\u53ca\u591c\u9593\u5598\u9cf4 (wheezes )\u72c0\u6cc1\u52a0\u5287 \uff0c\u65bc\u662f\u4f86\u5230\u6025\u8a3a\u5c31\u91ab \uff0c\u8840\u6c27\u98fd\u548c\u5ea6 (SpO2)96%(\u7121\u4f7f\u7528\u6c27\u6c23 )\uff0c\u8eab\u9ad4\u8a3a\u67e5\n\u767c\u73fe\u80ba\u90e8\u6709\u7030\u6f2b\u6027\u5598\u9cf4\u8072 \uff08diffuse wheezes\uff09\uff0c \u5c16\u7aef\u547c\u6c23\u6d41\u91cf (peak expiratory flow rate, PEFR )\u70ba\u9810\u6e2c\u503c\n\u768450%\uff0c\u53ef\u8003\u616e\u7d66\u4e88\u4e0b\u5217\u54ea\u4e9b\u8655\u7f6e \uff1f\n(1) \u5438\u5165\u578b\u77ed\u6548\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291 (short-acting \u03b22 agonist, SABA )\n(2) \u5438\u5165\u578b\u77ed\u6548\u6297\u81bd\u9e7c\u85e5\u7269 (short-acting muscuarinic antagonist \uff0cSAMA)\n(3) \u5168\u8eab\u6027\u985e\u56fa\u9187 (systemic corticosteroids )\n(4) \u786b\u9178\u9382\u6ce8\u5c04\u6db2 (magnesium sulfate )\n(5) Azithromycin   \nA.(1)+(2)\nB.(1)+(2)+(3)\nC.(1)+(3)+(4)\nD.(1)+(2)+(3)+(4)\nE.(1)+(2)+(3)+(4)+(5)\n": "[D]", "109-38.\u6709\u95dc\u6c23\u5598(asthma)\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u8f15\u5ea6\u6c23\u5598\u7684\u75c5\u60a3The Global initiative against asthma (GINA) 2020 \u4e0d\u518d\u5efa\u8b70\u55ae\u7368\u4f7f\u7528\u5438\u5165\u578b\u77ed\u6548\u4e59\u4e8c\n\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291 (short-acting \u03b22 agonist, SABA )\u4f5c\u70ba\u63a7\u5236\u85e5\u7269 (controller )\uff0c\u9700\u8981\u4f7f\u7528SABA\u6642\u5efa\u8b70\n\u8207\u4f4e\u5291\u91cf\u5438\u5165\u578b\u985e\u56fa\u9187 (inhaled corticosteroid, ICS )\u4e26\u7528\nB.\u9577\u6548\u578b\u6297\u81bd\u9e7c\u5291(long-acting muscarinic antagonists; LAMA)\u65bc\u4e2d\u91cd\u5ea6\u6c23\u5598\u7684\u63a7\u5236\u6c92\u6709\u89d2\u8272\nC.\u767d\u4e09\u70ef\u7d20\u62ee\u6297\u5291 (leukotriene receptor antagonist )\u5728\u63a7\u5236\u6c23\u5598\u6548\u679c\u8207\u9810\u9632\u6025\u6027\u767c\u4f5c\u4e0a\u8f03\u5438\u5165\u578b\u985e\u56fa\n\u9187(inhaled corticosteroid, ICS )\u5dee\nD.\u8f15\u5ea6\u6c23\u5598\u7684\u75c5\u60a3\u53ef\u65bc\u6709\u75c7\u72c0\u6642\u9593\u6b47\u6027\u4f7f\u7528budesonide-formoterol\nE.\u5438\u5165\u578b\u985e\u56fa\u9187 (inhaled corticosteroid, ICS )\u8207\u5438\u5165\u578b\u9577\u6548\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291 (long-acting \u03b22 \nagonist, SABA )\u4f75\u7528\u8f03\u55ae\u7368\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187\u65bc\u4e2d\u5ea6\u6c23\u5598\u60a3\u8005\u53ef\u9054\u5230\u8f03\u5feb\u901f\u7684\u75c7\u72c0\u6539\u5584\n": "[B]", "109-39.\u9ad4\u5916\u751f\u547d\u652f\u6301(Extracorporeal life support, ECLS)\u4f7f\u7528\u5728\u547c\u5438\u8870\u7aed\u75c5\u60a3\u53ef\u4ee5\u9054\u5230\u7684\u6548\u679c\uff0c\u4ee5\u4e0b\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u6539\u5584\u4f4e\u8840\u6c27(hypoxemia)\nB.\u6539\u5584\u9ad8\u78b3\u9178\u8840\u75c7(hypercapnia)   \nC.\u6e1b\u5c11\u547c\u5438\u5668\u5c0e\u81f4\u80ba\u640d\u50b7(ventilator-induced lung injury, VILI)\nD.\u6e1b\u5c11\u6a6b\u8188\u819c\u640d\u50b7(diaphragm myotrauma)\nE.\u6e1b\u5c11\u6cdb\u767c\u6027\u8840\u7ba1\u5167\u8840\u6db2\u51dd\u56fa\u75c7(disseminated intravascular coagulation,DIC)\u7684\u6a5f\u6703\n": "[E]", "109-40.65\u6b72\u7537\u6027\u6709\u9ad8\u8840\u58d3 \u3001\u7cd6\u5c3f\u75c5\u75c5\u53f2 \u3002\u56e0\u70ba\u767c\u71d2 \uff0c\u54b3\u55fd\u6709\u9ec3\u75f0\u4f86\u5230\u6025\u8a3a \u3002\u5728\u6025\u8a3a\u6642\u610f\u8b58\u6e05\u695a \uff0c\u8840\u58d3120/80 \nmmHg\uff0c\u5fc3\u8df3\u901f\u7387100 /min\uff0c\u9ad4\u6eab38.8\u00b0C\uff0c\u547c\u5438\u901f\u738726 /min\uff0c\u8840\u6c27\u98fd\u548c\u5ea6 (SpO2)95%(\u7121\u4f7f\u7528\u6c27\u6c23 )\uff0c\u8eab\u9ad4\n\u8a3a\u67e5\u767c\u73fe\u53f3\u4e0b\u80ba\u91ce\u6709\u7c97\u7206\u88c2\u97f3 (coarse crackles )\u3002\u80f8\u90e8X\u5149\u986f\u793a\u53f3\u4e0b\u80ba\u8449\u6d78\u6f64 \uff0c\u7121\u660e\u986f\u808b\u819c\u7a4d\u6c34 \u3002\u4ee5\u4e0b\u8655\n\u7f6e\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u53ef\u8003\u616e\u7d66\u4e88\u53e3\u670d\u6297\u751f\u7d20\u9580\u8a3a\u6cbb\u7642\nB.\u6d41\u884c\u6027\u611f\u5192\u6d41\u884c\u5b63\u7bc0\u61c9\u9032\u884c\u6d41\u611f\u6aa2\u6e2c\nC.\u53ef\u8003\u616e\u55ae\u7368\u7d66\u4e88azithromycin \u6216clarithromycin\nD.\u53ef\u8003\u616e\u7d66\u4e88Amoxicillin-clavulanate\u52a0\u4e0amacrolide\nE.\u53ef\u8003\u616e\u55ae\u7368\u7d66\u4e88respiratory fluoroquinolone\n": "[C]", "109-41.\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u9032\u5c55\u6210\u70ba\u56b4\u91cd\u65b0\u578b\u51a0\u72c0\u80ba\u708e(severe coronavirus disease 2019,Covid-19)\u7684\u5371\u96aa\u56e0\u5b50\uff1f    \nA.\u5e74\u9f61\u5c0f\u65bc65\u6b72\nB.\u6162\u6027\u80ba\u75be\u75c5\nC.\u7cd6\u5c3f\u75c5\nD.\u80a5\u80d6\nE.\u672b\u671f\u814e\u75c5(End Stage Renal Disease, ESRD)\n": "[A]", "109-42.\u4e0b\u5217\u9020\u6210\u6ffe\u51fa\u6027\u808b\u819c\u7a4d\u6c34 (Transudative pleural effusion) \u4e4b\u75c5\u56e0 \uff0c\u4f55\u8005\u6839\u64daLight 's criteria\u6700\u5e38\u88ab\u8aa4\u5224\u70ba\u6ef2\n\u51fa\u6db2(Exudate)\uff1f   \nA.\u9b31\u8840\u6027\u5fc3\u81df\u8870\u7aed(Congestive heart failure)\u60a3\u8005\u4f7f\u7528\u5229\u5c3f\u5291\u6cbb\u7642\nB.\u809d\u786c\u5316(cirrhosis)\nC.\u814e\u75c5\u75c7\u5019\u7fa4(nephrotic syndrome)\nD.\u4f4e\u767d\u86cb\u767d\u8840\u75c7(hypoalbuminemia)\nE.\u80ba\u584c\u9677(atelectasis)\n": "[A]", "109-43.50\u6b72\u7537\u6027\u56e0\u70ba\u767c\u71d2 \uff0c\u54b3\u55fd\u6709\u9ec3\u75f0\u4f34\u96a8\u5de6\u5074\u80f8\u75db\u4f86\u5230\u6025\u8a3a \u3002\u5728\u6025\u8a3a\u6642\u610f\u8b58\u6e05\u695a \uff0c\u8840\u58d3130/70 mmHg \uff0c\u5fc3\u8df3\n\u901f\u7387110/min\uff0c\u9ad4\u6eab39\u00b0C \uff0c\u547c\u5438\u901f\u738728 /min\uff0c\u8840\u6c27\u98fd\u548c\u5ea6 (SpO2)95%(\u7121\u4f7f\u7528\u6c27\u6c23 )\uff0c\u8eab\u9ad4\u8a3a\u67e5\u767c\u73fe\u5de6\u4e0b\u80ba\n\u91ce\u6709\u7c97\u7206\u88c2\u97f3 (coarse crackles )\u4e14\u547c\u5438\u97f3\u6e1b\u5c11 \u3002\u80f8\u90e8X\u5149\u986f\u793a\u5de6\u4e0b\u80ba\u8449\u6d78\u6f64 \uff0c\u540c\u6642\u6709\u808b\u819c\u7a4d\u6c34 \u3002\u4e0b\u5217\u6558\u8ff0\n\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u62bd\u51fa\u7684\u808b\u819c\u7a4d\u6db2\u5728\u9769\u862d\u6c0f\u67d3\u8272(Gram stain)\u4e0b\u770b\u5230\u7d30\u83cc\u5c31\u53ef\u8a3a\u65b7\u70ba\u81bf\u80f8\nB.\u80f8\u8154\u8d85\u97f3\u6ce2\u662f\u8a55\u4f30\u808b\u819c\u7a4d\u6db2\u662f\u5426\u6709\u9694\u9593(septations)\u6700\u4f73\u7684\u5de5\u5177\nC.\u82e5\u611f\u67d3\u6027\u808b\u819c\u7a4d\u6db2\u6709\u9694\u9593 (septations )\uff0c\u53ca\u65e9\u9032\u884c\u5f71\u50cf\u8f14\u52a9\u80f8\u8154\u93e1\u624b\u8853 (Video-Assisted Thoracoscopic \nSurgery ,VATS)\u53ef\u6e1b\u5c11\u624b\u8853\u4f75\u767c\u75c7\nD.\u82e5\u62bd\u51fa\u7684\u808b\u819c\u7a4d\u6db2\u70ba\u81bf (frank pus )\uff0c\u4f7f\u7528\u80f8\u7ba1\u5f15\u6d41\u52a0\u4e0atissue plasminogen activator (t-PA)\u4ee5\n\u53caDNase\u6bd4\u4e0a\u55ae\u7d14\u80f8\u7ba1\u5f15\u6d41\u53ef\u964d\u4f4e\u6b7b\u4ea1\u7387\nE.\u5982\u679c\u75c5\u60a3\u4e0d\u9069\u5408\u958b\u5200\uff0c\u5f15\u6d41\u81bf\u80f8\u4f7f\u752814-French\u80f8\u7ba1(chest tube)\u6216\u8c6c\u5c3e\u5c0e\u7ba1(pigtail catheter)\u5373\u53ef\n": "[D]", "109-44.\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u65bc\u665a\u671f\u767c\u5c0f\u7d30\u80de\u80ba\u764c\u7b2c\u4e00\u7dda\u6cbb\u7642\u9069\u5408\u55ae\u4e00\u4f7f\u7528pembrolizumab\u6ce8\u5c04\uff1f    \nA.EGFR mutations\nB.ALK gene rearrangements   \nC.\u75c5\u60a3\u6709\u63a7\u5236\u4e0d\u4f73\u7684\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\nD.PD-L1 tumor proportion score less than 1%\nE.PD-L1 tumor proportion score of 50% or greater\n": "[E]", "110-19.35\u6b72\u5973\u6027\u7591\u4f3c\u7e31\u8188\u8154\u816b\u7624 \uff0c\u56e0\u70ba\u5598\u4f86\u5230\u80f8\u8154\u5167\u79d1\u9580\u8a3a \u3002\u80ba\u529f\u80fd\u6aa2\u67e5\u767c\u73fe TLC 75 %, FRC 100 %, RV 120 %, \nFVC 60%, FEV\u2081 60 %, Raw 1.0, DLco80% (TLC total lung capacity; FRC functional residual capacity; RV \nresidual volume; FVC forced vital capacity; FEV1 forced expiratory volume in 1 s; Raw airway \nresistance; DLco diffusion capacity of lung for carbon monoxide )\uff0c\u5982\u4f55\u89e3\u91cb\u5979\u7684\u80ba\u529f\u80fd ?   \nA.\u56e0\u70ba\u80a5\u80d6\u9020\u6210\u7684\u4fb7\u9650\u6027\u80ba\u529f\u80fd\u969c\u7919\u3002\nB.\u56e0\u70ba\u6c23\u5598\u9020\u6210\u7684\u963b\u585e\u6027\u80ba\u529f\u80fd\u969c\u7919\u3002\nC.\u56e0\u70ba\u80ba\u6c23\u816b\u9020\u6210\u7684\u963b\u585e\u6027\u80ba\u529f\u80fd\u969c\u7919\u3002\nD.\u56e0\u70ba\u547c\u5438\u808c\u8089\u7121\u529b\u9020\u6210\u7684\u4fb7\u9650\u6027\u80ba\u529f\u80fd\u969c\u7919\u3002\nE.\u56e0\u70ba\u80ba\u7e96\u7dad\u5316\u9020\u6210\u7684\u4fb7\u9650\u6027\u80ba\u529f\u80fd\u969c\u7919\u3002\n": "[D]", "110-20.\u5982\u679c\u628a\u80ba\u90e8\u554f\u984c\u5206\u6210\u4e09\u90e8\u5206 \uff0c\u963b\u585e\u6027\u554f\u984c \uff0c\u9650\u5236\u6027\u554f\u984c \uff0c\u53ca\u80ba\u8840\u7ba1\u554f\u984c \u3002\u4e0b\u5217\u4f55\u8005\u4e0d\u5c6c\u65bc\u9650\u5236\u6027\u554f\u984c\n(1)\u985e\u8089\u7624(Sarcoidosis) ( 2)\u652f\u6c23\u7ba1\u64f4\u5f35 (3)\u91cd\u75c7\u808c\u7121\u529b (Myasthenia Gravis) ( 4)\u6162\u6027\u808b\u819c\u7a4d\u6c34 (5)\u5c0f\u652f\u6c23\u7ba1\u708e   \nA.(1)+(3)\u3002\nB.(2)+(5)\u3002\nC.(1)+(2)\u3002\nD.(2)+(4)\u3002\nE.(3)+(5)\u3002\n": "[B]", "110-21.\u80ba\u90e8\u60e1\u6027\u816b\u7624\u7684\u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u5206\u671f\uff0c\u5c0d\u65bc\u6cbb\u7642\u5f71\u97ff\u5f88\u5927\u3002\u4e0b\u5217\u6558\u8ff0\u5c0d\u65bc\u5224\u65b7\u6dcb\u5df4\u7d50\u5206\u671f\u4f55\u8005\u70ba\u975e?    \nA.\u6b63\u5b50\u6383\u63cf\u5c0d\u65bc\u6dcb\u5df4\u7d50\u5206\u671f(\u5206\u8fa8\u826f\u6027\u6216\u60e1\u6027\u6dcb\u5df4\u7d50)\u7684\u654f\u611f\u5ea6(sensitivity)\u8d85\u904e95%\u3002\nB.\u7e31\u8188\u8154\u93e1\u662f\u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u5206\u671f\u7684\u6a19\u6e96\u505a\u6cd5 \uff0c\u76ee\u524d\u5df2\u88ab\u652f\u6c23\u7ba1\u5167\u8d85\u97f3\u6ce2\u5c0e\u5f15\u7d93\u6c23\u7ba1\u7d30\u91dd\u7a7f\u523a\u8853 (EBUS \nTBNA)\u53d6\u4ee3\u3002\nC.\u6b63\u5b50\u6383\u63cf\u5c0d\u65bc\u826f\u6027\u6216\u60e1\u6027\u6dcb\u5df4\u7d50\u5224\u5225\u7684\u6e96\u78ba\u6027\u6bd4\u4e0d\u4e0a\u7e31\u8188\u8154\u93e1\u3002\nD.\u7e31\u8188\u8154\u93e1\u7121\u6cd5\u53d6\u6a23\u80ba\u9580\u6dcb\u5df4\u7d50\u3002\nE.\u7e31\u8188\u8154\u93e1\u53ca\u652f\u6c23\u7ba1\u5167\u8d85\u97f3\u6ce2\u5c0e\u5f15\u7d93\u6c23\u7ba1\u7d30\u91dd\u7a7f\u523a\u8853 (EBUS TBNA )\u7686\u7121\u6cd5\u53d6\u6a23\u4e3b\u52d5\u8108\u65c1\u6dcb\u5df4\u7d50 (Level \n5,6)\u3002\n": "[A]", "110-22.35\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u5c0f\u6642\u5019\u88ab\u8a3a\u65b7\u70ba\u6c23\u5598 \u3002\u6700\u8fd1\u5e7e\u5e74\u5e38\u5e38\u767c\u4f5c \uff0c\u5373\u4f7f\u7528\u4e86\u9ad8\u5291\u91cf\u5438\u5165\u6027\u985e\u56fa\u9187 \uff0c\u9577\u6548\u652f\u6c23\u7ba1\u64f4\n\u5f35\u5291\uff0c\u53e3\u670d\u985e\u56fa\u9187 \uff0c\u53e3\u670d\u6297\u767d\u4e09\u70ef (leukotriene )\uff0c\u4ecd\u4e0d\u6642\u767c\u4f5c \u3002\u4e0b\u5217\u54ea\u4e00\u7a2e\u6cbb\u7642\u65b9\u5f0f\u4e0d\u9069\u7576 ?   \nA.\u5982\u679c\u75c5\u4eba\u8840\u6db2Ig E\u589e\u52a0\uff0c\u53ef\u4ee5\u8003\u616eanti-IgE omalizumab\u3002\nB.\u55dc\u4f0a\u7d05\u6027\u767d\u8840\u7403\u589e\u52a0\uff0c\u53ef\u4ee5\u8003\u616ecyclosporin A\uff0c\u6291\u5236\u767c\u708e\u53cd\u61c9\u3002\nC.\u91cd\u65b0\u6aa2\u8996\u75c5\u4eba\u4f7f\u7528\u85e5\u7269\u7684\u9806\u5f9e\u6027\uff0c\u53ca\u5438\u5165\u578b\u85e5\u7269\u7684\u4f7f\u7528\u65b9\u5f0f\u3002\nD.\u5728\u6c92\u6709\u56b4\u91cd\u767c\u708e\u7684\u75c5\u4eba\uff0c\u8003\u616e\u7528\u652f\u6c23\u7ba1\u71b1\u6210\u5f62\u8853\u4f86\u71d2\u707c\u6c23\u9053\u4e0a\u7684\u5e73\u6ed1\u808c\u3002\nE.\u53ef\u4ee5\u8003\u616e\u4f7f\u7528theophylline\uff0c\u96d6\u7136\u6548\u679c\u6709\u9650\u3002\n": "[B]", "110-23.\u4e0b\u5217\u5c0d\u80ba\u764c\u7684\u63cf\u8ff0\u4f55\u8005\u70ba\u662f?    \nA.\u80ba\u764c\u7684\u9a45\u52d5\u7a81\u8b8a(driver mutation)\u4e0d\u5305\u62ecNTRK \u57fa\u56e0\u3002\nB.\u5c0f\u7d30\u80de\u80ba\u764c\u90fd\u5177\u6709P53, RB1\u7684\u7a81\u8b8a\u3002\nC.\u5229\u7528Chest X-ray\u7be9\u6aa2\u80ba\u764c\uff0c\u53ef\u4ee5\u6709\u6548\u964d\u4f4e20%\u80ba\u764c\u6b7b\u4ea1\u7387\u3002\nD.\u65e9\u671f\u80ba\u764c\u5efa\u8b70\u624b\u8853\u6cbb\u7642\uff0c\u5982\u7121\u6cd5\u624b\u8853\uff0c\u53ef\u4ee5\u8003\u616e\u6a19\u9776\u85e5\u7269\u6cbb\u7642\u3002\nE.\u5c0d\u65bc\u7b2c\u4e09\u671f\u7684\u75c5\u4eba\u5982\u679c\u7121\u6cd5\u958b\u5200 \uff0c\u5efa\u8b70\u540c\u6642\u5316\u5b78\u6cbb\u7642\u53ca\u653e\u5c04\u6cbb\u7642 \uff0c\u4e26\u65bc\u7642\u7a0b\u7d50\u675f\u5f8c\u4f7f\u7528\u514d\u75ab\u6cbb\u7642\u4e00\n\u5e74\u3002   \n": "[E]", "110-24.72\u6b72\u7537\u6027 \uff0c\u80ba\u764c\u7b2c\u56db\u671f\u63a5\u53d7\u514d\u75ab\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642 \u3002\u56e0\u70ba\u514d\u75ab\u6cbb\u7642 \uff0c\u9020\u6210\u9593\u8cea\u6027\u80ba\u75c5 \uff0c\u4f4f\u9662\u4f7f\u7528\u9ad8\u5291\u91cf\u7684\n\u985e\u56fa\u9187\u3002\u56e0\u70ba\u56b4\u91cd\u7684\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \uff0c\u5e7e\u4e4e\u6574\u5929\u81e5\u5e8a \u3002\u6709\u4e00\u5929\u4ed6\u7684\u5973\u5152\u5728\u5e6b\u4ed6\u6309\u6469\u817f\u90e8\u6642 \uff0c\u7a81\u7136\u8840\u58d3\u98fd\u548c\n\u5ea6\u4e0b\u964d\u523050 %\uff0c\u8840\u58d3\u4e0b\u964d40mmHg \uff0c\u4e0b\u5217\u4f55\u8005\u662f\u9020\u6210\u4f11\u514b\u6700\u6709\u53ef\u80fd\u7684\u539f\u56e0 \uff1f   \nA.\u80ba\u52d5\u8108\u6813\u585e\u3002\nB.\u5fc3\u5f8b\u4e0d\u6574\u3002\nC.\u904e\u654f\u6027\u4f11\u514b\u3002\nD.\u5927\u91cf\u5167\u51fa\u8840\u3002\nE.\u6557\u8840\u75c7\u4f11\u514b\u3002\n": "[A]", "110-25.\u611f\u67d3SARS -CoV-2\u7684\u75c5\u4eba\u6b7b\u4ea1\u7387\u504f\u9ad8 \uff0c\u5c0d\u65bcCOVID -19\u91cd\u75c7\u7684\u75c5\u4eba\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u662f ?\n(1)\u6c89\u9ed8\u7f3a\u6c27 (silent hypoxia )\u4e3b\u8981\u662f\u80ba\u6813\u585e\u9020\u6210 \uff0c\u5efa\u8b70\u5e38\u898f\u7528\u6297\u51dd\u8840\u5291\u6cbb\u7642\n(2)HFNC (high flow nasal cannula )\uff0c\u88ab\u7a31\u70ba\u6551\u547d\u795e\u5668 \uff0c\u4e3b\u8981\u7528\u4f86\u964d\u4f4e\u547c\u5438\u808c\u505a\u5de5\n(3)\u4f7f\u7528\u985e\u56fa\u9187\u53ef\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\n(4)\u975e\u4fb5\u8972\u6027\u6b63\u58d3\u547c\u5438\u5668\u53ef\u4ee5\u5e38\u898f\u7528\u4f86\u6cbb\u7642COVID -19\u9020\u6210\u7684\u547c\u5438\u8870\u7aed\n(5)\u4fef\u81e5\u901a\u6c23 (Prone Positioning )\u53ef\u4ee5\u964d\u4f4e\u6c27\u6c23\u9700\u6c42\u91cf   \nA.(1)+(2)+(3)+(5)\u3002\nB.(3)+(4)+(5)\u3002\nC.(3)+(5)\u3002\nD.(1)+(3)+(5)\u3002\nE.(2)+(3)+(5)\u3002\n": "[C]", "110-26.63\u6b72\u5973\u6027\u75c5\u4eba\u80ba\u764c\u7b2c\u56db\u671f\u6b63\u5728\u63a5\u53d7\u5316\u5b78\u6cbb\u7642 \uff0c\u6700\u8fd1\u56e0\u5598 \u3001\u808b\u819c\u7a4d\u6c34\u589e\u52a0 \uff0c\u4f4f\u9662\u63a5\u53d7\u6cbb\u7642 \u3002\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u9664\n\u4e86\u808b\u819c\u7a4d\u6c34\u5916 \uff0c\u4e5f\u6709\u5c11\u91cf\u5230\u4e2d\u91cf\u5fc3\u5305\u819c\u7a4d\u6c34 \uff0c\u53ca\u5fc3\u5305\u819c\u589e\u539a \u3002\u808b\u819c\u7a4d\u6c34\u6aa2\u67e5 \uff0c\u6de1\u9ec3\u8272\uff0c\u6ef2\u51fa\n\u6db2(exudate)\uff0c\u7d30\u80de\u5b78\u6aa2\u67e5\u7121\u764c\u7d30\u80de \uff0c\u4ee5\u6dcb\u5df4\u7403\u70ba\u4e3b \u3002\u7a4d\u6c34\u57f9\u990a\u70ba\u7d50\u6838\u83cc \u3002\u4ee5\u4e0b\u8655\u7f6e\u4f55\u8005\u4e0d\u9069\u7576 ?   \nA.\u61c9\u7acb\u5373\u7d66\u4e88\u6297\u7d50\u6838\u6cbb\u7642\u3002\nB.\u5982\u679c\u75f0\u6db2\u62b9\u7247\u70ba\u9670\u6027\uff0c\u4e0d\u9808\u9694\u96e2\u3002\nC.\u56e0\u70ba\u591a\u91cd\u75be\u75c5\u5efa\u8b70\u52a0\u4e0avit B6\u3002\nD.\u5fc3\u5305\u819c\u589e\u539a\u4e0d\u662f\u7d50\u6838\u611f\u67d3\u9020\u6210\uff0c\u61c9\u8a72\u63a5\u53d7\u5fc3\u5305\u819c\u5207\u9664\u8853\uff0c\u7e7c\u7e8c\u80ba\u764c\u6cbb\u7642\u3002\nE.\u56e0\u70ba\u5598\u3001\u808b\u819c\u7a4d\u6c34 \uff0c\u53ca\u5fc3\u5305\u819c\u7a4d\u6c34\u589e\u52a0 \uff0c\u53ef\u4ee5\u662f\u7d50\u6838\u611f\u67d3\u5f15\u8d77 \uff0c\u53ef\u4ee5\u66ab\u505c\u5316\u7642 \uff0c\u89c0\u5bdf\u6297\u7d50\u6838\u6cbb\u7642\u6548\n\u679c\u3002\n": "[D]", "110-27.70\u6b72\u7537\u6027 COPD\u5728\u9580\u8a3a\u8ffd\u8e64\u6cbb\u7642 \u3002\u5728\u4e00\u6b21\u91cd\u611f\u5192\u5f8c \uff0c\u75c5\u4eba\u89ba\u5f97\u8d8a\u4f86\u8d8a\u5598 \uff0c\u54b3\u55fd\u52a0\u5287 \uff0c\u5408\u4f75\u5c11\u8a31\u9ec3\u75f0 \uff0c\u56e0\n\u6b64\u4f86\u5230\u6025\u8a3a \u3002\u672a\u767c\u4f5c\u6642 \uff0c\u6700\u5f8c\u4e00\u6b21\u7684\u80ba\u529f\u80fdFEV\u2081 42 %\u3002\u5728\u6025\u8a3a\uff0c\u4e8c\u6c27\u5316\u78b3\u5206\u58d3 (PaCO\u2082)55mmHg \uff0c\u5169\u5074\n\u7030\u6f2b\u6027\u5598\u9cf4\u97f3 \uff0c\u80f8\u90e8X\u5149\u7121\u80ba\u708e\u8de1\u8c61 \u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u4f55\u8005\u8f03\u4e0d\u9069\u7576 \uff1f   \nA.\u7d66\u4e88\u5ee3\u6548\u6027\u6297\u751f\u7d20\u3002\nB.\u8d95\u5feb\u63d2\u7ba1\u4f7f\u7528\u547c\u5438\u5668\uff0c\u6cbb\u7642\u7b2c\u4e8c\u578b\u547c\u5438\u8870\u7aed\u3002\nC.\u4f7f\u7528\u975e\u4fb5\u8972\u6027\u6b63\u58d3\u547c\u5438\u5668\u3002\nD.\u975c\u8108\u6ce8\u5c04\u985e\u56fa\u9187\u3002\nE.\u589e\u52a0\u6c23\u7ba1\u64f4\u5f35\u5291\u7684\u4f7f\u7528\u3002   \n": "[B]", "110-28.\u6797\u5148\u751f60 \u6b72\uff0c\u6bcf\u5929\u62bd\u4e00\u5305\u83f8\u5230\u76ee\u524d\u5171\u62bd30 \u5e74\u3002\u5927\u7d04\u534a\u5e74\u524d\u958b\u59cb\u51fa\u73fe\u722c\u6a13\u68af\u547c\u5438\u6025\u4fc3 \uff0c\u5927\u7d04\u722c\u5230\u4e8c\u6a13\u5c31\u8981\n\u4f11\u606f\u3002\u6162\u6162\u7684\u9023\u7a0d\u5fae\u8d70\u4e00\u9ede\u5e73\u8def\u90fd\u6703\u89ba\u5f97\u5598 \uff0c\u540c\u6642\u4f34\u96a8\u54b3\u55fd\u8207\u767d\u75f0 \u3002\u4ed6\u5230\u9644\u8fd1\u91ab\u9662\u5c31\u91ab \uff0c\u80f8\u90e8X\u5149\u5448\u73fe\u5169\n\u5074\u80ba\u5bb9\u7a4d\u8207\u900f\u5149\u5ea6\u589e\u52a0 \u3002\u80ba\u529f\u80fd\u6aa2\u67e5\u7d50\u679c\u70ba \uff1aFEV\u2081/FVC=50%\uff0cFEV\u2081\u70ba\u9810\u6e2c\u503c\u768435 %\uff0c\u7d66\u4e88\u77ed\n\u6548\u03b2\u2082-agonist 15\u5206\u9418\u5f8cFEV \u2081\u6539\u55845%\u3002\u5169\u500b\u6708\u524d\u9084\u56e0\u70ba\u5598\u7684\u75c7\u72c0\u6025\u901f\u60e1\u5316\u4f4f\u9662\u6cbb\u7642\u4e00\u661f\u671f \uff0c\u5f8c\u7e8c\u53ef\u8003\u616e\u4e0b\n\u5217\u54ea\u4e9b\u6cbb\u7642\u65b9\u5f0f \uff1f(1) \u5efa\u8b70\u6212\u83f8 \uff0c(2) \u7d66\u4e88\u5438\u5165\u578bLong -acting Muscarinic Antagonists (LAMA)\uff0c(3) \u5408\u4f75\u5438\n\u5165\u578bLAMA \u8207Long-acting \u03b2\u2082-agonist(LABA)\uff0c(4) \u55ae\u7368\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187 \uff0c(5) \u5408\u4f75\u5438\u5165\n\u578bLAMA\uff0cLABA\u4ee5\u53ca\u5438\u5165\u578b\u985e\u56fa\u9187 \u3002   \nA.(1)+(2)+(3)\u3002\nB.(1)+(2)+(3)+(4)\u3002\nC.(1)+(2)+(3)+(4)+(5)\u3002\nD.(1)+(2)+(3)+(5)\u3002\nE.(1)+(3)+(4)+(5)\u3002\n": "[D]", "110-29.\u63a5\u7e8c\u4e0a\u984c \uff0c\u6797\u5148\u751f\u5728\u63a5\u53d7\u85e5\u7269\u6cbb\u7642\u5f8c \uff0c\u75c7\u72c0\u7a0d\u6709\u6539\u5584 \u3002\u4f46\u5169\u500b\u6708\u5f8c \uff0c\u6797\u5148\u751f\u547c\u5438\u6025\u4fc3\u7684\u75c7\u72c0\u52a0\u5287 \uff0c\u4e14\u54b3\u51fa\n\u7684\u75f0\u8b8a\u6210\u9ec3\u8272 \u3002\u7531\u65bc\u4f11\u606f\u6642\u4ecd\u7136\u6709\u547c\u5438\u6025\u4fc3\u7684\u73fe\u8c61 \uff0c\u56e0\u6b64\u738b\u5148\u751f\u4f86\u5230\u6025\u8a3a\u5c31\u91ab \u3002\u5728\u6025\u8a3a\u6642\u547c\u5438\u901f\u7387\u6bcf\u5206\n\u941828\u6b21\uff0c\u8840\u6c27\u98fd\u548c\u5ea6\u70ba89 %\u7121\u4f7f\u7528\u6c27\u6c23 \uff0c\u80f8\u90e8X\u5149\u8207\u5148\u524d\u7121\u660e\u986f\u5dee\u7570 \u3002\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u4e0d\u6070\u7576 \uff1f   \nA.\u7d66\u4e88\u5438\u5165\u578b\u77ed\u6548 \u03b2\u2082-agonist\u3002\nB.\u7d66\u4e88\u5438\u5165\u578b\u77ed\u6548Anticholinergic agent\u3002\nC.\u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u3002\nD.\u61c9\u907f\u514d\u7d66\u4e88\u6c27\u6c23\u4ee5\u9810\u9632\u8840\u4e2d\u4e8c\u6c27\u5316\u78b3\u4e0a\u5347\u3002\nE.\u7d66\u4e88\u53e3\u670d\u985e\u56fa\u9187\uff0c\u4f7f\u75285-10\u5929\u3002\n": "[D]", "110-30.\u95dc\u65bc\u6c23\u5598\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u5167\u6e90\u6027\u6c23\u5598(intrinsic asthma)\u8840\u6e05\u4e2dIgE\u7684\u6fc3\u5ea6\u901a\u5e38\u8f03\u9ad8\u3002\nB.\u898f\u5247\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187\u53ef\u9810\u9632\u904b\u52d5\u8a98\u767c\u6c23\u5598 (exercise-induced asthma, EIA)\u3002\nC.Long-acting \u03b2\u2082-agonist\uff08LABA\uff09\u61c9\u8207\u5438\u5165\u578b\u985e\u56fa\u9187\u5408\u4f75\u4f7f\u7528 \uff0c\u4e0d\u5b9c\u55ae\u7368\u4f7f\u7528 \u3002\nD.Long-acting Muscarinic Antagonists (LAMA)\uff0c\u65bc\u4f7f\u7528LABA\u5408\u4f75\u5438\u5165\u578b\u985e\u56fa\u9187\u6cbb\u7642\u4e0d\u4f73\u4e4b\u60a3\u8005 \uff0c\u53ef\u6539\n\u5584\u60a3\u8005\u80ba\u529f\u80fd \u3002\nE.\u60a3\u6709\u963f\u65af\u5339\u9748\u654f\u611f\u578b\u6c23\u5598 (aspirin sensitive asthma )\u4e4b\u75c5\u60a3\uff0c\u61c9\u907f\u514d\u670d\u7528 nonselective COX \ninhibitors \u3002\n": "[A]", "110-31.\u7576\u6c23\u5598\u63a7\u5236\u4e0d\u7406\u60f3\u6642 \uff0c\u9808\u8003\u91cf\u4ee5\u4e0b\u54ea\u4e9b\u56e0\u7d20\u4e4b\u5f71\u97ff \uff1f(1) \u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187\u9806\u5f9e\u6027\u4e0d\u4f73 \uff0c(2) \u662f\u5426\u6709\u8077\u696d\u5834\n\u6240\u904e\u654f\u539f\u4e4b\u66b4\u9732 \uff0c(3) \u662f\u5426\u540c\u6642\u60a3\u6709\u6162\u6027\u9f3b\u7ac7\u708e (chronic rhinosinusitis )\uff0c(4) \u662f\u5426\u6709\u8072\u5e36\u529f\u80fd\u7570\n\u5e38(Vocal-cord dysfunction )\uff0c(5) \u662f\u5426\u540c\u6642\u4f7f\u7528beta -adrenergic blockers, aspirin\u7b49\u85e5\u7269 \u3002   \nA.(1)+(2)\u3002\nB.(1)+(2)+(3)\u3002\nC.(1)+(2)+(5)\u3002\nD.(1)+(2)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[E]", "110-32.\u95dc\u65bc\u80ba\u6813\u585e (pulmonary embolism) \u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f    \nA.\u5fc3\u96fb\u5716\u6700\u5e38\u898b\u7684\u7570\u5e38\u662fS1Q3T3 sign\u3002\nB.\u75c5\u60a3\u8840\u6f3f\u4e2dD-dimer\u82e5\u4e0a\u5347\uff0c\u53ef\u7528\u4f86\u78ba\u8a3a\u80ba\u6813\u585e\u3002\nC.\u80ba\u704c\u6ce8-\u901a\u6c23\u6383\u63cf (ventilation-perfusion lung scanning)\u662f\u8a3a\u65b7\u80ba\u6813\u585e\u9996\u9078\u7684\u5f71\u50cf\u6aa2\u67e5\u3002   \nD.Rivaroxaban \u4ee5\u53ca apixaban\u53ef\u4ee5\u55ae\u7368\u4f7f\u7528\u65bc\u6cbb\u7642\u80ba\u6813\u585e\uff0c\u4e0d\u9808\u5148\u6ce8\u5c04\u6297\u51dd\u8840\u5291\u3002\nE.\u82e5\u75c5\u60a3\u767c\u751fSubmassive pulmonary embolism, \u4f46\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5448\u73fe\u53f3\u5fc3\u5ba4\u529f\u80fd\u4e0d\u5168 \uff0c\u61c9\u8003\u616e\u6ce8\n\u5c04recombinant tissue plasminogen activator (tPA)\u3002\n": "[D]", "110-33.\u95dc\u65bc\u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316(idiopathic pulmonary fibrosis, IPF) \u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u597d\u767c\u65bc\u7537\u6027\u3002\nB.\u8207\u62bd\u83f8\u4ee5\u53ca\u74b0\u5883\u7684\u66b4\u9732\u6709\u95dc\u3002\nC.Usual interstitial pneumonia (UIP) \u70ba\u4e3b\u8981\u7684\u75c5\u7406\u8b8a\u5316\u3002\nD.\u9700\u6392\u9664connective tissue diseases (CTDs) associated interstitial lung diseases (ILDs)\u3002\nE.\u6cbb\u7642\u4ee5\u514d\u75ab\u6291\u5236\u5291\u70ba\u4e3b\u3002\n": "[E]", "110-34.\u4e0b\u5217\u4f55\u7a2e\u6cbb\u7642\u53ef\u964d\u4f4e\u9700ICU\u7167\u8b77\u4e4bCOVID-19\u75c5\u60a3\u6b7b\u4ea1\u7387\uff1f    \nA.Remdesivir\u3002\nB.Baricitinib plus Remdesivir\u3002\nC.Interleukin-6 Receptor Antagonists (tocilizumab or sarilumab)\nD.Covid-19 convalescent plasma\u3002\nE.SARS-CoV-2 Neutralizing Antibody\u3002\n": "[C]", "110-35.\u4e0b\u5217\u4f55\u7a2e\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u9a45\u52d5\u7a81\u8b8a \uff08driver mutations\uff09\uff0c \u76ee\u524d\u4ecd\u672a\u6709\u6709\u6548\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5291\u53ef\u7528\u65bc\u665a\u671f\u975e\u5c0f\n\u7d30\u80de\u80ba\u764c\u60a3\u8005\u4e4b\u6cbb\u7642 \uff1f   \nA.EGFR mutations\u3002\nB.ALK rearrangements\u3002\nC.KRAS G12A mutation\u3002\nD.KRAS G12C mutation\u3002\nE.BRAF V600E mutation\u3002\n": "[C]", "110-36.\u6709\u95dcEGFR exon 19 deletion\u4ee5\u53caL858R\u967d\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u75c5\u60a3\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?    \nA.\u7b2c\u4e8c\u3001\u4e09\u671f\u7684\u75c5\u60a3\u8853\u5f8c\u670d\u7528Osimertinib\u4e09\u5e74\u8f14\u52a9\u6027\u6cbb\u7642\u76f8\u8f03\u65bc\u5b89\u6170\u5291 \uff0c\u53ef\u5ef6\u9577\u75c5\u60a3\u7121\u75be\u75c5\u5b58\u6d3b\n\u7387(disease-free survival )\u3002\nB.Afatinib\u65bc\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4e00\u7dda\u6cbb\u7642\u76f8\u8f03\u65bcGefitinib \uff0c\u53ef\u5ef6\u9577\u75be\u75c5\u7121\u60e1\u5316\u5b58\u6d3b\u671f \uff08progression -free \nsurvival\uff09\u3002\nC.Osimertinib\u65bc\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4e00\u7dda\u6cbb\u7642\u76f8\u8f03\u65bcGefitinib or Erlotinib \uff0c\u53ef\u5ef6\u9577\u6574\u9ad4\u5b58\u6d3b (Overall \nsurvival)\u3002\nD.\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4e00\u7dda\u6cbb\u7642\u4f7f\u7528Gefitinib or Erlotinib\u6cbb\u7642\u5f8c \uff0c\u6700\u5e38\u898b\u4e4b\u6297\u85e5\u6a5f\u8f49\u70ba\u7522\u751fsecondary \nT790M mutation \u3002\nE.\u7576\u7522\u751fsecondary T790M mutation \u5f8c\uff0c\u6700\u4f73\u7684\u6cbb\u7642\u65b9\u5f0f\u662f\u7d66\u4e88\u7b2c\u4e8c\u4ee3EGFR\u5c0f\u5206\u5b50\u6291\u5236\u5291Afatinib \u6cbb\n\u7642\u3002   \n": "[E]", "111-19.\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(Chronic obstructive pulmonary disease, COPD)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.COPD\u60a3\u8005\u82e5\u4f11\u606f\u6642\u8840\u6c27\u98fd\u548c\u5ea6 \u226488%\uff0c\u63a5\u53d7\u9577\u671f\u6c27\u7642 (long-term oxygen therapy, LTOT )\u53ef\u6539\u5584\u5b58\n\u6d3b\u3002\nB.\u4e0d\u5efa\u8b70\u9577\u671f\u4f7f\u7528\u53e3\u670d\u985e\u56fa\u9187\u3002\nC.\u6025\u6027\u767c\u4f5c(COPD exacerbation) \u5927\u7d04\u67091/3\u662f\u547c\u5438\u9053\u75c5\u6bd2\u611f\u67d3\u5f15\u8d77\u7684\u3002\nD.\u6025\u6027\u767c\u4f5c\u6642\uff0c\u8840\u6c27\u4e0d\u8db3\u6642\u61c9\u7d66\u4e88\u6c27\u6c23\u4ee5\u7dad\u6301\u8840\u6c27\u98fd\u548c\u5ea6\u226590%\u3002\nE.\u6025\u6027\u767c\u4f5c\u6642\uff0c\u7d66\u4e88\u5168\u8eab\u6027\u985e\u56fa\u9187(systemic corticosteroid)\u6cbb\u7642\u53ef\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\u3002\n": "[E]", "111-20.\u5468\u5148\u751f65 \u6b72\uff0c\u6bcf\u5929\u62bd\u5169\u5305\u83f8\u5171\u62bd30 \u5e74\uff0c\u4e94\u5e74\u524d\u7531\u65bc\u8f03\u5287\u70c8\u904b\u52d5\u5f8c\u6703\u547c\u5438\u6025\u4fc3 \uff0c\u56e0\u6b64\u6212\u83f8 \u3002\u6700\u8fd1\u4e00\u5e74\u5927\u7d04\n\u722c\u5230\u4e8c\u6a13\u5c31\u8981\u4f11\u606f \uff0c\u6162\u6162\u7684\u9023\u7a0d\u5fae\u8d70\u4e00\u9ede\u5e73\u8def\u90fd\u6703\u89ba\u5f97\u5598 \uff0c\u5e38\u5e38\u9700\u8981\u505c\u4e0b\u4f86\u4f11\u606f \u3002\u4ed6\u5230\u9644\u8fd1\u91ab\u9662\u5c31\u91ab \uff0c\u80f8\n\u90e8X\u5149\u5448\u73fe\u5169\u5074\u80ba\u4e0a\u8449\u5927\u80ba\u6ce1 (bullae)\u3002\u80ba\u529f\u80fd\u6aa2\u67e5\u7d50\u679c\u70ba \uff1aFEV1/FVC=50%\uff0cFEV1\u70ba\u9810\u6e2c\u503c\u768435 %\uff0c\u7d66\n\u4e88\u77ed\u6548\u03b22-agonist 15\u5206\u9418\u5f8cFEV 1\u6539\u55843%\u3002\u6700\u8fd1\u534a\u5e74\u56e0\u70ba\u5598\u7684\u75c7\u72c0\u52a0\u91cd\u5230\u91ab\u9662\u6025\u8a3a\u5c31\u91ab\u4e09\u6b21 \uff0c\u9580\u8a3a\u85e5\u7269\u6cbb\n\u7642\u4e0b\u5217\u4f55\u8005\u8f03\u4e0d\u6070\u7576 \uff1f   \nA.\u55ae\u7368\u7d66\u4e88\u5438\u5165\u578bLong-acting \u03b22-agonist (LABA)\u3002\nB.\u55ae\u7368\u7d66\u4e88\u5438\u5165\u578bLong-acting Muscarinic Antagonists (LAMA)\u3002\nC.\u5408\u4f75\u5438\u5165\u578bLAMA \u8207LABA\u3002\nD.\u5408\u4f75LABA\u8207\u5438\u5165\u578b\u985e\u56fa\u9187\u3002\nE.\u5408\u4f75\u5438\u5165\u578bLAMA\uff0cLABA\u4ee5\u53ca\u5438\u5165\u578b\u985e\u56fa\u9187\u3002\n": "[A]", "111-21.\u4e0b\u5217\u54ea\u4e00\u9805\u4e0d\u5c6c\u65bc\u7b2c\u4e8c\u578b\u6c23\u5598(Type 2 high-inflammation asthma)\u76f8\u95dc\u4e4b\u751f\u7269\u6a19\u8a18\uff1f    \nA.\u55dc\u9178\u6027\u767d\u8840\u7403 (eosinophils)\u3002\nB.\u55dc\u4e2d\u6027\u767d\u8840\u7403 (neutrophils)\u3002\nC.\u767d\u8840\u7403\u4ecb\u7d20-4 (Interleukin-4)\u3002\nD.\u767d\u8840\u7403\u4ecb\u7d20-5 (Interleukin-5)\u3002\nE.\u767d\u8840\u7403\u4ecb\u7d20-13 (Interleukin-13)\u3002   \n": "[B]", "111-22.\u4ee5\u4e0b\u54ea\u4e9b\u56e0\u7d20\u6709\u53ef\u80fd\u5f15\u767c\u6c23\u5598\u6025\u6027\u767c\u4f5c \uff1f\n(1)\u904b\u52d5 (2) \u904e\u5ea6\u63db\u6c23 (3) \u51b7\u7a7a\u6c23 (4) SARS-CoV-2 \u75c5\u6bd2\u611f\u67d3 (5) \u4f7f\u7528beta -adrenergic blockers, aspirin\u7b49\u85e5\n\u7269\u3002   \nA.(1)+(2)+(3)\u3002\nB.(1)+(2)+(5)\u3002\nC.(1)+(2)+(3)+(4)\u3002\nD.(1)+(3)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[E]", "111-23.\u95dc\u65bc\u793e\u5340\u6027\u80ba\u708e (Community-acquired pneumonia) \u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f    \nA.\u80f8\u8154\u8d85\u97f3\u6ce2\u8a3a\u65b7\u80ba\u708e\u7684\u9748\u654f\u5ea6\u8f03\u80f8\u90e8 X\u5149\u9ad8\u3002\nB.\u6162\u6027\u80ba\u75be\u75c5 (chronic lung diseases, structure lung diseases )\u662f\u7da0\u81bf\u687f\u83cc\u793e\u5340\u6027\u80ba\u708e (Pseudomonas \naeruginosa caused community -acquired pneumonia )\u7684\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00 \u3002\nC.\u5c3f\u6db2Streptococcus pneumoniae \u8207 Legionella pneumophila\u6297\u539f\u6aa2\u9a57\u90fd\u6709\u5f88\u9ad8\u7684\u8a3a\u65b7\u9748\u654f\u5ea6\u3002\nD.CURB-65\u8f03The Pneumonia Severity Index (PSI)\u7c21\u4fbf\u4e14\u6709\u6548\u5730\u5224\u65b7\u75c5\u60a3\u9700\u8981\u4f4f\u9662\u6216\u53ea\u8981\u63a5\u53d7\u9580\u8a3a\u6cbb\n\u7642\u3002\nE.\u63a5\u53d7\u9580\u8a3a\u6cbb\u7642\u7684\u75c5\u60a3 \uff0c\u53ea\u6709\u5728pneumococcal resistant to macrolide\u5c0f\u65bc50 %\u7684\u5730\u5340\u65b9\u53ef\u55ae\u7368\u4f7f\n\u7528macrolide\u6cbb\u7642 \u3002\n": "[B]", "111-24.\u95dc\u65bc\u6c27\u6c23\u6cbb\u7642(Oxygen Therapy)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u9f3b\u5c0e\u7ba1\uff08Nasal cannula\uff09\u7684\u6c27\u6c23\u6d41\u91cf\u4ee5\u4e0d\u8d85\u904e 6 liters/min\u70ba\u539f\u5247\u3002\nB.\u4f7f\u7528\u7c21\u55ae\u5f0f\u9762\u7f69 \uff08Simple face mask \uff09\u6642\uff0c\u82e5\u56fa\u5b9a\u6c27\u6c23\u6d41\u901f( 5 liters /min)\uff0c\u7576\u75c5\u60a3\u6bcf\u5206\u9418\u63db\u6c23\u91cf\u5347\n\u9ad8\uff0c\u5247FiO2\u6703\u96a8\u4e4b\u4e0b\u964d \u3002\nC.\u975e\u518d\u5438\u5165\u6027\u9762\u7f69\uff08nonrebreather face mask\uff09\u7d66\u4e88\u75c5\u60a3\u7684\u6c27\u6c23FiO2\u53ef\u90540.6-1.0\u3002\nD.Venturi mask\u7684\u597d\u8655\u662f\u53ef\u4ee5\u63d0\u4f9b\u75c5\u60a3\u76f8\u5c0d\u56fa\u5b9a\u7684FiO2\u3002\nE.\u9ad8\u6d41\u91cf\u9f3b\u5c0e\u7ba1 \uff08High-flow nasal cannula \uff09\u53ef\u7522\u751f\u5410\u6c23\u672b\u6b63\u58d3 (positive end -expiratory pressure )\uff0c\u4ee5\n\u907f\u514d\u80ba\u6ce1\u584c\u9677 \u3002\n": "[C]", "111-25.\u4e0b\u5217\u6709\u95dc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(acute respiratory distress syndrome, ARDS)\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u6839\u64daBerlin definition\uff0c\u56b4\u91cd\u5ea6\u662f\u4ee5PaO2/FiO2 ratio\u4f86\u5340\u5206\u3002\nB.\u6700\u5e38\u898b\u9020\u6210ARDS\u7684\u539f\u56e0\u662f\u80ba\u708e\u53ca\u6557\u8840\u75c7\u3002\nC.\u547c\u5438\u5668\u7684\u8a2d\u5b9a\u61c9\u63a1\u7528\u80ba\u4fdd\u8b77\u901a\u6c23\u7b56\uf976 (lung protective strategy )\uff0c\u4f7f\u7528\u8f03\u4f4e\u7684\u6f6e\u6c23\u5bb9\u7a4d (Tidal Volume; \n6 mL/kg)\uff0c\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387 \u3002\nD.Mild to moderate ARDS\u61c9\u8003\u616e\u4f7f\u7528\u4fef\u81e5\u5f0f\u901a\u6c23\u6a21\u5f0f(Prone positioning) \u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\u3002\nE.\u985e\u56fa\u9187\u7684\u4f7f\u7528\u7121\u6cd5\u964d\u4f4eARDS\u7684\u6b7b\u4ea1\u7387\u3002\n": "[D]", "111-26.\u4e0b\u5217\u54ea\u4e9b\u539f\u56e0\u6703\u9020\u6210\u6ef2\u51fa\u808b\u819c\u7a4d\u6db2 (exudative pleural effusion )?(1) Peritoneal dialysis (2) Superior vena \ncava obstruction (3) Asbestos exposure (4) Meigs' syndrome (5) Radiation therapy \u3002   \nA.(1)+(2)+(3)\u3002\nB.(1)+(2)+(4)\u3002\nC.(2)+(3)+(4)\u3002\nD.(3)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002   \n": "[D]", "111-27.\u95dc\u65bc\u60e1\u6027\u808b\u819c\u9593\u76ae\u7624(Malignant Pleural Mesothelioma)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u5f9e\u77f3\u7dbf\u66b4\u9732\u5230\u767c\u75c5\u6642\u9593\u53ef\u4ee5\u9577\u905420-50\u5e74\u3002\nB.\u6700\u5e38\u898b\u7684\u7d44\u7e54\u578b\u614b\u662fepithelioid mesothelioma\u3002\nC.Sarcomatoid mesothelioma\u53ef\u4ee5\u900f\u904e\u808b\u819c\u6db2\u7684\u6aa2\u9a57\u7372\u5f97\u8a3a\u65b7\u3002\nD.\u808b\u819c\u7a4d\u6db2\u7684\u63a7\u5236\u53ef\u4ee5\u5229\u7528\u5c0e\u7ba1\u5f15\u6d41\u8207\u6ed1\u77f3\u7c89\u808b\u819c\u6cbe\u9ecf\u8853(talc pleurodesis)\u3002\nE.\u653e\u5c04\u7dda\u6cbb\u7642\u7121\u6cd5\u6539\u5584\u75c5\u60a3\u5b58\u6d3b\u3002\n": "[C]", "111-28.\u67d078\u6b72COPD\u75c5\u4eba\u767c\u751f\u6025\u6027\u60e1\u5316 (acute exacerbation )\u3002\u610f\u8b58\u6e05\u695a \uff0c\u8840\u58d3140/78 mmHg \u3002\u807d\u8a3a\u5169\u5074\u80ba\u90e8\u6709\n\u5598\u9cf4\u8072\u3002\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790 (ABG) \u4f7f\u7528\u9f3b\u5c0e\u7ba1\u6c27\u6c232 L/min\u6642\u986f\u793a: pH 7.33, PaCO\u2082 58 mmHg, PaO\u2082 64 \nmmHg\u3002\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u4e0d\u9069\u7576 ?   \nA.\u7d66\u4e88\u975e\u4fb5\u8972\u6027\u96d9\u967d\u58d3\u547c\u5438\u5668(BiPAP)\u652f\u6301\u3002\nB.\u7acb\u5373\u63d2\u7ba1(endotracheal intubation)\u53ca\u4f7f\u7528\u547c\u5438\u5668\u3002\nC.\u7d66\u4e88\u5438\u5165\u6027\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u3002\nD.\u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u3002\nE.\u7d66\u4e88\u985e\u56fa\u9187\u6cbb\u7642\u3002\n": "[B]", "111-29.\u67d030\u6b72\u652f\u6c23\u7ba1\u64f4\u5f35\u75c7 (bronchiectasis )\u75c5\u60a3\u56e0\u53cd\u8986\u54b3\u8840\u81f3\u6025\u8a3a\u5c31\u91ab \u3002\u8840\u58d3 105 /80 mmHg \uff0c\u8840\u6c27(SpO\u2082) \n94%\uff0c\u4f46\u4ecd\u6301\u7e8c\u54b3\u55fd\u4e26\u5927\u91cf\u54b3\u8840 \uff0c\u80f8\u90e8X\u5149\u986f\u793a\u53f3\u4e0b\u80ba\u8f15\u5fae\u6d78\u6f64 \u3002\u6b64\u6642\u5728\u6025\u8a3a\u61c9\u512a\u5148\u5b89\u6392\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u6216\n\u8655\u7f6e\u6700\u70ba\u9069\u7576 ?   \nA.\u8f38\u8840\u3002\nB.\u652f\u6c23\u7ba1\u93e1\u6aa2\u3002\nC.\u6838\u91ab\u80ba\u704c\u6d41\u986f\u5f71(perfusion scan)\u3002\nD.\u96fb\u8166\u65b7\u5c64\u80ba\u8840\u7ba1\u651d\u5f71(CT angiography)\u3002\nE.\u7d66\u4e88\u975e\u4fb5\u8972\u6027\u96d9\u967d\u58d3\u547c\u5438\u5668(BiPAP)\u652f\u6301\u3002\n": "[D]", "111-30.\u6839\u64da\u6700\u65b0\u6c23\u5598GINA\u6307\u5f15\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u56b4\u91cd\u6c23\u5598\u7b2c\u4e94\u968e\u53ef\u8003\u616e\u7684\u6cbb\u7642\u9078\u9805?    \nA.Anti-IgE (Omalizumab)\u3002\nB.Anti-IL5 ( \u5982Mepolizumab \u6216Benralizumab)\u3002\nC.\u8336\u9e7c(theophyllines)\u3002\nD.\u9ad8\u5291\u91cf\u5438\u5165\u6027\u985e\u56fa\u9187-\u9577\u6548\u4e59\u4e8c\u578b\u523a\u6fc0\u5291(ICS-LABA)\u3002\nE.Tiotropium\u3002\n": "[C]", "111-31.\u67d080\u6b72COPD\u75c5\u4eba \uff0c\u5438\u5165\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u524dFEV 1\u70ba\u9810\u6e2c\u503c\u4e4b71 %\uff0c\u5438\u5165\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\n\u5f8cFEV1\u70ba78%\uff0cCOPD\u8a55\u4f30\u6e2c\u9a57 (CAT)\u5206\u6578\u70ba8\u5206\uff0c  \u904e\u53bb\u4e00\u5e74\u6709 1\u6b21COPD\u6025\u6027\u60e1\u5316\u4f4f\u9662 \u3002\u8acb\u554f\u6839\n\u64daGOLD\u6307\u5f15 \uff0c\u5176\u80ba\u529f\u80fd\u5206\u7d1a\u8207COPD\u56b4\u91cd\u5ea6\u5206\u7fa4\u70ba\u4f55 \uff1f   \nA.\u80ba\u529f\u80fd\u5206\u7d1a\u70baGOLD 1\uff0cCOPD\u56b4\u91cd\u5ea6\u70ba A\u7fa4\u3002\nB.\u80ba\u529f\u80fd\u5206\u7d1a\u70baGOLD 2\uff0cCOPD\u56b4\u91cd\u5ea6\u70ba B\u7fa4\u3002\nC.\u80ba\u529f\u80fd\u5206\u7d1a\u70baGOLD 1\uff0cCOPD\u56b4\u91cd\u5ea6\u70ba C\u7fa4\u3002\nD.\u80ba\u529f\u80fd\u5206\u7d1a\u70baGOLD 2\uff0cCOPD\u56b4\u91cd\u5ea6\u70ba C\u7fa4\u3002\nE.\u80ba\u529f\u80fd\u5206\u7d1a\u70baGOLD 3\uff0cCOPD\u56b4\u91cd\u5ea6\u5206\u7fa4\u70ba D\u7fa4\u3002\n": "[D]", "111-32.\u67d090\u6b72\u75c5\u4eba\u56e0\u4e7e\u54b3\u8207\u547c\u5438\u56f0\u96e3\u5c31\u91ab \uff0c\u904e\u53bb\u672a\u66fe\u5438\u83f8 \u3002\u807d\u8a3a\u6642\u4e0b\u80ba\u8449\u6709 crackles \uff0c\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u5982\u5716\u6240\n\u793a\u3002\u4e0b\u5217\u80ba\u529f\u80fd\u8207\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\u7d50\u679c\u4f55\u8005\u6700\u7b26\u5408\u5176\u8a3a\u65b7 ?      \nA.FVC 67%\uff0cFEV\u2081 70%\uff0cFEV\u2081/FVC 0.81\uff0cDLCO 40 %\uff0cPaO\u2082 75 mmHg \uff0cPaCO\u2082 40 mmHg \u3002\nB.FVC 92%\uff0cFEV\u2081 70%\uff0cFEV\u2081/FVC 0.70\uff0cDLCO 78 %\uff0cPaO\u2082 75 mmHg \uff0cPaCO\u2082 40 mmHg \u3002\nC.FVC 77%\uff0cFEV\u2081 90%\uff0cFEV\u2081/FVC 0.87\uff0cDLCO 80 %\uff0cPaO\u2082 75 mmHg \uff0cPaCO\u2082 55 mmHg \u3002\nD.FVC 100 %\uff0cFEV\u2081 70%\uff0cFEV\u2081/FVC 0.55\uff0cDLCO 40 %\uff0cPaO\u2082 65 mmHg \uff0cPaCO\u2082 40 mmHg \u3002\nE.FVC 57%\uff0cFEV\u2081 89%\uff0cFEV\u2081/FVC 0.75\uff0cDLCO 87 %\uff0cPaO\u2082 75 mmHg \uff0cPaCO\u2082 58 mmHg \u3002\n": "[A]", "111-33.\u67d0\u4f4d\u9ad4\u91cd60\u516c\u65a4\u4e4b65\u6b72\u7537\u6027\u75c5\u60a3\u56e0COVID -19\u4f75\u767c\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4 (ARDS)\u63a5\u53d7\u547c\u5438\u5668\u6cbb\u7642 \u3002\u5176\u547c\u5438\n\u5668\u8a2d\u5b9a(VC mode )\u70ba: FiO\u2082 0.55\u3001\u547c\u5438\u901f\u738716 \u6b21/min\u3001\u6f6e\u6c23\u5bb9\u7a4d (tidal volume) 600 mL \u3001\u6700\u9ad8\u5438\u6c23\u6d41\u901f70 \nL/min\u3001\u5410\u6c23\u672b\u967d\u58d3 (PEEP) 10 cmH \u2082O\u3002\u5176\u52d5\u8108\u8840\u6db2\u6c23\u9ad4\u5206\u6790\u70ba \uff1apH 7.34\u3001PaO\u2082 72 mmHg \u3001PaCO\u2082 51 \nmmHg\u3001HCO\u2083 28 mEq /L\u3002\u8acb\u554f\u61c9\u8abf\u6574\u90a3\u500b\u547c\u5438\u5668\u53c3\u6578\u503c\u6700\u70ba\u59a5\u7576 \uff1f   \nA.\u589e\u52a0\u547c\u5438\u901f\u7387\u3002\nB.\u6e1b\u5c11FiO\u2082\u3002\nC.\u6e1b\u5c11\u6f6e\u6c23\u5bb9\u7a4d(tidal volume)\u3002\nD.\u589e\u52a0\u5438\u6c23\u6700\u5927\u6d41\u901f\u3002\nE.\u6e1b\u5c11\u5410\u6c23\u672b\u967d\u58d3(PEEP)\u3002\n": "[C]", "111-34.\u67d0\u80ba\u708e\u5c0e\u81f4\u547c\u5438\u8870\u7aed\u75c5\u60a3\u63a5\u53d7\u547c\u5438\u5668\u6cbb\u7642\u6642\u7a81\u7136\u7522\u751f\u8840\u6c27\u8207\u8840\u58d3\u4e0b\u964d \uff0c\u807d\u8a3a\u6642\u53f3\u5074\u80ba\u90e8\u547c\u5438\u97f3\u6e1b\u4f4e \u3002\u4e0b\u5217\n\u4f55\u8005\u70ba\u9069\u7576\u4e4b\u8655\u7f6e ?(1) \u589e\u52a0\u5410\u6c23\u672b\u967d\u58d3 (PEEP) (2) \u589e\u52a0\u5438\u5165\u6c27\u6c23\u5206\u7387 (FiO\u2082)\u81f3100% (3) \u66ab\u6642\u812b\u96e2\u547c\u5438\n\u5668\uff0c\u4f7f\u7528\u7526\u9192\u7403\u6025\u6551 (Ambu) (4) \u7528\u80f8\u8154\u8d85\u97f3\u6ce2\u78ba\u8a8d\u8a3a\u65b7 (5) \u5982\u70ba\u5f35\u529b\u6027\u6c23\u80f8 \uff0c\u61c9\u7acb\u523b\u7528\u7d30\u91dd\u6216\u5f15\u6d41\u5c0e\u7ba1\u63d2\n\u5165\u808b\u819c\u8154\u6e1b\u58d3   \nA.(1)+(2)+(3)+(4)\u3002\nB.(2)+(3)+(4)\u3002\nC.(3)+(4)+(5)\u3002\nD.(2)+(3)+(4)+(5)\u3002\nE.(1)+(3)+(5)\u3002\n": "[D]", "111-35.\u67d0\u61f7\u5b5535\u9031\u4e4b\u786c\u76ae\u75c7\u7522\u5a66\u7dca\u6025\u5256\u8179\u7522\u5f8c\u547c\u5438\u56f0\u96e3\u52a0\u91cd\u8f49\u4f86\u5167\u79d1\u52a0\u8b77\u75c5\u623f \uff0c\u610f\u8b58\u6e05\u695a \uff0c\u8840\u58d3\u7531\u5256\u8179\u7522\n\u524d134/88 mmHg\u4e0b\u964d\u81f3 92 /50 mmHg \uff0c\u5fc3\u8df3 110 /min\uff0cSpO\u2082 90% (NRM )\u3002\u53f3\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u986f\u793a\u53f3\u5fc3\u623f\n\u58d3(RAP)\u70ba12 mmHg \uff0c\u5e73\u5747\u80ba\u52d5\u8108\u58d3 (mean PAP )\u70ba44 mmHg \uff0c\u80ba\u52d5\u8108\u6954\u58d3 (PA wedge pressure \n(PAWP))\u70ba14 mmHg \uff0c\u5fc3\u8f38\u51fa\u91cf\u70ba 3.0 L/min\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u932f\u8aa4 \uff1f   \nA.\u75c5\u60a3\u80ba\u8840\u7ba1\u963b\u529b\u70ba14 Wood units\u3002\nB.\u786c\u76ae\u75c7\u80ba\u52d5\u8108\u9ad8\u58d3(PAH)\u5982\u672a\u6cbb\u7642\u5247\u4e09\u5e74\u5b58\u6d3b\u7387\u4f4e\u65bc50%\u3002\nC.\u53ef\u4f7f\u7528\u80ba\u8840\u7ba1\u64f4\u5f35\u5291\u4ee5\u964d\u4f4e\u80ba\u8840\u7ba1\u963b\u529b\u3002\nD.\u4e0d\u61c9\u8a72\u7d66\u4e88\u5927\u91cf\u8f38\u6db2\u4f86\u63d0\u9ad8\u8840\u58d3\u3002\nE.\u53ef\u4f7f\u7528\u5438\u5165\u4e00\u6c27\u5316\u6c2e\u4ee5\u964d\u4f4e\u80ba\u8840\u7ba1\u963b\u529b\u3002\n": "[A]", "111-36.\u5c0d\u65bc\u80ba\u708e\u4f75\u767c\u4e4b\u808b\u819c\u7a4d\u6db2(parapneumonic pleural effusion), \u4e0b\u8ff0\u4f55\u8005\u4e0d\u662f\u9032\u884c\u80f8\u7ba1\u5f15\u6d41\u4e4b\u689d\u4ef6?    \nA.\u808b\u819c\u7a4d\u6db2\u7684\u767d\u8840\u7403\u6578\u76ee> 1000/uL\u3002\nB.\u808b\u819c\u7a4d\u6db2\u7684\u9769\u862d\u6c0f\u67d3\u8272(Gram stain)\u62b9\u7247\u767c\u73fe\u7d30\u83cc\u3002\nC.\u808b\u819c\u7a4d\u6db2\u7684pH\u503c\u70ba6.9\u3002\nD.\u808b\u819c\u7a4d\u6db2\u7684glucose\u503c\u70ba8 mg/dL\u3002\nE.\u808b\u819c\u7a4d\u6db2\u6709\u60e1\u81ed\u5473\u3002   \n": "[A]"}